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UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM8-K
CURRENT REPORT
Pursuant to Section 13 or IS(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 23, 2016

USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Utah
(State or other jurisdiction of incorporation)
001-35024
(Commission File No.)

~
87-0500306
{IRS Employer Identification
Number)

3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

D

Written communications pursuant to Ruic 425 under the Securities Act ( 17 CFR 230.425)

D Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
D

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D

Pre-commencement communications pursuant to Rule l 3e-4(c) under the Exchange Act ( 17 CFR 240. I 3e-4(c))

Item 8.01

Other Events.

On March 23, 2016, USA NA Health Sciences, Inc. issued a press release announcing changes to the make-up of its Board of Directors, which will
be proposed to shareholders at the Company's Annual Shareholder Meeting on May 2, 2016. The release provided an overview of the proposed
changes, including the election of three new members to the Board, increasing the size of the Board to seven directors, and the upcoming
retirement of two of its current Board members. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K
and is incorporated herein by reference. The company will also post this document on its corporate website, www.usanahcalthsciences.com.
The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by
reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information
in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the
information this Current Report contains is material investor information that is not otherwise publicly available.
Item 9.01

Financial Statements and Exhibits.
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te,

(d) Exhibits
Exhibit 99

Press release issued by USANA Health Sciences, Inc. dated March 23, 2016 {furnished herewith).
2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
USANA HEALTH SCIENCES, INC.

By:

Isl Paul A. Jones

Paul A. Jones, Chief Financial Officer
~

Date: March 23, 2016
3
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Exhibit 99

Investors contact:

Patrique Richards
Investor Relations
(80 I) 954-7961
investor.relations@us.usana.com

Media contact:

Dan Macuga
Public Relations
(801) 954-7280

USANA Health Sciences Announces Proposed
Expansion of its Board of Directors

SALT LAKE CITY, March 23, 2016 (BUSINESS WIRE)-USANA Health Sciences, Inc. (NYSE:USNA) today announced that it is proposing to
shareholders the election of three new members to its Board of Directors at its Annual Shareholder Meeting on May 2, 2016. The proposal would
increase the size of the Board to seven directors and expand the breadth of expertise, backgrounds and viewpoints of the Board. David A. Wentz,
Co-Chief Executive Officer of the Company, Frederic J. Winssinger and Feng Peng have been nominated by the Board to stand for election at the
Annual Shareholder Meeting. D. Richard Williams, who was appointed to the Board in March 2016, will also stand for re-election at the Annual
Shareholder Meeting, along with Dr. Myron W. Wentz, Robert Anciaux and Gilbert A. Fuller. Long time Board members Jerry G. McClain and
Ronald S. Poelman will retire from the Board when their current terms expire at the 2016 Annual Meeting. Mr. McClain has served as a director of
USANA since June 200 I, while Mr. Poelman has served as a director since I 995.
Mr. Wentz was appointed Chief Executive Officer of USA NA in July 2008 and became Co-Chief Executive Officer in August 2015. He has held a
number of other strategic positions with the Company since its inception in 1992. Mr. Wentz's addition to the Board will expand the Board's
industry expertise and further unify the Board's partnership with management.

Mr. Winssinger has more than two decades of experience in the financial markets, including serving as a portfolio manager in London with JP
Morgan Investment Management, Adelphi Capital, Capital@Work, and, most recently, RW Partners, where he was the managing partner. He is the
founder and managing director of PlanningCore Wealth Advisors in Phoenix, Arizona.
Mr. Peng has extensive business experience in China, financial and corporate strategy expertise, and a strong information technology background.
Since 2013, Mr. Peng has served as the Chief Financial Officer ofOssen Innovation Company, Ltd., a China-based manufacturing company listed
on the NASDAQ exchange. Prior to that, he served as Senior Vice President at MZ Group, where he provided strategic consulting services related
to U.S. capital markets to Chinese clients. Prior to working at MZ Group, he served in various capacities at Thomson Financial and Citigroup.
Myron W. Wentz, Ph.D., Chairman of the Board, commented, "Ron's and Jerry's expertise, wisdom and integrity have made immeasurable
contributions to the Board and USA NA over the years. They have played a significant role in our development into a global nutrition company.
On behalf of the Board, employees and shareholders, we are grateful for their many years of service and the significant contributions they have
made. We wish them all the best in their future endeavors."
Wentz added, "We are delighted that Dave, Frederic and Feng have accepted nominations to the USA NA Board and agreed to serve USA NA 's
shareholders. Their extensive industry, financial, and international expertise will provide significant value to the USANA Board and executive
team."
About USANA

USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to
Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South
Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia and Indonesia.
More information on USANA can be found at http://www.usanahealthsciences.com.
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UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 6, 2015

USANA HEALTH SCIENCES, INC.
(Exat:t name of registrant as specified in its charter)

Utah

~

(State or other jurisdiction of incorporation)

001-35024

87-0500306

(Commission File No.)

(IRS Employer Identification
Number)

3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

0

•
•
•

Written communications pursuant to Rule 425 under the Securities Act (I 7 CFR 230.425)
Soliciting material pursuant to Rule l 4a-12 under the Exchange Act ( 17 CFR 240. l 4a-12)
Pre-commencement communications pursuant to Ruic 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Ruic 13c-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07

Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Shareholders on May 6, 2015. A total of 11,684,325 shares (approximately 92%) of the issued and
outstanding shares of USA NA common stock were represented by proxy or in person at the meeting. The following matters were submitted and
voted upon at the Annual Meeting:
I.

USAN A shareholders voted to elect five individua Is to the Board of Directors for the succeeding year as set forth below:

Name

Myron W. Wentz, PhD
Ronald S. Poelman
Robert Anciaux
Jerry G. McClain

Number of
Shares For

10,928,959
9,669,463
10,971,616
10,941,790

Number of
Shares
Withheld

105,545
1,365,041
62,888
92,714

Number of
Shares
Abstaining
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Broker NonVotes

649,821
649,821
649,821
649,821

2.

649.821

USANA shareholders voted to approve the company's 2015 Equity incentive Award Pian as s1;;l furlh bduw:
Number of
Shares
Abstaining

Number of
Shares

Number of
Shares For

Withheld

Broker NonVotes

4,258

3,596,793

7,433,453
3.

148,974

10,885,530

Gilbert A. Fuller

649,821

USANA shareholders voted to ratify the Board's selection of KPMG LLP as our independent registered public accounting firm for.fiscal
year 2015 as set forth below:

Number of
Shares For

11,675,912

Number of
Shares

Number of
Shares

Withheld

Abstaining

Broker NonVotes

6,454

1,959

2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: Isl Paul A. Jones
Paul A. Jones, Chief Financial Officer
Date: May 8, 2015
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Use these links to rapidly review the document
TABLE OF CONTENTS
Table olTontcnts

UNITED STATES
SECURITIES AND EXCHANGE COMI\USSION
Washington, D.C. 20549

SCHEDULEI4A
Proxy Statement Pursuant to Section l 4(a) of
the Securities Exchange Act of 1934 (Amendment No.
Filed by the Registrant IBI
Filed by a Pa1ty other than the Registrant

•

Check the appropriate box:

0

Preliminary Proxy Statement

0

Confidential, for Use of the Commission Only (as permitted by Ruic I 4a-6(c)(2))

IBI

Definitive Proxy Statement

0

Definitive Additional Materials

0

Soliciting Material under §240.14a-l 2

USANA Health Sciences, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
IBI

No fee required.

0

Fee computed on table below per Exchange Act Rules l 4a-6(i)(l) and 0-11.
(l) Title of each class of securities to which transaction applies:
(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price orother underlying value of transaction computed pursuant to Exchange Act Ruic 0-11 (set forth the
amount on which the filing fee is calculated and state how it was dctcnnincd):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

D

Fee paid previously with preliminary materials.

0

Check box if any pan of the fee is offset as provided by Exchange Act Ruic 0-11 (a)(2) and identify the filing for which
the ofTscmng fee was paid previously. Identify the previous filing by registration statement number. or the Fom1 or
Schedule and the dale of its filing.
(I)

Amount Previously Paid:

(2)

Fonn, Schedule or Registrntion Statement No.:
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(3)

Filing Party:

(4)

Date Filed:

Persons who arc to respond to the collection of information contained in this form arc not required to respond
unless the form displays a currently valid 0MB control number.
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3838 West Parkway Boulevard
Salt Lake City, Utah 84120-6336
(801) 954-7100
March 25, 2015
Dear Shareholders,
You are cordially invited to attend the 2015 Annual Meeting of Shareholders ofUSANA Health Sciences, Inc. (the "Annual Meeting") to be held at
11 :00 a.m. MDT on Wednesday, May 6, 2015, at our offices at 3838 West Parkway Boulevard, Salt Lake City, Utah. Details regarding the meeting, the
business to be conducted, and infom1ation about USANA Health Sciences, Tnc. that you should consider when you vote your shares arc described in the
following pages, which contain the fonnal Notice of Annual Meeting and the Proxy Statement.
At the Annual Meeting, five persons will stand for re-election to the Board of Directors. We will also ask shareholders to approve the Company's 2015
Equity Incentive Award Plan, and to ratify the selection ofKPMG LLP as our independent registered public accounting finn for our fiscal year ending
January 2, 20 I 6. The Board of Directors recommends the approval of each of these proposals. Such other business will be transacted as may properly come
before the Annual Meeting.
Under Securities and Exchange Commission mies that allow companies to furnish proxy materials to shareholders over the Internet, we have elected to
deliver our proxy materials to the majority of our shareholders over the Internet. This allows us to mail our shareholders a notice instead of a paper copy of
our proxy materials. We believe this process will facilitate accelerated delivery of proxy materials, save costs, and reduce the environmental impact of our
Annual Meeting. On or about March 25, 2015, we began sending to our shareholders a Notice oflntcmct Availability of Proxy Materials containing
instructions on how to access our proxy statement for our Annual Meeting and our Annual Report to Shareholders on the Internet. This notice also provides
instructions on how to vote online orby telephone and includes instructions on how to receive a paper copy of the proxy materials by mail.
We hope you will be able to attend the Annual Meeting. Whether you plan to attend the Annual Meeting or not, it is important that you cast your vote.
You may vote overthe Internet as well as by telephone. In addition, if you requested to receive printed proxy materials, you may vote by completing,
signing, dating and returning your proxy card by mail. You are urged to vote promptly in accordance with the instructions set forth in the Notice oflntemet
Availability of Proxy Materials or on your proxy card. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting,
whether or not you can attend.
Sincerely,

David A. Wentz
Chief Executive Officer
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3838 West Parkway Boulevard
Salt Lal<e City, Utah 84120-6336
(801) 954-7100

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELDMAY6,20l5
TIME:

11 :00 a.m. MDT

DATE:

Wednesday, May 6, 2015

PLACE:

The olliccs ofUSANA Health Sciences, Inc.
3838 West Parkway Boulevard. Salt Lake City, Utah 84120

PURPOSES:

I.

To elect five directors to serve for one year each, until the next Annual Meeting of Shareholders and until
a successor is elected and shall qualify;

2.

To approve the Company's 2015 Equity Incentive Award Plan;

3.

To ratify the selection ofKPMG LLP as the Company's independent registered public accounting finn for
the fiscal year 2015; and

4.

To consider and act upon such other business as may properly come before the meeting or ul any
postponement or adjournment thereof
~

WHO MAY VOTE:
You will receive notice of and be entitled to vote at the Annual Meeting ifyou were the record ownerofUSANA Health Sciences, Inc. common stock at
the close of business on March 2, 2015. A list of shareholders of record will be available at the meeting and during the IO days prior to the meeting, at the
office of the Secretary at the above address.
All shareholders are cordially invited to attend the Annual Meeting. Whether you plan to attend the Annual Meeting or not, please vote by following the
instructions on the Notice of Internet Availability of Proxy Materials that you have previously received, which we refer to as the Notice, or in the section of
the Proxy Statement entitled "Important lnfomiation About the Annual Meeting-How Do I Vote," or, if you requested to receive printed proxy materials,
your proxy card. You may change or revoke your proxy at any time before it is voted. The Notice contains instructions on how our shareholders may access
our proxy materials and Annual Report over the Internet and how our shareholders may receive a paper copy of the proxy materials, including the Proxy
Statement, Annual Report on Form I 0-K, and a form of proxy card.
On or about March 25.2015. we began sending the Notice of Internet Availability of Proxy Materials to all shareholders entitled to vote at the annual
meeting.
By Order of the Board of Directors,

James H. Bramble

Corporate Secretary
Salt Lake City, Urah
March 25.2015
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IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR
THE SHAREHOLDER MEETING TO BE HELD ON MAY 6, 2015
This Proxy Statement and our annual report to shareholders for the fiscal year ended .January 3, 2015, along \\ith our proxy card, are available
for viewing, printing, and dcnmloading free of charge at www.proxyvote.com. To view these materials please have your 12-digit control number available
that appears on your Notice or proxy card. On this website. you can also elect to receive future distributions of our proxy statements and annual reports to
shareholders by electronic delivery.
Additionally, you can find a copy of our Annual Report on Fonn I 0-K, which mcludes our financial statements for the fiscal year ended January 3, 2015,
on the website of the Securities and Exchange Commission at www.sec.gov, or on the "Investor Relations" section of our website at
www.usanahealthsciences.com. You may also obtain a printed copy of our Annual Report on Fonn I 0-K, including our financial statements, free of charge,
from us by sending a written request to: Secretary, USANA Health Sciences, Inc .. 3838 West Parkway Boulevard, Salt Lake City, Utah 84120. Exhibits will be
provided upon written request and payment ofan appropriate processing Ice.
ii
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PROXY STATEMENT FOR
THE ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD MAY 6, 2015
The Board of Directors ofUSANA Health Sciences, Inc. ("We." "USANA." or the "Company") is soliciting the accompanying proxy to be used at the 2015
Annual Meeting of Shareholders (the "Annual Meeting") to be held on Wednesday, May 6, 2015, at 11 :00 a.m., local time, or at any adjournments thereof for
the pu1poses set fo11h in this Proxy Statement and in the accompanying notice of the meeting. On or about March 25, 2015, we began sending the Notice of
Internet Availability of Proxy Materials, which we refer to throughout this Proxy Statement as the Notice, to all shareholders entitled to vote at the Annual
Meeting.

IMPORTANT INFORMATION ABOUT THE MRETING
Why is the Company Soliciting My Proxy?

The Board of Directors ofUSANA is soliciting your proxy to vote at the Annual Meeting to be held at our offices, 3838 West Parkway Boulevard, Salt
Lake City, Utah, on Wednesday, May 6, 2015. at 11 :00 a.m. MDT and any adjournments of the meeting. The proxy statement along with the accompanying
Notice of Annual Meeting of Shareholders summarizes the purposes oft he meeting and the infomiation you need to know to vote at the Annual Meeting.
We have sent you the Notice and made this Proxy Statement and our annual report to shareholders for the 2014 fiscal year available to you on the
Internet because you owned shares ofUSANA common stock on the record date, which is March 2, 2015. We have also delivered p1inted versions of these
mate1ials to certain shareholders by mail. The Company commenced distribution of the Notice and the proxy mate1ials to shareholders on or about March 25,

2015.
Why Did I Receive a Notice in the Mail Regarding the Internet Availability of Proxy Materials Instead ofa Full Set of Proxy Materials?
As permitted by the rules of the U.S. Securities and Exchange Commission, or the SEC, we have elected to furnish our proxy materials to our shareholders
by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each shareholder. Most shareholders will not
receive printed copies of the proxy materials unless they request them. We believe that this process should expedite shareholders' receipt of proxy materials,
lower the costs of the annual meeting and help to conseive natural resources. If you received a Notice by mail or electronically, you will not receive a printed
or email copy of the proxy materials, unless you request one by following the instructions included in the Notice. Instead, the Notice will instruct you how
you may access and review all of the proxy materials and submit your proxy on the Internet. If you requested a paper copy of the proxy materials, you may
authorize the voting of your shares by following the instructions on the enclosed proxy card, in addition to the other methods of voting described in this
Proxy Statement.
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Table ofCon1en1s
Who Can Vote'!
Only shareholders who owned USANA common stock at the close of business on March 2.2015. or the record date. are entitled to vote at the Annual
Meeting. On this record date. there were 12,658,684 shares of our common stock outstanding and entitled to vote. Common stock is our only class of voting
stock.
You do not need to attend the Annual Meeting in person to vote your shares. Shares represented by valid proxies, received in time for the meeting and
not revoked prior to the meeting, will be voted at the meeting. For instructions on how lo change or revoke your proxy, sec "May I Change or Revoke My
Proxy?" below.
How Many Votes Do I Have?
Each share ofUSANA common stock that you own as of the record date entitles you lo one vote.
How Do I Vote'!
Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. All shares represented by valid proxies that we receive through
this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card or as instructed via lntemet or telephone. You
may specify whether your shares should be voted for or withheld for each nominee for director, and whether your shares should be voted for, against or
abstain with respect to any other proposal. If you properly submit a proxy without giving specific voting instmctions, your shares will be voted in accordance
with the Board's recommendations as noted below. Voting by proxy will not affect your 1ight to attend the Annual Meeting. If your shares are registered
directly in your name through our stock transfer agent, American Stock Transfer and Trust Company. or you have stock certificates registered in your name.
you may vote:
By Internet or by telephone. Follow the instructions included in the Notice or. if you received printed materials, in the proxy card. to vote by
Internet or telephone.
By mail. If you received your proxy materials by mail. you can vote by mail by completing, signing, dating and returning the proxy card as
instructed on the card. If you sign the proxy card but do not specify how you want your shares voted, they will be voted in accordance with the
Board's recommendations as noted below.
In person at the meeting. If you attend the meeting, you may deliver a completed proxy card in person or you may vote by completing a ballot,
which will be available at the meeting.
Telephone and Internet voting facilities for shareholders of record will be available 24-hours a day and will close at 11 :59 p.m. Eastern Time on May 5,
2015.
If your shares are held in "street name" (held in the name of a bank, broker or other holder of record or nominee), you will receive instructions from the
holder ofrccord. You must follow the instructions of the nominee in order for your shares to be voted. Telephone and Internet voting also will be offered to
shareholders owning shares through certain banks and brokers. If your shares are not registered in your own name and you plan to vote your shares in person
at the Annual Meeting, you should contact your broker or agent to obtain a legal proxy or broker's proxy card and bring it to the Annual Meeting in order to
vote.
How Does the Board of Directors Recommend That I Vote on the Proposals?
The Board ofDirectors recommends that you vote as follows:
"FOR" the election of the five nominees for director;
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"FOR" the approval of the Company's 20 I 5 Equity Incentive Award Plan; and
"FOR" the ratification of the selection of KPMG LLP as our independent registered public accounting firm for our 20 I 5 fiscal year; and
We do not expect any other business to come before the meeting. If any other matter is presented, your proxy provides that your shares will be voted by
the proxy holder listed in the proxy in accordance with his or her best judgment. At the time this Proxy Statement was first made available. we knew ofno
matters that needed to be acted on at the Annual Meeting, other than those discussed in this Proxy Statement.
May I Change or Revoke My Proxy?

If you give us your proxy, you may change or revoke it at any time before the meeting. You may change or revoke your proxy in any one of the
following ways:
by re-voting by Internet or by telephone as instructed above;
if you received printed proxy materials, by signing a new proxy card with a date later than your previously delivered proxy and submitting it
as instructed above;
by notifying our Secretary in writing before the Annual Meeting that you have revoked your proxy; or
by attending the meeting in person and voting in person. Attending the meeting in person will not in and ofitselfrcvoke a previously
submitted proxy unless you specifically request it.
Your most current vote, whether by telephone, Internet or proxy card, is the one that will be counted.

What ifl Receive More Than One Notice or Proxy Card'!
You may receive more than one Notice or proxy card ifyou hold shares ofourcommon stock in more than one account, which may be in registered form
or held in street name. Please vote in the manner described under "How Do I Vote?" for each account to ensure that all of your shares are voted.

What are "broker non-votes"?
If a broker or other financial institution holds your shares in its name and you do not provide voting instructions to it, New York Stock Exchange, or
NYSE, rules allow that firm to vote your shares only on routine matters. Proposal #3, the ratification of the appointment of our independent registered public
accounting firm for 2015, is the only matter for consideration at the meeting that NYSE rules deem to be routine. For all matters other than Proposal #3, you
must submit voting instructions to the firm (broker, bank, or other nominee) that holds your shares if you want your vote to count. When a firm votes a client's
shares on some but not all of the proposals, the missing votes are referred to as "broker non-votes."

Will My Shares be Voted ifl Do Not Vote?
If your shares are registered in your name, they will not be voted if you do not vote as described above under "How Do I Vote?" If your shares are held in
street name by a bank, broker or other holder of record (nominee) and you do not provide voting instructions to the nominee that holds your shares as
described above, the nominee has the authority to vote your unvoted shares only on the ratification of our independent registered public accounting firm
(Proposal #3), unless the nominee
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receives instructions from you. Therefore, we encourage you to provide voting instructions. This ensures your shares will be voted at the meeting and in the
manner you desire.
What Vote is Re11uired to Approve Each Proposal and How are Votes Counted'!
Proposal# I: Elcclion of Directors

Under Utah law, a nominee who receives a plurality of the
votes cast at the Annual Meeting will be elected as a
director. The "plurality" standard means the nominees who
receive the largest number of"for" votes (also known as a
"plurality" of the votes) will be elected. The number of
shares not voled for the election ofa nominee (and thc.
number of"withhold" votes cast with respect to that
nominee) are not counted and will not affect the
detem1ination ofwhetherthat nominee has received the
ncr~ssaty votes for election under Utah law. You may vote
either FOR all of the nominees, WITHHOLD your vote from
all oflhe nominees or WITHHOLD your vote from any one
or more of the nominees. Votes that are withheld will nol be
included in the vote tally for the election of directors.
Broker non-votes will have no effect on the results of this
vote.

Propos:.I #2: Ar1prov,1l or the Corn1mny's 2015 Equity
Incentive Award Plan

The aflirmativc vote of the shareholders representing a
majority of the shares present and entitled to vote at the
Annual Meeting is required to approve the Company's 20 I 5
Equity Incentive Award Plan. A shareholder who signs and
submits a proxy is "present," so an abstention will have the
same effect as a vote "Against" this Proposal. Broker nonvotes will not be considered entitled to vote with respect to
this Proposal and will have no effect on the outcome.

Proposal #3: Ratificution oflndependent Registered
Public Accounting Firm

The affinnativc vote of the shareholders representing a
majority of the shares present and entitled to vole at the
Annual Meeting is required to ratify the selection of
KPMG LLP as our independent registered public
accounting finn for our 2015 fiscal year. Shares present but
not voted because of abstention will have the same effect on
the results of this vote as a vote "Against." We are not
required to obtain the approval ofour shareholders to select
our independent registered public accounting firm.
However, if our shareholders do not ratify the selection of
KPMG LLP as our independent registered public
accounting finn for the 2015 fiscal year, our Audit
Committee of our Board of Directors may reconsider its
selection.

Is Voting Confidential?
We will keep all the proxies. ballots and voting tabulations private. We only let our lnspectorofElections examine these documents. Management, other
than the Inspector of Elections, will not know
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how you voted on a specific proposal unless it is necessary to meet legal requirements. \Ve will. however. forward to management any wrinen comments you
make, on the proxy card or elsewhere.
Who Will Count the Votes?

Broadridge Investor Communications Services will tabulate the votes that arc received prior to the Annual Meeting. Representatives ofUSANA will act
as the Inspectors of Election and will tabulate the votes, if any, that arc cast in person at the Annual Meeting.
Where Can I Find the Voting Results of the Annual Meeting?

The preliminary voting results will be announced at the Annual Meeting, and we will publish preliminary, or final results if available, in a Current
Report on Fo1m 8-K within four business days ofthe Annual Meeting. If final results arc unavailable at the time we file the Fo1m 8-K. then we will tile an
amended report on Fo1m 8-K to disclose the final voting results within four business days after the final voting results are known.

Who Pays the Costs of Soliciting these Proxies'!
These proxies arc solicited by our Board of Directors and we will pay all of the costs of soliciting these proxies. Our directors and employees may solicit
proxies in person or by telephone, fax or email. We will pay these employees and directors no additional compensation for these se,vices. We will ask banks,
brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to deliver proxies. We will
then reimburse them for their expenses.
What Constitutes a Quorum for the Annual Meeting?

The presence, in person or by proxy, of the holders ofa majority of the voting power of our common stock outstanding on the record date is necessary to
constitute a quorum at the meeting. As of the close of business on the record date, there were 12,658,684 shares of our common stock outstanding. Both
abstentions and broker non-votes are counted for purposes of detennining whether a quorum exists. For the purpose of detennining whether the shareholders
have approved mailers other than the election of directors, abstentions arc treated as shares present or represented and voting, so abstaining has the same
effect as a negative vote. Directors are elected based on a plurality of votes cast. Shares held by brokers who do not have discretionaiy autho1i1y to vote on a
particular matter and who have not received voting instiuctions from 1heir customers are counted for dete1mining the presence or absence of a quorum for
conducting business but arc not counted or deemed to be present or represented for the purpose of detcnnining whether shareholders have approved that
mailer.
Attending the Annual Meeting

The Annual Meeting will be held at 11 :00 a.m. local time on Wednesday. May 6.2015, at our offices at 3838 West Parkway Boulevard, Salt Lake City,
Utah. When you arrive at our offices, our personnel will direct you to the appropriate meeting room. You need not attend the Annual Meeting to vote.
Householding of Annual Disclosure Documents

SEC rules concerning the delivery of annual disclosure documents allow us or your broker to send a single Notice or, if applicable, a single set of our
proxy materials to any household at which two or more of our shareholders reside, ifwe or your broker believe that the shareholders arc members of the same
family. This practice, referred to as "householding," benefits both you and us. It reduces the volume of duplicate info1mation received at your household and
helps to reduce our expenses. The rule applies to our Notices, annual reports, proxy statements and info1mation statements. Once you receive
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notice from your broker or from us that communications to your address will be "houscholdcd," the practice will continue until you are otherwise notified or
until you revoke your consent to the practice. Shareholders who pa11icipate in houscholding will continue to have access to and utilize separate proxy voting
111stmct1ons.

If your household received a single Notice or, if applicable, set of proxy materials this year, but you would preferto receive your own copy, please
contact Broad1idge, by calling their toll free number 1-800-542-1061. If you do not wish Lo participate in "houscholding" and would like to receive your own
Notice or. if applicable. set of proxy materials in future years. follow the instructions described below. Conversely. if you share an address with another
USANA shareholder and together both of you would like to receive only a single Notice or, if applicable, set ofpmxy materials, follow these instructions:
If your USANA shares arc registered in your own name, please contact Broadridge and infom1 them of your request by calling them at 1-800542-106 I or writing them at Broadridge Houscholding Department, 51 Mercedes Way, Edgewood, NY 117 I 7.
If a broker or other nominee holds your USANA shares, please contact the broker or other nominee directly and inform them of your request.
Be sure to include your name, the name of your brokerage finn and your account number.
Electronic Deli\'ery of Company Shareholder Communications
Most shareholders can elect to receive notices of the availability offuture proxy materials by email instead of receiving a paper copy in the mail. You
can choose this option and save us the cost of producing and mailing these documents by following the instmctions provided on your Notice or proxy card
or following the instructions provided when you vote over the Internet at www.proxyvotc.com.
How Do I Submit and What arc the Deadlines for Submitting a Shareholder Proposal for Next Year's Annual Meeting'!
Shareholders are entitled to present proposals for consideration at the next annual meeting of shareholders, provided that they comply with the proxy
rules promulgated by the SEC and our Bylaws. Any shareholder who intends to submit a proposal for consideration at the 2016 Annual Meeting of
Shareholders must deliver such proposal to the Corporate Secretary, c/o USANA Health Sciences, Inc., 3838 West Parkway Blvd., Salt Lake City, Utah 84120,
not later than 120 days p1ior to the one-year anniversary of the date on which this Proxy Statement is first mailed, which date is November 26, 2015, if the
proposal is submitted for inclusion in our proxy materials for that meeting pursuant to Ruic I 4a-8 under the Securities Exchange Act of 1934 ("Exchange
Act").
Who Should I Call ifl Have Questions?

If you have questions about the proposals or the Annual Meeting, you may call Patrique Richards, USANA Investor Relations, at (801) 954-7100. You
may also send an e-mail to investor.re/ations@u.v.usana.com.

PROPOSAL #I-ELECTION OF DIRECTORS
Our Bylaws provide that the shareholders or the Board of Directors shall determine the number of directors from time to time, but that there shall be no
less than three directors. The Board of Directors, by resolution, has set the number of directors at five. The Governance, Risk and Nominating Committee of
the Board of Directors has nominated and recommends that our current five directors stand for re-election at the Annual Meeting. The Governance, Risk and
Nominating Committee believes that all directors must, at a minimum. meet the criteria set forth in the USANA Corporate
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Governance Guidelines and in the Charter of the Governance. Risk and Nominating Committee. wl11ch specify, among olherthings. that 1he comminee will
consider criteria such as the director's independence, expertise and experience applicable to our business, substantive knowledge of our industry, high
personal and professional ethics and the ability and willingness to devolc the required lime to the business of the Company.
Each director who is elected at the Annual Meeting will hold oflicc until the Company's Annual Meeting in 2016, until a successor is elected and
qualified. or until the director resigns, is removed, or becomes disqualified. The Board of Directors has no reason to believe that any of the nominees for
director will be unwilling or unable to serve, if elected. If due to unforeseen circumstances a nominee should become unavailable for election, the Board may
either reduce the number of directors or may substitute another person for that nominee, in which event your shares will be voted for that other person.
The Governance, Risk and Nominating Committee has determined that all of our directors meet the criteria and qualifications set forth in the Company's
Code of Ethics for Directors and Employees, Corporate Governance Guidelines and the Governance, Risk and Nominating Committee Charter. In addition,
each director possesses the personal qualities and attributes we believe are essential to allow the Board of Directors to fulfill its duties lo the shareholders,
including personal accountability, integrity, ethical leadership, risk management, business acumen, and the ability to exercise sound and independent
business judgment.

Direc:tor Nominees
Five directors will be elected at the Annual Meeting. The nominees to the Board of Directors in 2015 arc Robert Anciaux, Gilbert A. Fuller, Jerry G.
McClain, Ronald S. Poelman, and Myron W. Wentz, Ph.D. All of these nominees currently seIVe as members of the Board of Directors. Messrs. Anciaux,
Fuller, McClain, and Poelman are independent directors under the rules of the NYSE. The following information is famished with respect lo these nominees:
Robert Anciaux, 69, has served as a director ofUSANA since July 1996. Since 1990, he has been the Managing Director ofS.E.I. s.a., a consulting and
investment management firm in Brussels, Belgium. Additionally, since 1982, Mr. Anciaux has been self-employed as a venture capitalist in Europe, investing
in various commercial, industrial, and real estate venture companies. In some of these p1ivately held companies, Mr. Anciaux also serves as a director.
Mr. Anciaux received an lngenieur Commercial degree from Ecole de Commerce Solvay Universite Libre de Bruxelles. Mr. Anciaux's qualifications to sit on
our Board include his financial expertise and experience in providing consulting and strategic advisory services to complex organizations.
Gilbert A. Fuller, 74, has seIVcd as a director ofUSANA since September 2008. Prior to that, he served as our Executive Vice President, Chief Financial
Officer, and Secretary since January 2006. Mr. Fuller joined USANA in May 1996 as the Vice President ofFinancc and served in this role until June 1999,
when he was appointed as the Company's Senior Vice President. Before joining USANA, Mr. Fuller served in various executive positions for several
companies. Mr. Fuller served as Chief Administrative Officer and Treasurer ofMclaleuca, Inc .. a manufacturer and direcl seller of personal care products. He
was also the Vice President and Treasurer of Norton Company, a multinational manufacturer of ceramics and abrasives. He obtained his certified public
accountant license in 1970 and kept it current until his career path developed into corporate finance. Mr. Fuller received a B.S. in Accounting and an M.B.A.
from the University of Utah. In December 2012, Mr. Fuller was appointed as a director of Security National Financial Corporation, a NASDAQ-listed
company. Mr. Fuller's qualifications to sit on our Board include his 12 years of experience as an executive officer ofUSANA, his deep understanding ofour
business, people and products, his 15 years of experience as a financial officer in the direct selling industry, as well as his accounting, finance and corporate
strategy expertise.
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Jerry G. McClain, 74, has served as a director ofUSANA since June 200 I. Since January 2003, Mr. McClain has been self-employed, operating his own
investment and real estate business in Sall Lake City, Utah. From August 2000 to December 2002. Mr. McClain was the Chief Financial Officer of
Cerbe1ian. Inc., a priva1ely held company that was headquartered in Salt Lake City, Utah. From 1998 lo 2000, Mr. McClain was the ChiefFinancial Officer
and Sr. Vice President of Assentive Solutions, Inc., a company he also co-founded. From I 997 to 1998, Mr. McClain was the Chief Financial Officer for the
Salt Lake Organizing Committee for the 2002 Winter Olympic Games. Before 1997, Mr. McClain served as a key financial advisor to many companies as an
Audit Partner and a Managing Partner ofEmsl & Young LLP for 35 years in several cities throughout the world. Mr. McClain is a fonner CPA and a graduate
from the University ofSouthern Mississippi and Oklahoma State University, where he received a B.S. in Accounting and an M.S. in Accounting, respectively.
Mr. McClain's qualifications to sit on our Board include his extensive intemational experience with accounting and financial matters for public companies,
his years of experience as the chief financial onicer of various organizations, his corporate governance cxpe11isc and his years of expe1ience providing
independent audits and strategic advice to complex organizations.
Ronald S. Poelman, 61, has served as a director ofUSANA since 1995. Since l 994, he has been a partner in lhe Salt Lake City, Utah law fim1 of Jones,
Waldo. Holbrook & McDonough. where he is head of the Corporate and Securities Practice Group. Mr. Poelman began his legal career in Silicon Valley in
California, and has assisted in the organization and financing of numerous companies for over 30 years. Mr. Poelman is the Chairman of the Utah Chapter of
the National Association of Corporate Directors ("NACD") and frequently lectures at the meetings of this and other organizations. Mr. Poelman received a
B.A. in English from Brigham Young University and a J.D. from the University ofCalifomia, Berkeley. Mr. Poelman's qualifications to sil on our Board
include his more than 30 years of experience as a corporate, finance and securities attorney, his long association with and service to the NACD, as well as his
corporate governance and strategy expertise. Mr. Poelman is a 20 I 4 NACD Governance Fellow. which is a demonstration of his commitment to boardroom
excellence through completing NACD's comprehensive program of study for corporate directors.

Myron W. Wentz, Ph.D., 74, founded USANA in I 992 and served as the Chief Executive Officer and Chainnan of the Board ofUSANA from the time of

its inception to July 2008, when he retired as Chief Executive Officer. Dr. Wenlz continues to serve as Chairman of the Board. In I 974, Dr. Wentz founded
Gull Laboratories, Inc., which was a developer and manufacturer of medical diagnostic lest kils and was the former parent co1poration ofUSANA. Dr. Wentz
served as Chairman of Gull from 1974 until 1998. In 1998, Dr. Wentz founded Sanoviv, S.A. de C.V. ("Sanoviv"), a heallh and wellness centerthat is located
near Rosarito, Mexico. Joining a pathology group in Peoria, Illinois, from I 969 to I 973, Dr. Wentz served as infectious disease specialist and directed the
microbiology and immunology laboratories for three hospitals in the Peoria area. He received a B.S. in Biology from North Central College, Naperville,
Illinois, an M.S. in Microbiology from the University ofNorth Dakota, and a Ph.D. in Microbiology and Immunology from the University ofUtah.
Dr. Wentz's qualifications to sit on our Board include his vast education and professional experience as a microbiologisl, immunologist, and pioneer in !he
development of human cell culture technology, as well as his service as our founder, Chairman and fonnerly as our Chief Executive Officer.

RECOMMENDATION
The Board of Directors unanimously recommends a vote FOR each director nominee.
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BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
The Board of Directors is elected by and is accountable to the shareholders of the Company. The Board establishes policy and provides strategic
direction, oversight, and control of the Company. The Board met nine times du1ing fiscal year 2014. All directors attended at least 75% of the meetings of the
Board and the Board Committees of which they are members.
Board Leadership Str11ct11re; Lead /11depe11de11t Director
Our founder, Dr. Myron Wentz, is the Chainnan of our Board of Directors and David A. Wentz is our Chief Executive Officer, or CEO. The Board has not
adopted a specific policy on whether the same person should serve as both the CEO and chainnan of the board or, if the roles arc separate, whether the
chairman should be selected from the non-employee directors or should be an employee. The Board believes it is most appropriate to retain the discretion and
nexibility to make these detenninations at any given point in time in the way that it believes best to provide approp1iate leadership for the Company at that
time.
We believe it is currently appropriate to separate the roles of CEO and Chai1man oft he Board as a result of the differences between the two roles. Our
CEO is responsible for setting the strategic direction for the Company, with guidance from the Board. He is also responsible for the day-to-day leadership and
perfonnance of the Company, while the Chainnan of the Board provides guidance to the CEO and sets the agenda for Board meetings and presides over
meetings of the full Board. Although Dr. Wentz is not independent under the rules of the NYSE, the Board believes the experience, leadership and vision he
provides as Chainnan of the Board is essential to the short-and-long-tenn success of the Company.
The Board maintains a number of governance practices to ensure effective independent oversight of Board decisions. including (i) the appointment of
strong, independent directors who constitute a majority of the Board and intimately understand the Company's business and industry; (ii) executive sessions
of the independent directors in connection with every Board meeting; and (iii) annual evaluations of the perfonnance of the Board, carried out by the
independent directors. Because the Board also believes that strong. independent board leadership is an important aspect of corporate governance, the Board
established the position of Lead Director in 2013. The Lead Director is an independent director elected for a one year term by the independent directors. The
Lead Director chairs the Board meetings during all executive sessions and when the Chai1man is unable to participate in Board meetings, and is a contact
person for shareholders and third parties who may desire to contact the Board independently of the Chainnan. Mr. Poelman served as Lead Director dming
2014 and was again designated to serve as Lead Director in 2015. Additional responsibilities of the Lead Director include:
Setting the agenda for and leading regularly-held independent director sessions and briefing the Chainnan on those sessions;
Coordinating the activities of the independent directors;
Presiding at meetings of the Board at which the Chairman is not present, including executive sessions of the independent directors;
Acting as a liaison of the independent directors to the Chainnan and CEO for the views and any concerns and issues of the independent
directors; and
Perfonning other duties that the Board may from time to time delegate to assist the Board in the fulfillment of its responsibilities.
9
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Dirutor /111lepe11de11ce

NYSE rules and regulations generally require listed companies to have a board of directors with a majo,ity of independent directors. A majo,ity of the
members of our Board of Directors arc independent. as discussed below.
To assist the Board in making its dctennination regarding director independence, the Board has adopted independence standards that conform to the
independence requirements of the NYSE. In addition to evaluating each director's independence, the Board considers all relevant facts and circumstances in
making its independence <letc1mination. We assess director independence on an annual basis. The Board has determined, after careful review. that all of the
current directors, other than Dr. Myron Wentz, who has also been nominated for election at the 2015 Annual Meeting, are independent based on the
applicable mies of the NYSE and the applicable regulations of the SEC. In particular, the Board noted that, other than their service as directors of the
Company, Rohert Ancianx, .Jerry G. Mer.lain, Ronald S. Poelman ancl (iilhcrt A. Fuller had no material relationship with the Company (either directly or as a
partner, shareholder orofficer of an organization that has a relationship with the Company) and determined that each of them is "indcpcndeni" urHkr t..."r'SE
listing standards.
Co111m1micatiom; wit/r Dfrutors

Our shareholders or other interested parties wishing to communicate with the Board of Directors, the non-management directors as a group, or any
individual director may do so in writing by addressing the correspondence to that individual or group, c/o James H. Bramble, Corporate Secretary, USANA
Health Sciences, Inc., 3838 West Parkway Boulevard, Salt Lake City, Utah 84120. All such communications will be initially received and processed by our
Corporate Secretary. Accounting, audit, internal accounting controls and other financial matters will be referred to our Audit Committee chair. Other matters
will be referred to the Board of Directors, the non-management directors, or individual directors as appropriate.
Directors are encouraged by the Company to attend the Annual Meeting of Shareholders if their schedules pennit. All directors. except Messrs. Anciaux
and Poelman, were present at the Company's Annual Meeting of the Shareholders that was held in April 2014.
Committees oftl,e Boartl of DfrecttJrs

The Board of Directors has a separately-designated standing Audit Committee, Compensation Committee. and Governance, Risk and Nominating
Committee. Information about the composition and responsibilities of each committee is provided below.

Governance. Risk and Nominating Committee. The Govemancc, Risk and Nominating Committee of the Board of Directors (the "Govemance
Committee") was established in Febmary 2004. The Governance Committee met four (4) times during 2014. Members of the Governance Committee during
fiscal 2014 and at the date of this Proxy Statement arc Gilbert A. Fuller, Chainnan, Robert Anciaux, Jerry G. McClain, and Ronald S. Poelman. Each member
of the Governance Committee meets the definition of"independent" set forth in the rules of the NYSE.
The Governance Committee's responsibilities include: (i) overseeing corporate governance matters, (ii) risk oversight and management, (iii) identifying
and evaluating prospective nominees for director, (iv) nominating the directornominees for election at the annual meeting of shareholders, and
(v) periodically reviewing the performance of the Board and its members and determining the number, function, and composition of the Board's committees.
The Board has delegated much of its responsibility for risk oversight and management to the Governance Committee. The Governance Committee conducts
these risk oversight and management functions as part of its corporate governance
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oversight and reports its findings with respect to risk oversight and management to the entire Board. More information about the Board of Directors and
Govemance Committee's risk oversight and management practices is provided below under the caption "Risk Oversight and Management".
The Governance Committee believes, among other things, that the Company's Board ofDin::ctors should be composed of directors with varied,
complementary backgrounds, which reflect a diversity ofviewpoints, backgrounds, experience and other factors. The Governance Committee also believes
that directors should, al a minimum. (i) have expertise that may be useful to the Company, (ii) possess the highest personal and professional ethics, and
(iii) be willing and able to devote the required amount of time to the Company's business. In light of these beliefs, the Governance Committee considers
many factors in evaluating the suitability of candidates for Board membership, and also determining whether a director should be retained and stand for reelection, including: whether the candidate meets the requirements for independence; the candidate's background and experience. pa11icularly in the
Company's industry; the candidnte's personal qualities, accomplishments, character and reputation in the business community; and the fit of the candidate's
individual skills and personality with those of the Company's other directors.
The Governance Committee may from time to time consider qualified nominees who are recommended by shareholders. The Governance Committee
docs not have different standards for evaluating nominees based on ,vhether they have been suggested by our shareholders or by our directors. Shareholders
who wish to make such a recommendation may do so by sending a written notice, as desc1ibed under the heading "How do I submit a shareholder proposal for
next year's Annual Meeting?" in the section of this Proxy Statement titled "Questions and Answers about the Meeting."

Audit Commillee. The Audit Committee of the Board of Directors (the "Audit Committee") is a standing committee of the Board, which has been
established as required by Section 3(a) of the Exchange Act and the rules of the NYSE. The Audit Committee met five (5) times during 2014. Members of the
Audit Committee during fiscal 2014 and at the date of this Proxy Statement arc Jerry G. McClain, Chairman, Ronald S. Poelman, Gilbert A Fuller, and Robert
Anciaux, each ofwhom meets the independence standards set forth above. The Board has determined that both Mr. McClain and Mr. Fuller are "audit
committee financial experts," as defined by the applicable regulations promulgated by the SEC under the Exchange Act. The Board also believes that each
memberofthc Audit Committee meets the NYSE composition requirements, including the requirements regarding financial literacy. The Audit Committee's
responsibilities include: (i) appointing the independent registered public accounting firm of the Company, (ii) reviewing, approving and monitoring the
scope and cost of any proposed audit and non-audit services that arc provided by, as well as the qualifications and independence of, the independent
registered public accounting firm, (iii) reviewing and monitoring with the independent registered public accounting firn1, and internal audit staff, the results
of audits, any recommendations from the independent registered public accounting finn and the status of management's actions for implementing such
recommendations, as well as the quality and adequacy ofour intcmal financial controls and internal audit stafl: and (iv) reviewing and monitoring the
Company's annual and quarterly financial statements. internal controls and the status of material pending litigation and regulatory proceedings.
Compensation Commiuee. The Compensation Committee of the Board of Directors (the "Compensation Committee") met four (4) times during 2014.
Members of the Compensation Committee during fiscal 2014 and at the date ofthis Proxy Statement are Ronald S. Poelman, Chaimmn, Robert Anciaux, and
Jeny G. McClain, each of whom meets the definition of"independent" set forth in the rules of the NYSE. In addition, all members of the Compensation
Committee are outside directors as defined by Rule I 62(m) of the Internal Revenue Code and are non-employee directors as defined by the applicable
regulations promulgated by the SEC under the Exchange Act. The Compensation Committee's responsibilities include: (i) reviewing and
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recommending to the full Board of Directors the salaries, bonuses. and other fom1s of compensation and benefit plans for management and {ii) administering
USANA's equity compensation plans. The duties of the Compensation Committee as the administrator of those plans include, but arc not limited to,
dcte1mining those persons who arc eligible to receive awards. establishing lenns nfall awards, authorizing ofliccrs nfthc Company to execute grants of
awards, and interpreting the provisions of the equity compensation plans and grnnts that arc made under those plans. The Compens;ition Commit1ce is also
responsible for reviewing and approving the Compensation Discussion and Analysis included in this Proxy Statement.
Risk Oversight a11d Mu11ageme11t

Our Board of Directors is actively involved in the oversight and management oft he material 1isks that could a fleet the Company. Historically, our Board
of Directors has carried out its risk oversight and management responsibilities by both monitoring risk directly as a full board and, where appropriate, through
Rnanl c.ommittrr.s The Ro:ir<l's din~cl role in our 1isk man:igemrnt process inchulcs receiving ree11l:ir reports from nnr executive ofliccrs and other memhers of
senior management on areas of material risk to the Company. including operational. strategic, financial, legal and regulatory risks. The Board has ddegaled
much of its direct risk oversight and management responsibility to the Governance Committee. The mandate of the Governance Committee with respect to
risk management is to work with management to carry-out an etlicicnt process for assessing and reporting material risk to the Governance Committee and,
ultimately, the Board.
The Board has also historically delegated the oversight and management of certain risks to the Audit Committee and Compensation Committee. The
Audit Committee is responsible for the oversight of Company 1isks relating to accounting matters, financial and internal control rcpo11ing and related party
tmnsactions. To satisfy these oversight responsibilities, the Audit Committee regularly meets with and receives reports from the Company's Chief Financial
Officer, Executive Director of internal audit, the Company's independent registered public accounting fim1, KPMG LLP. and the Company's in-house and
outside legal counsel. The Audit Committee is also responsible for discussing with management, our independent registered public accounting firm and the
chair of the Governance Committee, the areas of1isk management overseen by the Govemance Committee.
The Compensation Committee is responsible for the oversight of risk relating to the Company's compensation and benefits programs. To satisfy these
oversight responsibilities, the Compensation Committee regularly meets with and receives reports from the Company's Chief Executive Officer and Chief
Financial Officer to understand the financial, human resources and shareholder implications of compensation and benefits decisions.

Compensation Risk A11u/ysis
Our Compensation Commitlce considers the risk to the Company associated with each component of our executive compensation program, namely base
salary, and short-and-long term incentive compensation. In conside1ing these risks, the Compensation Committee believes that the following factors, among
others, reduce the likelihood of excessive risk taking in connection with executive compensation at USANA:
Our compensation components provide a balanced mix of(i) cash and equity compensation, (ii) short-term and long-te1m incentive
compensation, and (iii) financial and non-financial performance metrics;
Our executives generally all participate in the same short-term incentive program with similar perfom1ance metrics;
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Maximum pay-oul levels for short-tcnn incentive compensation an: generally capped at I 00% of an executive's base salary;
Our equity awards generally vest over several years and arc only valuable if the Company perfom1s well financially and our stock p1icc
increases over lime;
We maintain strict internal controls overthe determination and pay-out of each cornponcnl of executive compensation;
We do not typically enter inlo employment, severance or other management agreements with any of our executive ollicers that contain pos1tem1ination or change-in-control payments; and
We generally do not provide significant perquisites or personal benefits lo our executive oflicers.
Based on the Compensation Committee's review of these factors and others, the Committee docs 1101 believe that the Company's executive compensation
program creates risks that are reasonably likely to have a material adverse effect on the Company.

B,,an/ Committee Charters
A written charter has been adopted for each of the Audit Committee, Compensation Committee and Governance. Risk and Nominating Committee.
Copies of the Audit Committee Charter, Compensation Committee Charter, and Governance, Risk and Nominating Committee Charter are available, free of
charge, on the Company's website al www.usa11ahealt/rscicnces.com under the "Co1porate Governance" lab. The info1mation contained on the website is not
incorporated by reference in, or considered part of, this Proxy Statement.

Corporate Govemance Guide/foes
TI1e Company has adopted Corporate Governance Guidelines that outline the Company's corporate governance policies and p1inciples. The Company's
Corporate Governance Guidelines arc available, free of charge, on the Company's website at www.11sa11a/realthscie11ces.com under the "Corporate
Governance" tab. The information contained on the website is not incorporated by reference in, or considered part of, this Proxy Statement.

Code of Ethics
We have adopted a code of ethics that applies to all of our directors, officers (including our Chief Executive Olliccr and Chief Financial and Accounting
Officer), and employees. We require that all ofour directors, officers and employees certify on an annual basis that they are in compliance with the code. A
copy of the Code of Ethics for Directors and Employees is available on the corporate governance section of our web site at www.usa11a/realthsciences.com. In
the event the Company makes any amendments to, or grants any waivers of, a provision of its code of ethics that applies to the principal executive officer,
principal financial officer or principal accounting officer of the Company that requires disclosure under applicable SEC rules, the Company intends to
disclose such amendment or waiver and the reasons therefor on a Current Report on Form 8-K or on its next periodic report filed under the Exchange Act.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

The Compensation Committee during fiscal 2014 was composed of Ronald S. Poelman, Chairman, Robert Anciaux and Jerry G. McClain. All members of
the Compensation Committee are independent directors. During the fiscal 2014, there were no relationships or transactions between the Company and any
member of the Compensation Committee requiring disclosure hereunder.
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EXECUTIVE OFFICERS
The executive officers ofUSANA at January 3, 2015, and as of the date of this Proxy Statement were:
Position

Name

Myron W. Wentz,
Ph.D.
David A. Wentz
Paul A. Jones
Kevin G. Guest
Deborah Woo
James H. Bramble
Jim Brown
Daniel A. Macuga
Doug Braun
Rick Stambaugh

Chairman of the Board
ChiefExccutive Officer
Chief Financial Officer
President, USANA Health Sciences, Inc.
President, Asia and Greater China
Chief Legal Officer
Chief Operating Ofliccr
Chief Communications Officer and Executive Vice President of Field Development for
the Americas
Chief Marketing Olliccr
Chieflnfonnation Officer

Biographical infon11ation for Myron W. Wentz is included above with the other nominees for director. The following infom1ation is provided for each of
our other executive officers.

David A. Wentz, 44, Chief Executive Officer. Mr. Wentz joined USANA as a part-time employee in 1992. He has been a full-time employee since March
1994. From J 993 until April 2004, he was a member of the Company's Board of Directors. Mr. Wentz was appointed Chief Executive Officer in July 2008. He
served as President from July 2002 to July 2008 and previously served as the Company's Executive Vice President from October 200 I to July 2002. He
served as the Company's Senior Vice President of Strategic Development from June 1999 to October 200 I, and as the Company's Vice President of Strategic
Development from August 1996 to June 1999. Mr. Wentz received a 8.S. in Bioengineering from the University of California, San Diego. Mr. Wentz is the
son of Dr. Wentz. who is the founder of the Company and Chai,man of the Company's Board of Directors.
Paul A. Jones, 51, ChiefFinancial Officer. Mr. Jones joined USANA in 2005 as Vice President of Human Resources and served in this role until June
2007. when he left to complete a three year service mission. Mr. Jones returned 10 USANA as Vice President of Human Resources in July 20 IO and served in
this role until December 2012, when he was appointed ChiefFinancial Officer. Prior to joining USANA, Mr. Jones was employed as Vice President of Human
Resources and later as Vice President of Operations for Associated Food Stores, Inc. Mr. Jones received a B.S. in finance from Utah State University and a
m.istcr of arts in organizational management from the University of Phoenix. Mr. Jones is also a Certified Management Accountant.
Kevin G. Guest, 52, President, USANA Health Sciences, Inc. Mr. Guest joined USANA on a part-time basis in April 2003, as Executive DirectorofMcdia
and Events. Following the Company's acquisition of FMG Productions, a media, video, and event productions company that was founded by Mr. Guest, he
became a full-time employee of the Company and was promoted to Vice President of Media and Events in February 2004. In January 2006, he was appointed
as the Company's Executive Vice President ofMarketing and served in that role until July 2008, when he was appointed Chief Marketing Officer. Mr. Guest
served in this role until May 2011, when he was appointed as President of North America. In October 2012, he was appointed as President of the Americas,
Europe and South Pacific. In August 2014, Mr. Guest became the President of the Company. Prior to joining USANA full-time, from 1992 to February 2004,
Mr. Guest served as the Managing Partner ofFMG Productions. Mr. Guest earned a B.A. in Communications from Brigham Young University.
Deborah Woo, 61, President of Asia and Greater China. Mrs. Woo joined USANA as General Manager ofUSANA Hong Kong in 1999 and served in that
role until 2003. In 2003, she was promoted
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to Regional General Manager and became responsible for the Hong Kong, Taiwan, and Singapore markets. Mrs. Woo was subsequently promoted to Vice
President of Greater China and East Asia in 2005. As a result ofUSANA's strategic regional alignment in 2007, Mrs. Woo was appointed as Vice President of
Greater China and North Asia. In 2008, Mrs. Woo was promoted to Executive Vice President of Asia. In February 20 I 0, Mrs. Woo was promoted to Executive
Vice President of Sales and served in this role until May 2011, when she was appointed President of Asia Pacific. In October 2012, she was appointed
President of Asia and Greater China. Mrs. Woo entered the direct selling industry in 1990 as a Disuibutor Relations Manager for Amway Hong Kong. She
later became Director of Sales for Caring International (Hong Kong) Limited in 1996 where she headed up multi functional teams in operations. distributor
relations, and marketing.

James H. Bramble, 45, Chief Legal Officer and Corporate Secretary. Mr. Bramble joined USANA in March 1998 10 manage the Compliance and Legal
Departments. In April 2006 he was appointed Vice President and General Counsel. In July 2008, Mr. 13ramble was also appointed Corporate Secretary, and
served in these roles until May 2011, when he was appointed Chief Legal Officer and Corporate Secretary. Prior to joining USANA, Mr. Bramble was
employed with Novus Services. Mr. Bramble received a B.S. in political science with a minor in Spanish from the Universi1y ofU1ah in Salt Lake City, Utah.
He received his J.D from the SJ. Quinney College of Law at the University ofUtah.
Jim Brown, 46, Chief Operating Oflicer. Mr. Brown joined USANA in 2006 as Vice President of Operations. In July 2011, he was appointed Vice
President of Global Operations and seived in that role until July 2012, when he was appointed Chief Production Ollicer. He seived in 1hat role until
November 2013 when he was appointed Chief Operating Officer. Prior to joining USANA, Mr. Brown was previously employed at Sonoco as a plant manager
where he was responsible for safety, quality, finance, production, and maintenance. Mr. Brown received a bachelor's degree with a double major in computer
science and math as well as an M.B.A. from Francis Marion University in Florence, South Carolina.

Daniel A. Macuga, .Jr., 45, Chief Communications Officer and Executive Vice President of Field Development for the Americas. Mr. Macugajoined
USANA in 2007 as Vice President of Network Development and Public Relations. In July 2008, he was appointed as Vice President of Marketing, Public
Relations and Social Media and served in that role until December 2011, when he was appointed Chief Communications Officer. He served in that role until
February 2014 when he was appointed Chief Communications Officer and Executive Vice President of Field Development for the Americas. Prior to joining
USANA, Mr. Macuga was employed at the Chrysler Corporation, where he spenl 15 years working closely with independent dealership entrepreneurs to help
them build their businesses, increase awareness for their products, and keep !hem focused on effective customer relationship management. Mr. Macuga
received a B.A. in communications from the University ofCalifomia, San Diego.
Doug Braun, 53, Chief Marketing Officer. Mr. Braun joined USANA as Vice President of Marketing in December 2011. He seivcd in this capacity until
March 2012, when he was appointed as Vice President of Marketing and Recognition and served in that role until July 2012, when he was appointed Chief
Marketing Officer. Mr. Braun brings 20 years of direct selling experience to USANA. Priorto joining USANA. Mr. Braun was self-employed in 2011 and
served as temporary chief executive oflicer of GrowLife, Inc. from May 2011 to September 2011. Prior to that he was president ofNikken International, Inc.
from December 2008 to January 2011, vice president of sales & marketing ofNikken International. Inc. from July 2007 to November 2008 and vice president
of marketing ofNikken International, Inc. from July 2005 to June 2007. Prior to that. he served as vice president of marketing ofFionda, LLC, and senior vice
president of global marketing at Herbalife International, Inc. where Mr. Braun spent ten years. He has a BBA from the University of Cincinnati and an MBA
from Xavier University.

15

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table of Contents
Rick Stambaugh, 54, Chief Jnfommtion Officer. Mr. Stambaugh joined USANA as Executive Director of Digital Marketing in September 2013. He
served in that capacity until December 2013, when he was appointed as Chief lnfom1ation Officer. Mr. Stambaugh brings more than 30 years of direct selling
cxpe1ience 10 USANA. Priortn jninine USA NA, Mr. S1ambaugh wa~ the President and CEO ofTekVation, LLC from May 20 I 2 to Septemberof2013. P1iorto
that, he served as President and CEO of The Fionda Group Companies. LLC from June 2004 to May 2012. President from January 2002 to June 2004. and
Executive Vice President from Januaiy 2000 10 January 2002. P1ior to that, he se1vcd as Director of Corporate Marketing at He1balifo International.
Mr. Stambaugh attended the University ofNebraska. Omaha. and majored in education.

EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
hrtrod11ction

The following Compensation Discussion and Analysis desciibes the material elements of the compensation and benefit programs for our Chief Executive
Ollicer, Chief Financial Officer, and the three other most highly-compensated executive officers as of the end of fiscal year 20 I 4. In this Proxy Statement, we
refer to these officers as our "Named Executive Olliccrs." Our Named Executive Officers arc also referred lo herein individually as an "Executive" and
collectively as "Executives".
Execmive Summary and Overview
Summary of 10 I 4 Accomplish111e11/s. Fiscal 2014 was an exceptional year for USANA. From a financial perspective. we delivered our 12'h consecutive
year of record net sales, as well as our highest annual earnings-per-share in the history of the Company. These results were driven by a number of
accomplishments during the year, including our achievement of more than 31 % growth in the number of Active Associates who use and sell our products
around the world. We ended the 2014 fiscal year with a record 349,000 Active A,;sociates and 81,000 Preferred Customers worldwide. Associate and customer
growth is our highest priority as we continue to focus on improving the overall health and nutrition of individuals and families around the world.

In 2014, we continued to sec our business accelerate through improvement in a number of metrics that we use to evaluate the strength of our business.
These metrics include Auto Order sales, world-wide unit volume, the number of Associate check earners and Associate rank advancements. At the end of
fiscal 2014, Auto Orders made up 48.3% ofour total product volume, compared to 41.7% at the end of fiscal 2013. Our Auto Order program is a key part of
our operating strategy, as it has been shown to increase the success and longevity of a USANA customer. We also continued to see solid growth in our worldwide unit volume, the number of Associate check earners, and Associate rank advancements-all of which are essential to o_ur business.
In 2014, we also continued to sec our business grow in China. Specifically, annual net sales in China increased over 103% on a year-over year basis and
the number of Active Associates increased over 94%. We also made significant progress during the year on the construction of our new state-of-the-art
production facility in Beijing, as well as the renovation and improvement of our branch service center locations throughout China.
Finally, in 2014 we completed essentially all pre-market planning and preparations to open a new market in 2015. We have announced that this market
will be in our South East Asia Pacific Region and we will open it during the latter part of 2015.
Overview o_f Compensation Program. We believe that our Executives and employees, as well as the compensation programs that incent them, arc key
factors in driving our strong financial and operational pcrfonnance. Our executive compensation program is designed to provide a competitive and internally
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equitable compensation and benefits package. We also strive to ensure that our executive compensation program reflects a pay-for-pcrfonnance philosophy
and promotes Executive motivation and retention.
Our executive compensation program includes base salal)'. shon-tenn incentive compensation (in the fonn of a cash bonus). and long-tenn incentive
compensation (in the form of equity awards). Sho11-te11n incentive compensation is perfo1mance-based and designed to motivate our Executives to achieve
annual financial and non-financial perfonnance objectives. To minimize potential risk. the potential for shon-te1m incentive compensation is typically
capped at I 00% of an Executive's base salary. Long-tenn incentive compensation utilizes equity awards, which vest over several years. These awards reward
the Executive for sustainable Company perfonnance and align the financial interests of our Executives with those of our shareholders.
Other than as described above, we typically do not provide benefits to our Executives that arc different from or in addition to those that are provided to
our general employees. Additionally, we typically do not enter into pre-ammged severance agreements or contracts with our Executives that contain posttermination or change-in-control payment provisions, or provide significant perquisites or personal benefits to our Executives.

Compensation Philosophy and Objectives
The Company's compensation philosophy, as approved by the Compensation Committee, is to establish and maintain executive compensation programs
that arc designed to accomplish the following objectives:
To attract and retain, through a fair and competitive compensation plan, Executives who have the intelligence, education, and experience that
is required to effectively administer the affairs of the Company;
To motivate our Executives to achieve ce11ain financial and non-financial performance objectives for the benefit of our shareholders by tying
components of their total compensation to individual and Company performance; and
To ensure that compensation practices do not impair USANA's financial strength or future success.
The Compensation Committee intends to meet these objectives by utilizing and maintaining a balance among three major components of compensation:
base salary, short-term incentive compensation (cash bonus). and long-tcnn incentive compensation (in the form of equity awards). The Committee believes
that these three components provide the appropriate framework to attract, retain and motivate our Executives, and align a significant ponion of executive
compensation with sho11-and long-tenn pe1fo1mancc objectives that drive shareholder value. As shown in the compensation tables following this report, our
Executives do not currently receive retirement benefits, pre-dete1mined severance arrangements, deferred compensation opportunities. or other perquisites
that are commonly provided to executives of similarly sized companies.

Role of Compe11sation Committee
Our executive compensation philosophy and practice has been developed through a collaborative effort of the Compensation Committee, the CEO, and
the CFO. While these officers offer ideas, opinions, and proposals in Compensation Committee meetings, the Compensation Committee functions and votes
independently from these officers. The Compensation Committee is responsible for all changes to the executive compensation philosophy and program. The
Compensation Committee consists of three members ofUSANA's Board of Directors, all of whom arc "independent" under the rules of the NYSE. These
members are appointed to the Compensation Committee by the Board of Directors.
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The Compensation Committee acts under a \Vlitten charter, which outlines the commince's authority and responsibilities.

R'1le of Corpontte Le11Clership i11 Assisti11g C11mpe11satio11 C'1mmittee
The Compensation Committee has the prima1y authority to dete1mine the Company's compensation philosophy and to establish compensation for the
Company's Named Executive Officers. It is responsible for ensuring that executive compensation decisions are thoroughly researched and implemented. All
of the Company's Executives and employees participate in an annual performance review with their immediate supctvisor, during which the Executive or
employee receives input about his or her perfom1ance and contributions to the Company's results for the period being assessed. The Compensation
Committee seeks input from the Company's CEO and CFO to identify key factors and to obtain information that is related to executive compensation. These
key factors and information generally involve the individual Executive's level of responsibility, his or her years of experience, his or her current overall
compensation level in relation to external market studies and internal equity analysis between executives, the impact of current compensation practices on
the Company's finaneiai statements. and the rciationship between executive compensation and performance of the Company.
The Company's CFO takes direction from and makes suggestions to the Chainnan of the Compensation Committee in establishing the quarterly
committee meeting agenda and in preparing the materials to be presented to the Compensation Committee. These matetials contain minutes from prior
meetings, key items to be addressed, and background info1mation to help the Compensation Committee in its decision-making process.

Compe11sation Cons11/ta11ts
During 2014, the Compensation Committee did not engage or consult with a compensation consultant in connection with rendering decisions on 2014
Executive compensation. The Compensation Committee utilized the following materials, along with other resources and tools, to render compensation
decisions for 2014: (i) surveys and reports of executive compensation paid by public companies, with charactetistics similar to USANA, on a national basis;
and (ii) surveys from Mercer, ERi, U.S. Direct Selling Association, and Western Management Group of executive compensation paid by certain of the
Company's direct competitors, consisting of both public and p1ivatc companies, on a local and national basis. These materials and resources help provide
solid benchmarks for each component of our executive compensation as well as a general understanding of the total compensation offered by companies in
our industry who arc competing for top talent.
In late 2014, the Compensation Committee retained Frederic W. Cook & Co., or FWC, as its independent compensation consultant to assist the
committee in reviewing our executive compensation program, to provide compensation data and alternatives to the committee, and lo provide advice to the
committee as requested. FWC does not perfom1 any work for the Company outside of the services it perfmms for the Compensation Committee. The
Compensation Committee will consider the compensation data and alternatives provided by FWC to analyze compensation decisions in 2015 and beyond.
including setting annual base salary compensation, short-tenn incentive compensation and long-term incentive compensation for our Executives.
As a basis for the market data provided to the Compensation Committee, FWC utilized compensation data from a group of22 peer companies set 0111
below. These companies are all within a reasonable range of the Company's revenue, operating income, and market capitalization. As of the date of our 2014
fiscal year-end, we were at or near the median of the peer group with respect to revenue, operating income and market capitalization. This information was
gathered and analyzed forthe 25th, 50th and 75th percentiles for annual salary, short-term incentive pay elements and long-term incentive pay elements.
Where possible, our Executives were matched to appropriate proxy and survey
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positions based on job duties and level of responsibility. The peer group infom1ation and other data provided by FWC are among several factors that the
Compensation Committee will utilize in making compensation decisions in 2015 and beyond. The following companies \Vere included in the 2014 peer
group.
Blyth, Inc.
Coty, Inc.
Elizabeth Arden, Inc.
GNC Holdings, Inc.
The Hain Celestial Group, Inc.
Herbalifc, Ltd.
International Flavors and Fragrances Inc.
Inter Parfums, Inc.
Life Vantage Corporation
Mannatech, Incorporated
Naturnl Health Trends Corp.

Nature's Sunshine Products, lnco1poratcd
Nu Skin Enterprises, Inc.
Nutraceutical International Corporntion
Nut,iSystem Inc.
Penigo Company pie
Prestige Brands Holdings, Inc.
Prime,ica, Inc.
Revlon, Inc.
Tupperware Brands Corporation
Vitamin Shoppe, Inc.
Weight Watchers International, Inc.

Cnmp011ents of Cnmpe11satinn

Base Salary
Base salary represents the fixed component of executive compensation. It is designed to compensate our Executives fairly and competitively at levels
necessary to attract, retain and motivate qualified executives in our indust1y. Consistent with this philosophy, the Compensation Committee, on an annual
basis, evaluates our Executives' base salaries. The Committee asks for input and recommendations from the CEO and CFO and then considers (i) the
Executive's scope ofrcsponsibilities, maturity in role, demonstrated level of perfom1ancc, accomplishments and contributions to the Company; (ii) the
performance ofUSANA, both financially and operationally; (iii) current market data and salary levels for each Executive's particular position; and (iv) the
total compensation paid to each Executive. The Committee then renders a decision for each Executive's base salary based on the total mix of the foregoing
infom1ation.
As part of its 2014 Executive compensation evaluation, the Compensation Committee, after reviewing the infonnation outlined above, approved the
Named Executive Officers' base salaries from July 2014 through June 2015 as follows:
2013 - 2014
t::nculivr

~

DavidA.
;
Wentz
Kevin G.
Guest
Deborah
Woo
Paul A.
Jones
JamesH•.
Bramble

:chiefExecutive·0fficer·
President, USANA Health
Sciences, Inc.

~sident ofAsia and dreatetChina< , .:
ChiefFinancial Officer

Chief Legal Officer

2014 - 201$ Base

Base
Salary (S)

Appointed Office

Salary (S)*

$

575,000 · s

300,000

$

583,495

600,000

.· $
$
:·$·:

$

..,'..:sso.31s.:·.-s ..
320,000 $
37;1~527

s·

',580~78
340,000
382,673-

For 2014-2015, Mr. Wentz informed the Compensation Committee that, pursuant to his discussions with and approval from the Board
of Directors, he would be reducing his time in the office to spend more time with his family from August 2014 through August 2015.
Mr. Wentz also infonned the committee that, notwithstanding his reduced time in the office, he would continue to work on several
strategic initiatives for the Company, as well as attend several significant events with the Company's Associate sales force. In light of
these factors, Mr. Wentz recommended that the Compensation Committee reduce his base salary to $300,000 for 20I4-2015. The
Compensation Committee agreed with Mr. Wentz's recommendation and reduced his base salary. With respect to Mr. Guest, the
Compensation Committee adjusted his base salary in August 2014 for 2014-2015 in

19

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table of Contents
connection with his promotion to President ofUSANA and authorized a quarterly cash bonus to Mr. Guest of$25,000 for the period of
time that Mr. Wentz is reducing his time in the office. With respect to Ms. Woo, Mr. Jones and Mr. Bramble, the Compensation
Committee set each Executive's base sala1y for 2014-2015 following its evaluation of all of the factors sci 0111 in (i) through (iv) in the
paragraph above.
The actual base salaries paid to our Named ExecUlivc Officers during the year ended January 3, 2015 arc reflected in column (c) of the Summary
Compensation Table of this Proxy Statement.

Ntm-Eq11itv lnc:e11tive Plan C,111,pe11satitm
We offer our Named Executive Officers non-equity incentive plan compensation in the fonn ofa cash bonus that is based on USANA's
achievement of certain financial and non-financial perfonnance objectives during the applicable year. Cash bonuses are based on a percentage of the
Executive's base salary. Each year, the Compensation Committee sets the range of the cash bonus for which each Executive is eligible and sets the
performance objectives on which cash bonuses for that year will be based.
2014 No11-Equily /ncenlive Plan
For 2014, the Compensation Committee approved the 2014 Executive Bonus Plan (the "2014 Bonus Plan"), which was based on growth in net
soles and profitability. The Compensation Committee approved this single financial perfonnancc objective to: (i) focus the Cu111pa11y's Exc1.:utivcs 011
growing net sales in 2014 without sacrificing profitability; (ii) continue 10 align the bonus opportunity under the 2014 Bonus Plan for all Executives
to promote intemal equity; (iii) foster teamwork among markets and Executives; and (iv) also align the 2014 Bonus Plan offered to Executives with
the profit sharing plan oflcred to all other employees of the Company.
Under the 2014 Bonus Plan, 9% of the Company's adjusted operating profits, which exceed I 0% of net sales, were to be paid to Executives in the
form of a cash bonus. For purposes of the 2014 Bonus Plan, the tenn "adjusted operating profit" is calculated as (i) the Company's earnings from
operations, plus (ii) positive adjustments to earnings from operations for Executive and employee bonus accruals and equity compensation expense.
Payments under the 2014 Bonus Plan were dist1ibuted as an equal percent of the Executive's base salary.
Underthe 2014 Bonus Plan, Executives were eligible to receive a cash bonus of between zero and I 00% of their base salary, depending on the
pcrfom1ance of the Company under the criteria of the plan. Each Executive's target bonus percentage under the 2014 Bonus Plan was 50% of the
Executive's base salary.
2014 Executive Bonus Plan Payout
Shortly after the end of fiscal 2014, the Compensation Committee reviewed the foregoing performance objectives and evaluated the actual
performance delivered by the Company under the 2014 Bonus Plan. The Compensation Committee determined that the Company delivered excellent
financial and operating performance in 2014 and, in particular, noted that the Company:
Achieved 2014 net sales of$790.5 million, which is a I 0.1 % increase compared to fiscal 2013;
Achieved 2014 adjusted operating profit of$138.l million; and
Achieved 2014 adjusted operating profit in excess of l 0% of net sales of$59 million.
Based on the Company's perfonnance, and the criteria of the 2014 Bonus Plan, the Compensation Committee detennined that each Executive had earned
a cash bonus equal to 46.9% of the Executive's base salary under the 2014 Bonus Plan. Consequently, the committee awarded this bonus amount to
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each Executive. The actual cash bonuses paid to our Named Executive Ollicers under the 2014 Bonus Plan are reflected in column (g) of the Summary
Compensation Table of this Proxy Statement.

2015 Executive Bonus Plan
For 2015, the Compensation Committee approved the 2015 Executive Bonus Plan (the "2015 Bonus Plan"). which is based on the same perfonnance
objectives as the 2014 Bonus Plan: growth in net sales and profitability. As part of its determination to again utilize this bonus criteria and stmcture, the
committee noted: (i) the strong operating results delivered by the Executives and the Company in 2014; (ii) the successful alignment of the Company's
Executives under the 2014 Bonus Plan, and (iii) the intemal equity among Executives that was created by the 2014 Bonus Plan.
Under the 2015 Bonus Plan, 9% of the Company's adjusted operating profits, which exceed I 0% of net sales. will again be paid to Executives in the form
of a cash bonus. Payments under the 2015 Bonus Plan will be distributed as an equal percent of the Executive's base salary. Under the 2015 Bonus Plan,
Executives will be eligible to receive a cash bonus of between zero and I 00% of their base salary, depending on the perfonnance of the Company underthe
criteria of the plan. Each Executive's target bonus percentage under the 2015 Bonus Plan is 50% of the Executive's base salary. Future estimated payouts
under the 2015 Bonus Plan arc reflected in the Grants of Plan-Based Awards table of this Proxy Statement.

E,1uitv Comne11sation
Equity compensation is an integral part ofUSANA's compensation philosophy. We believe that equity grants that vest over a period of years tie a portion
of our Executives' compensation to the Company's long-term performance and. thereby. align the interests of our Executives with the interests of our
shareholders. Our equity compensation program delivers compensation to Executives only when the Company pe1fonns and the value of the Company's
stock increases. USANA provides equity-based compensation primarily through the issuance of Stock-Settled Stock Appreciation Rights ("SSARs"). Grants of
equity awards are made for both Executives and other eligible employees at regular Compensation Committee meetings and at special meetings, as needed.
The Compensation Committee's philosophy has been to issue intermittent SSAR awards to Executives to drive long-1e1m Company perfonnance as well
as individual Executive performance. In general SSAR awards arc granted to Executives as they enter into a qualifying position and vest annually in equal
installments over a five-year period. Additional grants arc awarded to Executives as seen necessaiy by the Compensation Committee to maintain sufficient
long term incentive to accomplish the objectives outlined above. These additional grants typically do not vest in the first two years, but only at the end of
years three, four and five, and such vesting for a particular Executive commences when the vesting schedule of that Executive's particular SSAR award ends.
The grant p1ice for equity awards is the fair market value of the award as of the date of grant as detc1mined by the closing price of the Company's common
stock on the date of grant.
In 2014, the Compensation Committee issued SSAR awards to the Named Executive Officers as detailed in the Outstanding Equity Awards At Fiscal
Year-End Table of this Proxy Statement. The 2014 awards sequentially follow the Company's last broad SSAR award issuance in 2010. After the 2010 awards
complete vesting and expire in 2015, the 2014 awards will begin to vest in 2016.

Other Compe11salion
Other than as described above, USANA does not at this time provide benefits to its Named Executive Officers that arc different from or in addition to
those that are provided to its general employees. Those benefits are described below.
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Retirement: Exccu1ives may pai1icipale in Company sponsored 40l(k) retirement plans on the same terms and conditions, including Company
matching provisions. as other employees. For the year ended January 3, 2015, we contributed matching funds totaling $1,302,741 to our 40 I (k) plan in
which all eligible employee pa1ticipants shared. During 2014, each of our eligible Executives participated in our 40 I (k) plan and shared matching fonds
totaling $72,800. Mrs. Woo is not eligible to participate in our 40 I (k) plan and the Company pays retirement compensation to her, as disclosed in the
Summary Co.mpcnsation Table, pursuant to Hong Kong law. Except as disclosed in this paragraph, we provide no other retirement benefits to our Executives.
Severance: USANA has no pre-arranged severance agreements or contracts with any of our Executives that contain post-tennination or change-incontrol payment provisions. We have, however, provided severance benefits to Executives on a case-by-case basis.

Perquisites: lt is our general practice not to provide significant perquisites or personal benefits to our Executives. The Compensation Committee,
however, retains the discretion 10 consider and award reasonable perquisites or per.,onal hcncfits to Executives as necessary to accomplish the objectives
undcrourcompensation philosophy. In this regard, ii should be noted that we do not currently provide pension ammgements, post-retirement heaith
coverage, or similar benefits for our Executives or employees. In 2014, we paid health, life, and disability insurance premiums on behalf of our Executives, all
on the same tem1s as those that we provide to all of the Company's employees.
l11sura11ce Plans and Other Be11ejits: We provide insurance plans and other benefits to our Executives that arc similar to those plans and benefits that
arc customarily provided to general employees of the Company.
/11tlf:11111ificuliu11: Atticlc VI of our Amended and Restated Articles oflncorporation and Article 5 of our Bylaws provide for indemnification of our
directors, officers, employees, and other agents to the extent and under the circumstances permitted by the Utah Revised Business Corporation Act. We have
entered into agreements with our directors and officers that will require us, among other things, to indemnify them against certain liabilities that may arise by
reason of their status or service as directors or officers to the fullest extent allowed. Insofar as indemnification for liabilities arising under the Securities Act of
1933, as amended (the "Securities Act"), may be pennittcd to directors, officers, or persons controlling us under the foregoing provisions, the SEC has stated
that such indemnification is against public policy, as expressed in the Securities Act, and, therefore, such indemnification provisions may be unenforceable.
Sectio11162fm) Treat111e11t Rerwrdi,,g Performa11ce-Based EquitvAwards
Under Section I 62(m) of the Internal Revenue Code of 1986, us amended ("Section l 62(m)"), a public company is generally denied deductions for
compensation paid to the chief executive officer and the next four most highly compensated executive officers to the extent the compensation for any such
individual exceeds S 1,000,000 for the taxable year. The Company's executive compensation programs arc designed to preserve the deductibility of
compensation payable to executive olliccrs. although deductibility is just one among a number of factors considered in determining appropriate levels or
types of compensation.

The Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act"), required that we include in our proxy statement for the 2014
Annual Meeting of Shareholders (the "2014 Annual Meeting") a non-binding, advisory shareholder vote to approve the compensation ofourNamcd
Executive Officers. At the 2014 Annual Meeting, our shareholders voted for approval of the compensation ofour Named Executive Officers (99% of votes
cast). Historically, the Compensation
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Committee has recommended, and shareholders have approved (67% of votes cast) the Company's detennination to include a shareholder advisory vote on
executive compensation in its fiuurc proxy materials once every three years. The Compensation Committee has affirmed its recommendation to the Board
that this advisory vote be held once eve1y three years and the Board has approved the committee's recommendation. This will be the frequency of such
advisory votes until the next required vote on the frequency of advisory votes on executive compensation, which will occur at the Company's Annual
Meeting of shareholders in 2017, or until the Compensation Committee, or Board ofDirectors, otherwise determines a different frequency for such
shareholder advisory votes.
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REPORT OF THE COMPENSATION COMMITTEE
The Compensation Committee of the Board of Directors has reviewed and discussed the Compensation Discussion and Analysis required by Item 402{b)
of Regulation S~K with management. Based on this review and discussion, the Compensation Committee recommended to the Board that the Compensation
Discussion and Analysis be included in this Proxy Statement.
Respectfully submitted by the members of the Compensation Committee:
Ronald S. Poelman (Chair)
Jcny G. McClain
Robert Anciaux
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SUMMARY COMPENSATION TABLE
The following table summarizes all compensation paid to our Named Executive Ollicers in each of the three most recently completed fiscal years.
(h)

(I)

(e)
(c)

S11lary
(S)
Name and Principal Position Year
(b)

(a)

Myron W. Wentz
Chairman

(d)
Stuck
Bonus Awards
(S)(I)

Option
Awards
(S)(l)

(S)

Change in
Pension Value
and
(g)
Nonqu:dified
Non-Equity
Deferred
(i)
Incentive Plan Compensation All Other
Cumpensi11ion
E11mings Compensation

Total

(S}

(S)

($)(3)

IS)(4)

(j)

2014
:!.OIJ
2012

-S

9,100 S1,715,385
8,575 S 828,704

S1,018.958 S
-S

218,096
289,360

2012 S565.289

-S

284.275

2014 $329,534
2013 $317,688

-s
-s

148,666
153.192

486,045 S

95.396

S1,036.679 S
-S

274,156
318,104

-s
-S

9,100 S1,934,778
8,575 S 910,174

2012 $574,671

-S

288,993

-s

8,575 S 872,239

Deborah Woo(6)
Pn:sidcnt of Asia &
&. Greater China

2014 $583,546
2013 SS7S.0S2
2012 SSSS,651

-S1,027,818 S

271,229
262,696
279,266

-s
-s

-S

87,580 S1,970,173
83.513 S 921,261
76,879 S. 91 l,~02

James H. Bramble
Chief Legal Officer &
Cmporale Sa:rctmy

2014 $376,843
2013 $365,909
2012 SJSS,251

-S 655.677 S

-s

9,100 $1,216,775
8,575 S 573,967
8,575 S 542,476

David A. Wcnt1:
Chief Executive Officer

Paul A. Jonc:s
Chief Fin1111cial Officer

KL-vin G. Gucst(S)
President ofUSANA

2014 $469,231
2013 S530, 769

-

2012 $189,697

-S

2014 $589,843 25,000
2013 $583,495

-

-S

-s

175,155
199.483
178,650

-S

-S

-s
-s

-s
-S
-S

-S

-s

8,575 S 858,139
9,100S 487,300
8.575 S 479,455
8,575 S 779,713

(I)

Consists ofa quarterly cash bonw; ofS25.000 paid to Mr. Guest as our President for additional setVices and rcsponsibililies while the Company's CEO, Mr. Wentz. has reduced
his time in the office from August 2014 through August 201 S.

(2)

Amounts in this column rcflCCI the grant date fair value of stock-settled stock appreciation rights ("SSARs") granted during the year computed in accordance with Financial
Accounting Standards Board Accounting Standards Codification Topic 718. In computing these amounts, the Company ignored the impact of the forfeiture rate relating to setVicc
based vesting conditions. TI1ese amounts do not n:pn:scnt the actuul amounts paid 10 or realized by the Executive for these awards during the applicable fiscal year. Assumptions
used in the calculation ofthc.<e amounts an: included in the Equity Based Comprnsa1ion footnote to the Company's consolidated financial statements that an: included in the
Company's Annual Report on Fonn 10-K for the year ended January 3, 2015.

(3)

Rellccts amounts paid.in fiscal 2015 for pa1onnancc realized in liscal year 2014, under the Company's short-tam incentive plan (cash bonus) discussed in the Compensation
Discussion and Analysis section of this Proxy Statement.

(4)

Reflects employer's matching contribution to the Executive's 401(k) plan, except in the case of the compensation paid 10 Mrs. Woo whicl1 is set out in (5) bdow.

(S)

Until August 2014. Mr. Guest's title was President of the America.<, Europe and South Pacific. He wa.< named President oflhc Company in August 2014.

(6)

Mrs. Woo is our Pn:sidc:111 of Asia & Greater China and resides in Hong Kong. In connection with Mr.;. Woo's ovmca.< employment, column (i) rellects $87,580 paid by the
Company lo Mrs. Woo in 2014 as retirement compensation pur.mant to local law.
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GRANTS OF PLAN-BASED A WARDS
The following table contains infonnation regarding equity awards granted to the Named Executive Officers during the fiscal year ended January 3, 20 l S
and the estimated or targeted payouts under the 20 IS Bonus Plan described in the Compensation Discussion and Analysis section of this Proxy Stalement.
Eslimalcd fulun.- p:.iyouls
under
non-eqully incentive plan
awards(I)

(b)
(c)
(d)
Granl Thrnhold Target
Dale
(S)(I)
(S)

(a)
Name

(i)

1-:s1im;ilrd future payouts
undrr equiry incrnti,•r plan
awards

All
ulhrr
slock

(j)
:1w1mfs: ,\II olhcr
Number option
of
awanls:
shares Number or
of
scc:urilin
(r)
(f)
(g)
(h)
slock or undttlylng
Maximum Thrnhold Targr1 Maximum unils
upliuns
(SJ
(S)
(S)
(S)
(#)
(#)(2)

(1)
(k)
Granl
Exercise
d111e
or base fair nluc
price of
of
option s1ock anti
:nv.irds opliun
($/Sh)
awards
(3)

(S)

Myron W.
Wentz
David A.
57,500

57.f,Z 1.0J8,95S

Sl!,500

57.62 1.036,679

S80.J78

58,000

57.6:? 1.027.818

-Sl91.336 S 382.673

37,000

57 62

WmlZ

NIA

-SISO.000S 300.000

P11ul A.
Jona
Kevin G.

NIA

-$170,000S 340,000

Guest

NIA

-

Debonb
Woo
James II.

NIA

-·s200. Js9 ·s

Bramble NIA

$300,000 S 600.000

<,55,677

(I)

TI1crc is no guar:uuco:l paymcn1 lo our Namal Executive OJlic:as under 1he 2015 Executive Bonus Plan. If the 111inimum pa1ormancc ohjcct1vcs are nor achieved, 1hey will receive
no payout under 1he 2015 Excanivc: Bonus Plan. The amoun1s shown in culumn (ti) rdlc.1 the 1111gc1 payoul. which is 50% of 1hc: fac:anive's base salmy. The amounts shown in
column (c) rdkcl IOO% of the Exca.nivc's ba<c salary. which is 1hc maximum payout 1h:11 can be ob1ai11cd under lhc 2015 Exccu1ivc Ronus Plar1.

(2)

All equity awards granlrd lo lhe Named Exa.-utivc Officers were SSARs and gr.inlcd undct lhc 200(, Equity lnccolivc Award Pl1111. Mr. Jones did nol receive an SSAR awanl in
2014 as a n:sull of awards gr:rnlcd lo him in prior years.

(3)

All Equily Awards gr.inlcd lo the Named Executive om~'Cl'S were gr.inlcd al lhe closing stock price on the date of gram.
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OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
The following table includes certain information with respect to the value of all equity awards previously granted to the Named Executive Officers at the
end of the fiscal year ended Janua,y 3, 2015.
Stock ,\ward,

Option awards

(j)
(i)

(b)
(c)
Number or Number or
s«urilics
stturilics
undrrlying underlying
uncxercistd uneurcistd
options (#) options (#)
enrcis11blc unexercisable

(a)

Name

(d)
Equity
inttnlivc
plan
awards:
Number nr
s«uritin
underlying
unrnrci1>cd
unearned
options (#)

(::)
Number
or
shara
or
units of
stnck
(c)
that
Option
(f)
have
e:u-rcise Option
not
price expiration •·cslcd

(h)
Markel
v:dur
or
1,harcs
or
units
of
stock
th:u
ha•·e
not
,·cstcd

_j!L__ ~ ~ _!!L_

Ec111i1y
inccnli•·c
pl:111
awanh:
Number
of
unramt-d
sharrs,
unit!. or
other
1ii:hts
that havt11111
vrstt-d (II)

E1111ily
incl'ntive
plan
:nvanls:
i\l:nket
or
pay11u1
•·alue of
uneamt'd
shares,
1111irs or
other
1i::hts
that havt'
11111
vrslrd tS)

Myron W.

-S
-S

Wenl2

David A.
30,000

WcnlZ(I)

-

57.500

S 35.47 27-0ct-15
15-Mar-S 57.62
18

Paul A.
Joncs(2)

7,000
Kevin G.
Guest())

Deborah
Woo(l)

'.

....:..
James H.
Bramble(!)

10.200

-S 39.40 26-Jan-16

21.000

-S 38.23 16-Jun-l8

25,250

-S 35.47 27-0ct-15

58,500

-S 57.62

32.000 ·.

- S ·35.47 27-<kt-lS
IS-Mnr•
_; S S7.62
18

58,000
15,000
37,000

15-Mar•
18

-S 35.47 27-0ct-15
IS-Mar-S 57.62
18

(I)

The SSAR srams lo Mr. Wcnt7~ Mr. Guest, Mrs. Woo, and Mr. Rr.uublc which expire on October 27, 201 S. vest 50% in April 2014 and 50% in April 201 S. The SSAR grants to
Mr. Wentz, Mr. Guest, Mrs. Woo, and Mr. Bramble which expire on March 15, 2018. vest 50% in August 2016 and 50% in August 2017.

(2)

The SSAR gr.int lo Mr. Jones. which expires on Janmuy 26. 2016, vcs1s 50¾ in July 201-1 and SO¾
vc::s1s 20°1. annually, bc-i;inning on the fir.-1 annivmary of the date of grant

111

July 2015. The SSAR grJ11I to Mr. Jones, which expires on June 16, 2018.
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OPTION EXERCISES AND STOCK VESTED
The following table summarizes certain infomtation with respect to the awards exercised by the Named Executive Officers during the fiscal year ended
January 3, 2015.
·
Option aw:uds
(b)

Number or
shares
acquired on
cxcrdse (#)

(a)

NRme

N-;fyron"w:-wc~wz:_-,':
David A. Wentz

Paul:A. Jones :

(c)
Value
rcali:r.cd on

cxm:isc (S)

.. :;:~-:~- -. r:::'.'~~Di'06~J~3:;gl~D;$.f2t~~l'.4 ·_·. · ·
22,484 $

1,627,148

12,635 $

897,133

7,895 $

619,950

Stork aw:mls
(cl)
Number or
(c)
V:ilue
sham
acquired on
realized on
vrsling(S)
vesting(#)

·,; ::· :.,:::,;-::,~;}/ . :>_-(QJif:-i$;~?.l!1l~~~10 ·

Kevin G. Guest
Del:!omhWoo.
James H. Bramble

-BJ1s::.:.s'.~•emJli?·tt.::-·.
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COMPENSATION OF DIRECTORS
The table below summarizes the compensation paid by the Company to directors of the Company for the fiscal year ended January 3, 2015, other than
Dr. Wentz, the Company's Chai1man of the Board, whose compensation is included in the Summary Compensation Table and who received no compensation
for his seivices as a director in 2014.

~

(a)

(b)

(I)

fl."tS

Change in
pension value
and
non11ualiliccl
compensi11ion
earnings($)

earned
or paid
in
cash (S)

Name
_(_I)_
Robrrt
Andaui S 126,()00
Jerry G.
McClain S 143.950
Ronald S.
Podman S 150.250
Gilbert A.
Fuller s 133.050

M
(d)
Option

Non-equity
incentive plan
Stock
awards awards (S) compensation
(S)
___J!L_ _(_2)_
(c)

-s

Cg)
All other
compensation
(h)
_ _ _(S..:.)__ Total($)

-

213,2(,4

S 339.864

-S 213,2M

-

S 357,214

-s

213.264

-

S 363.514

-S 213,2"4

-

S 346,314

(I}

Effective July 2014. each 11011-cmployec dircclor receives an annual cash retainer of S88.800. 111c chair of the Company's Audit Commillcc:, which is currently Mr. McClain,
n.'Ccivcs an additional annual ca~h n:taincr nfS17,800. TIie d1air of the Compensation Commillcc, which is currently Mr. Poelman, receives an annual cash retainer of SI 1,000 and
the chair of the Govcmance. Risk and Nominating C'ommittc:c. which is currently Mr. Fuller, receives an annual cash retainer of S6.600. The Board Sccn:tmy, which is currenlly
Mr. Poelman, also n:cdvcs au annual ca.~h retainer of S 13,200. The amounts in column (b) reflect a combination of the rctnincr fee:$ for 2014. The Company also reimbur.;~ all
directors for lhc ou1-of-pocket expenses that lhcy incur in connection with their services as directors. which include tr.ivcl. lodging. and relalcd expense:. from allending conferences
10 continue their education and cxprnisc a.~ directors. as well as participating in meetings of the shareholders, Board of Directors, and committees of the Board.

(2)

Amounts in this column rcllce1 1hc grant da1c fair value of stock-settled stock appreciation rights ("SSARs") computed in accordance with Financial Accounting Standards Board
Accounting Standards Codification Topic 718. In computing these amounts, the Company ignorw lhe impact of the forfeiture rate relating 10 service based vesting comlilions.
These amounts do not n=pn:scnt 1hc actual amounts paid to or realized hy the directors for these awards during the applicable fiscal year. Assumptions used in the calculation of
these amounts are included in the Equity Based Compcnsauon footnote 10 the Company's consolidated financial statements 1ha1 arc included in the Company's Annual Rcpo1t on
Form 10-K for the year ended January 3. 2015.
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SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets fonh certain infonnation regarding the beneficial ownership of our common stock, as of March 2, 2015, by (l) each person
known to be the beneficial owner of more than 5% of the issued and outstanding common stock based upon their most recent filings or correspondence with
the SEC. (2) the Named Executive Officers and the directors ofUSANA individually, and (3) the Named Executive Officers and directors as a group. Except as
indicated in the footnotes below, each of the persons listed below is believed to exercise sole voting and investment power over the shares of common stock
that are listed for such individual or entity in this table.
Number of
Name and Address

Shares(!)

Percent or
Class(?)

Beneficial Owners of More Than 5%

Gt.

Gull Holdings, Ltd.
4 Finch Road
Douglas, Isle of Man

6,498.110

51.3%

FMR LLC(3)
82 Devonshire Street
Boston, MA 02109

1,146,907

9.1%

~

Renaissance Technologies LLC(4)
800 Third Avenue
New York, NY 10022

Directors and Named Executive Officers
Myron W. Wentz, Ph.D.(5)
Chairman of the Board
David A. Wentz,(6)
ChiefExecutive Officer

797,883

6.3%

6,498,110

51.3%

478,591

3.8%

4,35 I

*

Kevin G. Guest(8)
President

16,995

*

Deborah Woo(9)
President ofAsia and Greater China

20,762

*

James H. Bramble(l 0)
Chieflegal Officer

10,354

*

Robe1t Anciaux, Dircctmtl I)

3,626

*

Jerry G. McClain, Dircctor(l 2)

7.166

•

Ronald S. Poelman, Director( 13)

5,702

*

Gilbert A. Fuller, Di.-ector(l4)

1,443

Paul A. Jones(?)
ChicfFinancial Officer

Directors and Officers as a group (10 persons)

7,047.100

Less than one percent.
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( l)

All entries exclude beneficial ownership of shares that are issuable pursuant to options or SSARs that have not vested or that are not
otherwise exercisable as ofthe dale hereof and which will not become vested or exercisable within 60 days of March 2, 2015.

(2)

Percentages are rounded to nearest one-tenth of one percent. Percentages are based on 12,658,6&4 shares outstanding on March 2,
2015. Shares of common stock subjected to options and/or SSARs that are presently exercisable or exercisable within 60 days of
March 2, 2015 are deemed to be beneficially owned by the person holding the options or SSARs for the purpose of computing the
percentage ownership of that person, but are not treated as outstanding forthe purpose of computing the percentage of any other
person.

(3)

Reflects the number of shares held at year-end, as reported on Fonn SC I 3G/ A filed on February 13, 2015.

(4)

Reflects the number of shares held at year-end, as reported on Form SC I 3G/A filed on February 12, 2015.

(5)

Includes 6,498.110 shares held of record by Gull Holdings, Ltd., an Isle of Man company, which is I 00% owned by Dr. Wentz.
Because of his control of Gull Holdings, Ltd, Dr. Wentz is deemed to be the beneficial owner of the shares that are owned of record by
Gull Holdings, Ltd.

(6)

Includes 19,465 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days of March 2, 2015. This share count assumes settlement of this individual's SSAR.s at the closing market price on March 2,
2015. Also includes I 0,361 shares that arc held in the executive's 40 I {k) account and 448,765 shares that arc held of record.

(7)

Includes 4,351 shares that are issuable pursuant to SSAR.s, which are presently exercisable or which become exercisable within
60 days of March 2, 2015. This share count assumes settlement of this individual's SSAR.s at the closing market price on March 2,
2015.

(8)

Includes 16,383 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days ofMarch 2,2015. This share count assumes settlement of this individual's SSARs at the closing market price on March 2,
2015. Also includes 612 shares that arc held in the executive's 40 I (k) account.

(9)

Includes 20.762 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days of March 2, 2015. This share count assumes settlement of this individual's SSAR.s at the closing market price on March 2,
2015.

(I 0)

Includes 9,733 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days of March 2, 2015. This share count assumes settlement of this individual's SSARs at the closing market price on March 2,
2015. Also includes 621 shares that are held in the executive's 40 I (k) account.

(II)

Includes 722 shares that are issuable pursuant to SSARs, which are presently exercisable or which become exercisable within 60 days
of March 2.2015. This share count assumes settlement of this individual's SSARs at the closing market price on March 2, 2015. Also
includes 2,904 shares that arc issuable pursuant to Deferred Stock Units ("DSUs"), which arc presently vested or which become vested
within 60 days ofMarch 2, 2015.

(12)

Includes 1,443 shares that arc issuable pursuant to SSARs, which are presently exercisable or which become exercisable within
60 days of March 2, 2015. This share count assumes settlement of this individual's SSAR.s at the closing market price on March 2,
2015. Also includes 5,723 shares that are issuable pursuant to DSUs. which are presently vested or which become vested within
60 days ofMarch 2, 2015.
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(13)

Includes 1,443 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days ofMarch 2, 2015. This share count assumes seulement of this individual's SSARs at the closing market price on March 2,
2015. Also includes 4.259 shares that arc issuable pursuant to DSUs, which arc presently vested or which become vested within
60 days of March 2, 2015.

(14)

Includes 1,443 shares that are issuable pursuant to SSARs, which arc presently exercisable or which become exercisable within
60 days ofMarch 2, 2015. This share count assumes settlement of this individual's SSARs at the closing market price on March 2,
2015.
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EQUITY COMPENSATION PLAN INFORMATION
The following table sels forth infonnation regarding ou1s1anding awards and shares rcscrvcd for future issuance under our equity compensation plans as
of January 3,2015.

Numbrrofsn:urities to be
issufd upon eurcise of
outstanding awards(I)
(11)

Plan Cal~ory

Equity
compensation
plans approved
by security
holders
Equity
compensation
plans not
approved by
security holders
Total·

Wrightrd-avrragr
cxrrcisr price nf
outstanding awards
(bl

Number nfsn:uritic:s
remaining available for
lulurr isrnaocr under ~uily
l"Umpcnsation plans
(excluding St'curities reOtttcd
in rolumn (a))

l ,568.288(2)$

49.20(3)

7,457,733

None
·l·,568.288(2)$

NIA
49.20(3)

7.457,733

None

(l)

Consists of shares of common stock issuable under the USANA 2006 Equity Incentive Award Plan.

(2)

Includes 12,886 DSUs that will entitle each holder to the issuance of one share of common stock for each unit. Also, includes
1,555,402 SSARs. A SSAR is the right to receive the appreciation in fair market value of common slock between the exercise date and
the date of grant in shares of common stock. Based on the closing stock price of$ I 02.28 on the last trading day of fiscal 2014 and the
exercise price ofSSAR's that were in-the-money. 807,227 shares of common stock would be issued upon the exercise ofthese awards.

(3)

Calculated without taking into account 12,886 shares of common stock subject to outstanding DSU's, which are issuable without any
cash consideration orotherpayment required for such shares.
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PROPOSAL #2-APPROVAL OF THE COMPANY'S 2015
EQUITY INCENTIVE AW ARD PLAN

The Board of Directors has adopted, subject to shareholder approval, the USANA 2015 Equity Incentive Award Plan (the "2015 Plan" or the "Plan"). The
2015 Plan is being adopted in anticipation of the expiration of the Company's 2006 Equity Incentive Award Plan (the "2006 Plan") and will allow us to
continue to provide equity awards to directors, executive officers, employees and consultants in connection with the Company's long-tenn incentive
compensation philosophy. Our directors and Named Executive Officers may have an interest in the approval of the 2015 Plan because they are eligible fur
awards under the 2015 Plan.
If approved by the shareholders at the Annual Meeti~g. the 2015 Plan would govern future grants of stock-based awards ("stock awards") to our
employees, directors, and consultants. This 11roposal will not affect existing equity aw.mis granted nndcrour?.006 Plan. All nurstanding options under the
2006 Plan will remain outstanding, but no further grants will be made under the 2006 Plan if the 2015 Plan is approved. As of March 2, 2015, there were
1,555,402 SSARs and 12,886 DSUs outstanding under the 2006 Plan.
Under the NYSE rules, we are required to obtain shareholder approval of the 2015 Plan. Shareholder approval of the 2015 Plan also will constitute
approval of(i) the perfo1mance criteria upon which perfo1mance-based awards that are intended to be deductible by us under Section I 62(m) of the Internal
Revenue Code of 1986, as amended (the "Code") may be based under the 2015 Plan; (ii) the one-year per participant Ii mil of 500,000 shares of common slock
underlying stock options and stock appreciation rights awards that may be made under the 2015 Plan; (iii) the one-year per pa11icipant limit of 500,000
shares of common stock for awards I hat are intended to be "pcrfonnance-based compensation" under Section I 62(m) of the Code; (iv) the one-year per
participant limit of$3,000,000 for awards that are inlcndcd lo be "performance based compensation" under Section l 62(m) of the Code; and (v) the one-year
per director limit of$500,000 for awards granted to directors under the 2015 Plan.
Shareholders arc requested in this Proposal #2 to approve the 2015 Plan. The affinnativc vote of a majority of the shares cast on this Proposal #2 either
present in person or represented by proxy and entitled to vote at the meeting will be required to approve this Proposal #2. Shares present but not voted
because of abstention will have the same effect on the results of this vote as a vote against. Shares subject to a broker non-vote will not be considered entitled
to vote with respect to this Proposal and will have no effect on the outcome. The Board believes that the adoption of the 2015 Plan is in the best interest of
the Company. The appropriate use of equity awards remains an essential component ofouroverall compensation philosophy. The Board believes that the
2015 Plan is necessary for us to continue to attract and retain well-qualified employees and directors who will contribute to our success. and to provide
incentives to motivate such employees and directors that are directly linked to increases in shareholder value and will therefore benefit all ofour
shareholders.
A summary of the principal features of the 2015 Plan is provided below, but is qualified in its entirety by reference to the full text of the Plan as proposed
to be amended, which is attached as Annex A to this Proxy Statement.
Summary of the 2015 Plan

Administration
The Compensation Committee of the Board of Directors administers the 2015 Plan. The Compensation Committee may delegate to a committee of one or
more members of the Board the authority to grant or amend awards to participants other than senior executives of the Company who are subject to Section 16
of the Exchange Act, or employees who are "covered employees" within the
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meaning of Section I 62(m) of the Code. The Compensation Commillee includes at least two directors, each of whom qualifies as a non-employee director
pursuant to Rule 16b-3 of the Exchange Act, and an "outside director" pursuant to Section I 62(m).
The Compensation Commillec has the exclusive authority to administer the 2015 Plan, including the power to dctennine eligibility, the types and sizes
of awards, the price and timing of awards and the acceleration or waiver of any vesting restriction, provided that the Compensation Committee does not have
the authority to accelerate vesting or waive the forfeiture of any perfo1mance-based awards.
Eligibility
Persons eligible to participate in the 2015 Plan include non-employee members of the Board, consultants to the Company, and all of the employees of
the Company (including executive otliccrs) and its subsidiaries. as dctennined by the Compensation Committee.
Li111itutio11 on A wurds um/ Shares A vuiluble

If approved by the shareholders at the Annual Meeting, the maximum number of shares of common stock available for issuance under the 2015 Plan is
5,000,000 (the "Available Shares"). The Available Shares, however, will be made up entirely of shares that were previously made available under the
Company's 2006 Equity Incentive Award Plan and not utilized. As such, the Company will not allocate any additional authorized but unissued shares of
common stock to fund the Available Shares under the 2015 Plan.
To the extent that an award tcnninates, expires or lapses for any reason, any shares subject to the award may be used again for new grants under the 2015
Plan. In addition, shares tendered or withheld to satisfy the grant or exercise p1ice or any tax withholding obligation may be used for grants under the 2015
Plan. Shares issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any fo1m of combination by the Company or any
of its subsidiaries will not be counted against the shares available for issuance under the 2015 Plan. Notwithstanding the foregoing, no shares will become
available (a) upon the cancellation of existing awards or any similar transactions following the 10 th anniversary of shareholder approval of the 2015 Plan or
(b) if the return of shares would require additional shareholder appmval of the 2015 Plan pursuant to applicable rules of the NYSE. The shares of common
stock covered by the 2015 Plan may be authorized but unissued shares, or shares purchased in the open market.

Awards
The 2015 Plan provides for the grant of incentive stock options and nonqualificd stock options, restricted stock, stock appreciation rights, perfo1mancc
shares, perfotmance stock units, dividend equivalents, stock payments, deferred stock. restricted stock units, other stock-based awards and performance-based
awards. The Compensation Committee has the discretion to detennine the types and amounts of awards that will be granted to specific individuals pursuant
to the 2015 Plan.
Stock options, including incentive stock options, as defined under Section 422 of the Code, and nonqualified stock options may be granted pursuant to
the 2015 Plan. The option exercise price of all stock options granted pursuant to the 2015 Plan will be at least I 00% of the fair market value of the common
stock on the date of grant. Stock options may be exercised as detennined by the Compensation Committee, but in no event earlier than six months after the
date of grant or after the I 0 th anniversary of the date of gr.int. The aggregate fair market value of the shares with respect to which options intended to be
incentive stock options arc exercisable for the first time by an employee in any calendar year may not exceed $100,000, or such other amount as the Code
provides.
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Upon the exercise ofa s1ock oplion, the purchase price musl be paid in full in either cash or i1s equivalent, by delivering a promissory note bearing
interest at no less than such rate as shall 1hen preclude 1hc imputation of interest under lhe Code, or by tendering previously acquired shares of common stock
with a fair market value at the lime of exercise equal 10 the exercise price or other propcny acceptable to the Compensation Committee (including lhmugh
the delivery of a notice that the participant has placed a market sell order with a broker with respect to shares then issuable upon exercise of the option, and
tha1 the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction oft he option exercise price,
provided that payment of such proceeds is then made lo the Company upon setllement of such sale). However, no participant who is a member of the Board or
an executive officer of the Company will be pennitted 10 pay the exercise price of an option in any method in violation of Section I J(k) of the Exchange Act.
Restricted stock may be granted pursuant to the 2015 Plan. A restricted stock award is the grant of shares of common stock that is nonrransferable and
may be subject lo substantial risk of forfeiture until specific conditions arc met. Conditions may be based on continuing employment or achieving
performance goals. During the period ofrest1iction, participants holding shares of restricted stock may have full voting and dividend rights with respect to
such shares. The restrictions will iapse in accordance with a schedule or other conditions determined by the Compensation Committee.
A stock appreciation right (an "SAR") is the right to receive payment of an amount equal to the excess of the fair market value of a share of common
stock on the date of exercise of the SAR over the fair market value of a share of common stock on the date of grant of the SAR. Payments will be made by the:
Company in cash or common stock.
The othertypes of awards that may be granted under the 2015 Plan include performance shares, performance stock units, defe1Ted stock, restricted stock
units, and other stock-based awards.

Cl1a11ges bi Cllpital S11·11c:ture
In the event ofa stock dividend. stock split. combination or exchange of shares, merger, consolidation, spin-off, recapitalization, distribution of assets or
any other corporate event affecting the common stock or the share price of the common stock in a manner that causes dilution or enlargement of benefits or
potential benefits under the 2015 Plan, then the Compensation Committee will make proportionate adjustments to: (i) the aggregate number of, and types of,
shares of stock subject to the 2015 Plan, (ii) the terms and conditions of any outstanding awards (including any applicable performance targets) and (iii) the
gr.mt or exercise price for any outstanding awards. In addition, in such a case or in the event of any unusual or nonrecurring trJnsactions or events affecting
the Company or of changes in applicable laws, the Compensation Committee, may, subject to the terms of the 2015 Plan. take any of the following actions if
it determines that such action is appropriate in order to prevent the dilution or enlargement of benefits or potential benefits intended to be made available
under the 2015 Plan or with respect to any award: (i) provide for either the termination, purchase or replacement of the awards, (ii) provide that the awards
shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar awards covering the stock of
the successor or survivor corporation. or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices, (iii) make
adjustments in the number and type of shares of stock (or other securities or prope1ty) subject to outstanding awards and/or in the tenns and conditions of
(including the exercise price), and the c1iteria included in, outstanding awards which may be granted in the future, (iv) provide for the acceleration of vesting
or exercisability of the awards and (v) provide that the awards cannot vest or be exercised after the event that triggers the action.
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A111e11dment am/ Termillatio11
The Compensation Committee. subject to approval of the Board. may tcm1inate. amend, or modify the 2015 Plan at any time; provided, however, that
shareholder approval must be obtained for any amendment to the extent necessary or desirable to comply with any applicable law, regulation or stock
exchange mle, to increase the number of shares available under the 2015 Plan or to allow a material increase in the benefits or change the eligibility
requirements under the 2015 Plan. In addition, without approval of the Company's shareholders, no option or SAR may be amended to reduce the per share
exercise price of the shares subject to such option or SAR below the per share exercise price as of the date the option or SAR was grnnted and, except to the
extent pennitted by the 2015 Plan in connection with changes in the Company's capital structure, no option or SAR may be granted in exchange for, or in
connection with, the cancellation or smTender of an option or SAR having a higher per share exercise price.
fn no event may an award be granted pursuant to the 20 I 5 Plan on or after the 10 th anniversa1y of the effectiveness of the Plan.

Securities Law
The 2015 Plan is intended to conf01m to the extent necessary with all provisions of the Secu1ities Act and the Exchange Act, and any and all regulations
and rules promulgated by the SEC thereunder, including without limitation Ruic I 6b-3. The 2015 Plan will be administered, and awards will be granted and
may be exercised, only in such a manner as to confonn to such laws, mies and regulations. To the extent permitted by applicable law, the 2015 Plan and all
awards granted thereunder shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.

Federal Income Tax Cn11seque11ces
The tax consequences of the 20 I 5 Plan under cun-ent federal law are summaiized in the following discussion which deals with the general tax p1inciples
applicable to the 2015 Plan, and is intended for general infonnation only. Alternative minimum tax and state and local income taxes are not discussed. Tax
laws arc complex and subject to change and may vary depending on individual circumstances and from locality to locality. The tax infonnation summarized
is not tax advice.

Nonqual(/ic:d Stock Oprions. For federal income tax pmposes, an optionec generally will not recognize taxable income on the grant of a nonquali tied
stock option (an "NQSO") under the 2015 Plan, but upon the exercise of an NQSO will recognize ordinary income, and the Company generally will be
entitled to a deduction. The amount of income recognized (and the amount deductible by the Company) generally will be equal to the excess, if any, of the
fair market value oft he shares at the time of exercise over the aggregate exercise p1ice paid for the shares, regardless of whether the exercise price is paid in
cash or in shares or other property. An optionee's basis for the stock for purposes of determining his or her gain or loss upon a subsequent disposition of the
shares generally will be the fair market value of the stock on the date of exercise of the NQSO, and any subsequent gain or loss will generally be taxable as
capital gains or losses.
Incentive Stock Options. An optionee generally will not recognize taxable income upon either the grant or exercise ofan Incentive Stock Op1ion (an
"ISO"); however, the amount by which the fair market value of the shares at the time of exercise exceeds the exercise price will be an "item of tax preference"
for the optionee for purposes of the alternative minimum tax. Generally, upon the sale or other taxable disposition of the shares of the common stock acquired
upon exercise ofan ISO, the optionec will recognize income taxable as capital gains in an amount equal to the excess, if any, ofthe amount realized in such
disposition over the option exercise price, provided that no disposition of the shares has taken place within either (a) two years from the date of grant of the
ISO or (b) one year from the date of exercise. If the shares of common stock arc sold or otherwise disposed of before the

37

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table of Contents
end of the one-year and two-year periods specified above, the difference between the ISO exercise price and the fair market value of the shares on the date of
exercise generally will be taxable as ordinary income; the balance of the amount realized from such disposition, if any, generally will be taxed as capital
gain. If the shares of common stock are disposed of before the expiration of the one-year and two-year periods and the amount realized is less than the fair
market value of the shares at the date of exercise, the optionee's ordinary income generally is limited to excess, if any, of the amount realized in such
disposition over the option exercise price paid. The Company (or other employer corporation) generally will be entitled to a tax deduction with respect to an
ISO only to the extent the optionee has ordinary income upon sale or other disposition of the shares of common stock.

Stock Appreciation Rights. No taxable income is generally recognized upon the receipt ofan SAR, but upon exercise of the SAR the fair market value
of the shares (or cash in lieu of shares) received generally will be taxable as ordinary income to the recipient in the year of such exercise. The Company
generally will be entitled to a compensation deduction for the amount the recipient recognizes as ordinary income.
Reslricted Stock and Deferred Stock. A parlicipanl lo whom n;slricte<l or<.lt:fen-ed stock is issued genernlly will nol recognize taxable income upon
such issuance and the Company generally will not then be entitled to a deduction, unless, in the case of restricted stock, an election is made by the
participant under Section 83(b) of the Code. However, when restrictions on shares of restricted stock lapse. such that the shares arc no longer subject to a
substantial risk of forfeiture, the employee generally will recognize ordinary income and the Company generally will be entitled to a deduction for an
amount equal to the excess of the fair market value oft he shares at the date such restrictions lapse over the purchase price therefore. Similarly, when deferred
stock vests and is issued to the employee, the employee generally will recognize ordinary income and the Company generally will be entitled to a deduction
for the amount equal to the fair market value of the shares at the date of issuance. If an election is made under Section 83(b) with respect to restricted stock,
the employee generally will recognize ordinary income at the date of issuance equal to the excess. if any, of the fair market value of the shares at that date
over the purchase price therefore and the Company will be entitled to a deduction for the same amount. The Code docs not· permit a Section 83(b) election to
be made with respect to defcn·ed stock.
Dividend Equivalents. A recipient of a dividend equivalent award generally will not recognize taxable income at the time of grant, and the Company
will not be entitled to a deduction at that time. When a dividend equivalent is paid, the par1icipan1 generally will recognize ordina1y income. and the
Company will be entitled to a corresponding deduction.
Pe,formance Awards. A participant who has been granted a performance award generally will not recognize taxable income at the time of grant, and the
Company will not be entitled to a deduction at that time. When an award is paid, whether in cash or common stock, the participant generally will recognize
ordinary income, and the Company will be entitled to a corresponding deduction.
Stock Payments. A participant who receives a stock payment in lieu ofa cash payment that would otherwise have been made will generally be taxed as
if the cash payment has been received, and the Company generally will be entitled to a deduction for the same amount.
Section I 62(m) Limitation. In general, under Section I 62(m), income tax deductions of publicly held corporations may be limited to the extent total
compensation (including base salary, annual bonus, stock option exercises, transfers of property and benefits paid under nonqualified retirement plans) for
certain executive officers exceeds $1 million (less the amount of any "excess parachute payments" as defined in Section 280G of the Code) in any one year.
However, under Section I 62(m), the deduction limit does not apply to certain "performance-based compensation." Under Section 162(m), stock options and
SARs will satisfy the "performance-based compensation" exception if the awards of the
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options or SARs arc made by a conunittee of the Board of Din:ctors consisting soldy of two or more "outside directors," the plan sets the maximum number of
shares that can be granted to any person within a specified period, and the compensation is based solely on an increase in the stock p1icc afterthe grant date
(i.e., the option or SAR exercise price is equal to or greater than the fair market value oft he stock subject 10 the award on the grant date). Othertypes of
awards may only qualify as "perfonnance-based compensation" if such awards are granted or payable only lo the recipients based upon the attainment of
objectively dete,minable and pre-established performance targets established by a qualifying committee of the Board and related to performance goals
approved by our shareholders.
The 2015 Plan has been designed in order to petmit the Compensation Committee to grant stock options and SARs that will qualify as "performancebased compensation" under Section I 62(m). In addition, in order to permit awards other than stock options and SARs to qualify as "performance-based
compensation,'' the 2015 Plan allows the Compensation Committee to designate as "Section I 62(m) Participants" employees whose compensation for a given
fiscal year may be subject to the limit on deductible compensation imposed by Section 162(111). The Compensation Committee may grant awards to
Section l 62(m) Participants that vest or become exercisable upon the attainment of spcci fie perfi.)1mance targets that are related to one or more of the
performance goals set forth in the 2015 Plan.

New Pla11 Benefits
If the 2015 Plan under Proposal #2 is approved by our shareholders, the Compcnsat ion Committee in its sole discretion wi II determine the number and
types of awards that will be granted under the Plan going forward and will also dctennine the persons to whom awards will be granted. Therefore, the number
of shares to be issued under the 2015 Plan and the net values to be realized upon such issuances are discretionary, and therefore, not determinable.
RECOMMENDATION
The Board of Directors unanimously recommends a vote FOR the Company's 2015 E,1uity Incentive Award Plan.

PROPOSAL #3-RATIFICATION OF SELECTION OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee of the Board of Directors has selected KPMG LLP ("KPMG") as the independent registered public accounting firm to audit the
financial statements of the Company and its subsidiaries for the fiscal year ending January 2, 2016. KPMG has served as our independent registered public
accounting firm since September 16, 2013 and audited the Company's financial statements for the fiscal year ended January 3, 2015.

Change in Independent Regi.vtered Public Acco,mting Firm
As previously disclosed, KPMG was engaged as the Company's independent registered public accounting firm on September 16, 2013 following the
Audit Committee's dismissal of PricewaterhouseCoopers LLP ("PWC") as our independent registered public accounting firm. The reports of PWC on our
consolidated financial statements as of and for the year ended December 29, 2012 did not contain an adverse opinion or a disclaimer of opinion, and were not
qualified or modified as to uncertainty, audit scope or accounting principles. During the year ended December 29, 2012, and through September 16, 2013,
there were no: (i) disagreements with PWC on any matter of accounting ptinciplcs or practices, financial statement disclosure, or auditing scope or procedure,
which disagreements, if not resolved to PWC's satisfaction, would have caused PWC to make reference to the
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subject matter thereof in connection with its rerorts for such years; or (ii) reportable events, as described under Item 304(a}( I )(v) of Regulation S-K.
PtJ/icy tJII Pre-ApprtJw1I ofAudit t111tl Permissible Ntm-Audit Sen>ic:es
The Audit Committee pre-approves any engagement ofKPMG and has the ultimate autho1ity and responsibility to select, evaluate and where
appropriate, replace the independent registered p't1blic accounting fim1 and nominate an independent registered public accounting tiim for shareholder
approval. While ratification of the selection of accountants by the shareholders is not required and is not binding upon the Audit Committee or the Company.
in the event ofa negative vote on such ratification, the Audit Commitlee might choose to reconsider its selection.
Prior to the performance of any services, the Audit Committee approves all audit and non-audit services to be provided by the Company's independent
registered public accounting firm and the fees to be paid therefor. Although the Sarbanes-Oxley Act of2002 permits the Audit Committee to pre-approve
some types orcatcgmies of services to be provided by the independent registered public accounting finn, it is the current practice of the Audit Committee to
specifically approve all services provided by the independent registered public accounting firm in advance, rather than to pre-approve any type of service. In
connection with this practice, the Audit Committee has considered whether the provision of non-audit services is compatible with maintaining KPMG's
independence.

J11depe11dence
KPMG has advised us that it has no direct or indirect financial interest in the Company or in any of its subsidia1 ies a11J that du1 iug 2014 it haJ m,
con111:ction with the Company or any of its subsidiaries, otherthan as its independent registered public accounting finn or in connection with certain other
activities, as described below.

Fi11a11cial Stateme11ts u11d Reports
The financial statements of the Company for the year ended January 3, 2015, and the report of the independent registered public accounting finn will be
presented at the Annual Meeting. KPMG will have a representative present at the meeting who will have an opportunity to make a statement, ifhe or she so
desires, and to respond to appropriate questions from shareholders.

Services
During the fiscal year 2014, KPMG perfo1med services consisting of the audit of the annual consolidated financial statements of the Company, and the
effectiveness of our internal controls over financial repo11ing, review of the quarterly financial statements for the quarters ended March 29, 2014, June 28,
2014 and September 27, 2014, stand-alone audits of subsidiaries, and accounting consultations, consents, other services related to SEC filings by the
Company and its subsidiaries, tax compliance services and transfer pricing srevices. KPMG did not perform any financial information systems design and
implementation services for the Company for the fiscal year 2014.
During fiscal year 2013, KPMG performed services consisting of the audit of the annual consolidated financial statements of the Company, and the
effectiveness of our internal controls over financial reporting. review of the quarterly financial statements for the quarters ended September 28, 2013, standalone audits of subsidiaries, and accounting consultations, consents, and other services related to SEC filings by the Company and its subsidiaries. KPMG
did not perfonn any financial infonnation systems design and implementation services for the Company for the fiscal year 2013.
Also, during fiscal year 2013, PWC provided services consisting of reviews of the quarterly financial statements for the quarters-ended March 31, 2013
and June 30, 2013, stand-alone audits of subsidiaries,
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and accounting consultations. consents, and other scniiccs related to SEC filings and rcgistrntion statements that were filed by the Company and its
subsidiaries. PWC also provided other services to the Company in fiscal year 2013, consisting primarily of tax consultation and related services. P\VC did not
perfo1m any financial infonnat10n systems design and implementation services for the Company for the fiscal year 2013.
The following table summarizes the fees that were paid to KPMG and PWC by the Company during fiscal years 20 I 4 and 2013.
Fimil Yc-.ir 2013
Tvpr or Servlcr and F~'C

KPMG LLP

Audit Fees
Audit Related Fees
Tax Fees
All Other Fees
Total Fees

$ 1,706,462

$ 1,706,462

Flsc;il Yr.ir 2014
KPMG LLP

PricrwatcrhouseCooprrs LLP

$

181,110 $
37,293 $
127,259 $

$

$

$

345,662 $

$
$

1,423,415
43,050
1,466,465

RECOMMENDATION
The Board of Directors unanimously recommends a vote FOR ratification of the appoinhnent ofKPMG LLP, as the Company's independent
registered public accounting firm for fiscal year 2015.
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REPORT OF THE AUDIT COMMITTEE
The Audit Committee is responsible for monitoring the Company's financial auditing, accounting and financial reporting processes and the Company's
system ofintemal controls, and selecting the independent registered public accounting fim1 on behalf of the Board of Directors. Management has the primary
responsibility for the financial statements and the repo11ing process. including the systems of internal controls. The independent registered public accounting
firm, KPMG LLP, is responsible for perfom1ing an independent audit of the Company's consolidated financial statements and the effectiveness of internal
controls over financial repor1ing in accordance with standards of the Public Company Accounting Oversight Board (United States) and issuing an opinion
thereon. In this context, the Audit Committee met regularly and held discussions with management, the internal audit depai1ment and KPMG LLP.
Management represented to the Audit Committee that the consolidated financial statements for the fiscal year 2014 were prepared in accordance \vith U.S.
generally accepted accounting principles.
·
The Audit Committee hereby reports as follows:
The Audit Commitlee has reviewed and discussed the audited consolidated financial statements and accompanying management's discussion
and analysis of financial condition and results of operations with management and KPMG LLP. This discussion included KPMG LLP's
judgments about the qua I ity, not just the acccplahi lity, oft he accounting principles, the reasonableness of significant judgments, and the
clarity of disclosures in the financial statements.
The Audit Committee also discussed with KPMG LLP the mailers required to be discussed by the Statements on Auditing Standards No. 61, as
amended (AICPA, Professional Standards, Vol. I. AU section 380). as adopted by the Public Company Accounting Oversight Board in
Rule 3200T.
KPMG LLP also provided to the J\udil Commillee the written disclosures and the letter required by the applicable requirements of the Public
Accounting Oversight Board regarding KPMG LLP's communications with the Audit Committee concerning independence, and the Audit
Committee has discussed with KPMG LLP the accounting firm's independence. The Audit Committee also considered whether non-audit
services provided by KPMG LLP during the last fiscal year were compatible with maintaining the accounting firm's independence.
Based on the review and discussions referred to above, the Audit Committee has recommended to the Board of Directors that lhc audited consolidated
financial statements of the Company be included in the Company's Annual Report on Fom1 I 0-K for the year ended January 3, 2015, for filing with the
Sccu1ities and Exchange Commission.
Respectfully submitted by the members of the Audit Committee:
Jerry G. McClain (Chair)
Robert Anciaux
Gilbert A. Fuller
Ronald S. Poelman
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EMPLOYMENT CONTRACTS AND OTHER ARRANGEMENTS
The Company has no employment agreements with any of its executive officers.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section I 6(a) of the Exchange Act requires our oflicers. directors. and persons who beneficially own more than I 0% of our common stock to file reports
of ownership and changes in ownership with the SEC and with the NYSE. Officers, directors, and greater-than-ten-percent shareholders are also required by
the SEC to furnish us with copies of all Section I 6(a) fo1ms that they file.
Based solely upon a review of these fonns that were furnished to the Company, and based on representations made by certain persons who were subject
to this obligation that such filings were not required lo be made, the Company believes that all reports that are required to be filed by these individuals and
persons under Section I 6(a) were filed on time in fiscal year 2014, except that the SSAR award to each of the Named Executive Officers and Directors in fiscal
2014 was reported late on Fom14.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Policies and P,-oced11,-es Reg"rdi11g Related Party Tra11sa,·titJns
In the ordinary course of business. we may engage in transactions which have the potential to create actual or perceived conflicts of interest between
USANA and our directors and officers or their immediate family members. The Audit Committee cha11er requires that the Audit Committee review and
approve any related party transaction or. in the alternative, that it notify and request action on the related party transaction by the full Board of Directors.
While we have not adopted formal written procedures for reviewing such transactions, in deciding whether to approve a related party transaction, the Audit
Committee may consider, among other things, the following factors:
information regarding the goods or services that are proposed to be provided, or that arc being provided, by or to the related party;
the nature of the transaction and the costs to be incurred by the Company;
an analysis of the costs and benefits that are associated with the transaction and a comparison of altemativc goods or services that arc available
to the Company from unrelated parties;
an analysis of the significance of the transaction to the Company;
whether the transaction would be in the ordinary course of our business;
whether the transaction is on tenns that are comparable to those that could be obtained in an arm's-length dealing with an unrelated third
party;and
whether the transaction could result in an independent director no longer being considered to be independent under the NYSE rules.

'\iiV

After considering these and other relevant factors, the Audit Committee either (I) approves or disapproves the related party transaction, or (2) requests
that the full Board of Directors consider the matter. The Audit Committee will not approve any related party transaction which is not on terms that it believes
are both fair and reasonable to USANA.
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Related Party Tram,actirm
The Company's Founder and Chai1man of the Board, Myron W. Wentz. PhD, is the sole beneficial owner of Gull Holdings, Ltd., which is the largest
shareholder of the Company. Gull Holdings, Ltd. o\lmcd 5 I .5% ofour issued and outstanding shares as of January 3, 2015. Dr. Wentz devotes much of his
personal time, expertise, and resources to a number ofbusiness and professional activities outside ofUSANA. The most significant of these is the Sanoviv
Medical Institute. which is a unique, fully integrated health and wellness center located near Rosa1ito, Mexico that Dr. Wentz founded 1998. Dr. Wentz's
private entity, Sanoviv S.A. DE C.V. ("Sanoviv"), contracts with Medicis. S.C. ("Medicis"). an entity that is owned and operated independently of Dr. Wentz,
to conduct the operations oft he Sanoviv Medical Institute. Sanoviv leases the medical building to Medicis and Medicis canics out all of the operations of
the medical institute, which include employing all of the medical and healthcare professionals who provide services at the medical institute. The Medicis
medical and healthcare professionals possess expertise in the fields of human health, digestive health, nutritional medicine, Ii fcstyle medicine and other
medical fields that arc important to USANA.
In 2014, Medicis performed a variety of contract research services on behalf of USANA, which included: (i) research and development of novel product
formulations for future development and production by USANA; and (ii) research and development of improvements in existing USANA product
formulations. Also. in 2014, Medicis performed heath assessments and physical examinations for ce11ain of our executives. In exchange for these services.
USANA paid Medicis approximately $314,000 during 2014. The Company's agreements with Medicis were approved by the Audit Committee in advance of
the Company's entry into the agreements. Our collaboration with Medicis is te1minablc at will by us at anytime, without any continuing commitment by
USANA.

OTHER MATTERS

Shareholder P;oposa/s. As of the date of this Proxy Statement, the Board of Directors does not intend to present, and has not been infonned that any
other person intends to present, any matter for action at the Annual Meeting, other than as set fonh herein and in the Notice of Annual Meeting. Jf any other
matter properly comes before the meeting, it is intended that the holders of proxies will act in accordance with their best judgment on these matters.
Shareholders who intend to present proposals at the 2016 Annual Meeting under SEC Rule I 4a-8 must ensure that such proposals arc received by the
Secretary of the Company not later than November 26, 2015. Such proposals must meet the requirements of the SEC to be eligible for inclusion in our 2016
proxy materials.

ANNUAL REPORT
A copy of the our Annual Repon on Form I 0-K for the fiscal year ended January 3, 2015, as filed with the SEC, will be made available on our website
and, to each shareholder of record at March 2, 2015 who requests such materials, mailed concurrently with, this Proxy Statement. The Annual Report on
Form I 0-K is not deemed a part of the proxy soliciting material for the Annual Meeting.
Notwithstanding any general language that may be to the contrary in any document filed with the SEC, the information in this Proxy Statement under
the captions "Audit Committee Report" and "Compensation Committee Report" shall not be incorporated by reference into any document filed with the SEC.

FURTHER INFORMATION
Additional copies of the Annual Report on Form I 0-K for the year ended January 3, 2015 (including financial statements and financial statement
schedules) that has been filed with the SEC may be obtained without charge by writing to USANA Health Sciences, Inc .• Attention: Investor Relations, 3838
West Parkway Blvd., Salt Lake City, Utah 84120-6336. Our reports and other public filings,
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including this Proxy Statement, also may be obtained from the SEC's on-line database, located at www.sec.gov.
By Order of the Board of Directors,

9-IJlf,i,,/1_
James H. Bramble,
Corporate Secretmy
Date: March 25, 2015

45

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Table 'of Contents

ANNEX A

USANA HEALTH SCIENCES, INC.
2015 EQUITY INCENTWE AWARD PLAN
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USANA HEAL TH SCIENCES, INC.
2015 EQUITY INCENTIVE AW ARD PLAN

ARTICLE I
PURPOSE
The purposes of the USANA Health Sciences. Inc.2015 Equity Incentive Award Plan (the "Plan") are to:
(I) Closely associate the interests of management, employees, directors and consultants ofUSANA Health Sciences, Inc., a Utah co1poration (the

"Company"), with the shareholders of the Company by reinforcing the relationship between participants' rewards and shareholder gains;
(2} Provide management and employees with an equity ovroership in the Company commensurate with Company performance, as reflected in
increased shareholder value;
(3) Maintain competitive compensation levels; and
(4) Provide an incentive to management and employees to remain in continuing employment with the Company and to put forth maximum
efforts for the success of its business.
The Plan is fu1ther intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of members of the Board,
Employees and Consultants upon whose judgment, interest, and special effort the successful conduct of the Company's operation is largely dependent.

ARTICLE 2
DEFINITIONS AND CONSTRUCTION ·

Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The
singular pronoun shall include the plural where the context so indicates.
2.1 ''Award" means an Option, a Restricted Stock award, a Stock Appreciation Right award, a Performance Share award, a Performance Unit award, a
Dividend Equivalents award, a Stock Payment award, a Deferred Stock award, a Restricted Stock Unit award, an Other Stock-Based Award, or a PerfomianceBased Award granted to a Participant pursuant to the Plan.
2.2 "Award Agreement"means any written or electronic agreement, contract, or other instrument or document evidencing an Award.
2.3 ''Board"means the Board of Directors of the Company.
2.4 "Change in Control"means the occurrence of any of the following in one or a series of related transactions: (i) an acquisition after the date hereof by
an individual or legal entity or "group" (as described in Rule 13d-5(b)(l) under the Exchange Act) of more than thirty percent (30%) of the voting rights or
equity interests in the Company; provided, however, that any of the following acquisitions shall not be deemed to be a Change in Control: (A) any
acquisition by the Company or any Subsidiary, (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company
or any Subsidiary, (C) any acquisition by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) any acquisition by
any person ofthe voting rights or equity interests in the Company from the Company, ifa majority of the Incumbent Directors approves in advance such
acquisition; (ii) a replacement, during a 24-month period. of more than one-half of the members of the Board that is not approved by those individuals who
are members of the Board on the date hereof(or other directors previously approved by such individuals) (collectively "the Incumbent Directors"); provided,
however, that no individual initially elected or nominated as a member of the Board as a result of an actual or threatened election contest with respect to
members of the Board or
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as a result of any other actual or threatened solicitation ofproxies by oron bchalfofany person other than the Board shall be deemed to be an incumbent
Director; (iii) consummation of a merger or consolidation of the Company or any Subsidiary or a sale of more than one-half of the assets of the Company in
one or a se1ies of related transactions, unless follo,ving such transaction or series of transactions, the holders of the Company's securities p1ior to the first such
transaction continue to hold at least one-half of the voting rights and equity interests of the surviving entity or acquircr of such assets and such voting rights
among the holders thereof is in substantially the same proportion as the voting rights of such among the holders thereof immediately prior to the transaction;
(iv) a recapitalization, reorganization or other transaction involving the Company or any Subsidiary that constitutes or results in a transfer of more than onehalf of the voting rights or equity interests in the Company; or (v) consummation of a "Rule I 3e-3 transaction" as defined in Rule I 3e-3 under the Exchange
Act with respect to the Company.
2.5 "Code" means the Internal Revenue Code of 1986, as amended.
2.6 "Committee"means the committee of the Board dcsc1ibcd in Atiicie 12.
2.7 "Co11sulta111"mcans any consultant or adviser it:
(a} The consultant or adviser renders bona fide services to the Company;

(b) The se1vices rendered by the consultant or adviser arc not in connection with the offeror sale of securities in a capital-raising transaction and
do not directly or indirectly promote or maintain a market for the Company's securities; and
(c) The consultant or adviser is a natural person who has contracted directly with the Company to render such se1vices.
2.8 ''Covered Employee"means an Employee who is, or may be, as determined by the Committee, a "covered employee" within the meaning of
Section I 62(m) of the Code.
2.9 "Deferred Stock" means a right to receive a specified number of shares of Stock during specified time periods pursuant to Article 8.
2.10 "Disabili(1 1 " means that the Pa11icipant qualifies to receive long-term disability payments under the Company's long-term disability insurance
program, as it may be amended from time to time.
2.11 "Dividend Equivalents" means a right granted to a Participant pursuant to Article 8 to receive the equivalent value (in cash or Stock) of dividends
paid on Stock.
2.12 "Effective Date" shall have the meaning set fOJ1h in Section 13. l.
2. l 3 "Eligible Individual" means any person who is an Employee, a Consultant or a member of the Board, as determined by the Committee.
2.14 "Employee" means any officer or other employee (as defined in accordance with Section 340 I (c) of the Code) of the Company or any Subsidiary.
2.15 "Exchange Act"mcans the Securities Exchange Act of 1934, as amended.
2.16 "Fair Market Value"means, as of any given date, the fair market value ofa share ofStock on the date determined by such methods or procedures as
may be established from time to time by the Committee. Unless otheiwise determined by the Committee, the Fair Market Value ofa share of Stock as of any
date shall be (i) the closing price ofa share of Stock on the principal exchange on which shares of Stock are then trading, if any, on such date, or if shares were
not traded on such date, t'1en on the closest preceding date on which a trade occurred; or (ii) ifStoek is not traded on an exchange, the mean between the
closing representative bid and asked prices for the Stock on such date as reported by NASDAQ or, if NASDAQ is not then in existence, by its successor
quotation system; or
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(iii) if Stock is not publicly traded, the Fair Market Value ofa share of Stock as established by the Commillee acting in good faith.
2.17 "b,centive Stock Option" means an Option that is intended to meet the requirements of Section 422 of the Code or any successor provision thereto.
2.18 "l,1depende11t Director" means a member of the Board who is not an Employee of the Company.
2.19 "Non-Employee Director" means a member of the Board who qualifies as a "Non-Employee Director" as defined in Ruic I 6b-3(b)(3) of the Exchange
Act, or any successor definition adopted by the Board.
2.20 "Non-Qualified Stock Option "means an Option that by its terms does not qualify or is not intended to be an Incentive Stock Option.
2.21 "Option" means a right granted to a Participant pursuant to Article 5 of the Plan lo purchase a specified number of shares of Stock at a specified price
during specified time periods. An Option may be either an Incentive Stock Option or a Non-Qualified Stock Option.
2.22 "Optionee" means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
2.23 "Other Stock-Based Award"means an Award granted or denominated in Stock or units of Stock pursuant to Section 8.7 of the Plan.
2.24 "Participant" means any Eligible Individual who, as a member of the Board or Employee or Consultant, has been granted an Award pursuant to the
Plan.
2.25 "Pe1:forma11ce-Based Award" means an Award granted to selected Covered Employees pursuant to Articles 6 and 8, but which is subject to the 1e1ms
and conditions set fo11h in Article 9. All Performance-Based Awards are intended to qualify as Qualified Performance-Based Compensation.
2.26 "Pe1.formanc£' Criteria" means the criteria that the Commillee selects for purposes of establishing the Performance Goal or Pe1fom1ance Goals for a
Participant for a Perfo,mance Period. The Performance Criteria that will be used to establish Performance Goals are limited to the following: net eamings
(either before or after interest, taxes, depreciation and amortization), economic value-added (as determined by the Committee), sales or revenue, net income
(either before or after taxes), operating earnings, cash flow {including, but not limited to, operating cash flow and free cash flow), cash flow return on capital,
return on net assets, return on shareholders' equity, return on assets, return on capital, shareholder returns, return on sales, gross or net profit margin,
productivity, expense, margins, operating efficiency, customer growth, customer satisfaction, working capital, earnings per share, p1icc per share of Stock, and
market share, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results ofa peer group.
The Comminee shall, within the time prescribed by Section I 62(m) of the Code, define in an objective fashion the manner of calculating the Perfo1mance
Criteria it selects to use for such Performance Period for such Participant.
2.27 "Pe,formance Goals"means, for a Performance Period, the goals established in writing by the Committee for the Performance Period based upon the
Performance Criteria. Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of
overall Company performance or the performance of a division, business unit, or an individual. The Committee, in its discretion, may, adjust or modify the
calculation of Performance Goals for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants (a) in the event of.
or in anticipation of, any unusual or extraordinary corporate item, transaction, event, or development, or (b) in recognition of, or in anticipation of. any other
unusual or
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nonrecuning events affecting the Company, orthc financial statements of the Company. or in response to, or in anticipation of, changes in applicable laws,
regulations, accounting principles, or business conditions.
2.28 "Pe1j'orma11ce Period" means the one or more periods of time, which may be of varying and overlapping durations, as the Commillee may select,
over which the attainment ofone or more Performance Goals will be measured for the pu1pose of determining a Participant's 1ight to, and the payment of, a
Performance-Based Award.
2.29 "Pe,:formanc:e Share"means a right granted lo a Participant pursuant to A11icle 8, to receive Stock, the payment of which is contingent upon
achieving ce11ain Performance Goals or other performance-based targets established by the Committee.
2.30 "Pe,j<>rmcmc:e Unit"mcans a tight granted to a Pa11icipant pursuant to Article 8, to receive units of value, including dollar value of shares of Stock,
the payment of which is contingent upon achieving certain Perfonnancc Goals or other pciformancc-bascd targets established by the Committee.
2.31 "Plan" means this USANA Health Sciences, Inc.2015 Equity Incentive Award Plan, as it may be amended from time to time.
2.32 "Quaftfied Pe1forma11ce-Based Compe11satio11"means any compensation that is intended to qualify as "qualified pe1formance-based compensation"
as described in Section I 62(m)(4 )(C) of the Code.
2.33 "Restricted Stock" means Stock awarded to a Participant pursuant to A11iclc 6 that is subject to ce11ain rest1ictions and may be subject to risk of
forfeiture.
2.34 "Restricred Stock Unit"means an Award granted pursuant

to

Section 8.6.

2.35 "Section 409A Award" shall have the meaning set forth in Section 15. I.
2.36 "Securities Act" shall mean the Securities Act of 1933, as amended.

2.37 "Stock" means the common stock of the Company, par value $.00 I per share, and such other securities of the Company that may be substituted for
Stock pursuant to Article 11.
2.38 "Stock Appreciarion Right" or "SAR" means a right granted pursuant to Article 7 to receive a payment equal to the excess of the Fair Market Value
of a specified number of shares of Stock on the date the SAR is exercised over the Fair Markel Value on the date the SAR was granted as set forth in the
applicable Award Agreement.
2.39 "Stock Payment"means (a) a payment in the form of shares of Stock, or (b) an option or other right to purchase shares of Stock, as pa11 of any bonus,
deferred compensation or other arrangement, made in lieu of all or any portion of the compensation, granted pursuant lo Article 8.
2.40 "Subsidiary" means any "subsidiary corporation" as defined in Section 424(1) of the Code and any applicable regulations promulgated thereunder or
any other entity of which a majority of the outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company.
2.41 "Substitute Awards" shall mean Awards granted or shares of Stock issued by the Company in assumption of, or in substitution or exchange for,
Awards previously granted, or the right or obligation to make future Awards, in each case by a company acquired by the Company or any Subsidiary or with
which the Company or any Subsidiary combines.
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ARTICLE 3
SHARES SUBJECT TO THE PLAN
3.1

Number of S/wrcs.
(a) Subject to Article 11 and Section 3.1 (b), the aggregate number of shan:s of Stock which may be issued, transfc1Ted or reserved for issuance
pursuant lo Awards under the Plan shall be five million (5,000.000) shares. In order that the applicable regulations under the Code relating to
Incentive Stock Options be satisfied, the maximum number of shares of Stock that may be delivered upon exercise oflncentive Stock Options shall be
the number specified in this Section 3.1 (a). Shares of Stock that may be issued upon exercise of Options under the Plan shall be authorized and
unissued shares ofStoek. In the absence of an effective registration statement under the Secu1ities Act of 1933 (the "Act"). all Options granted and
shares of Stock subject to their exercise will be restricted as to subsequent resale or transfer. pursuant to the provisions of Rule 144, promulgated
under the Act.

(b) To the extent that an Award terminates, expires, or lapses for any reason, or an Award is settled for cash (in whole or in part) or otherwise does
not result in the issuance of all or a portion of the shares of Stock subject to such Award (including on payment in shares of Stock on exercise ofa
Stock Appreciation Right), any shares of Stock subject to the Award, to the extent of such termination, expiration, lapse, cash settlement ornonissuance, shall again be available forthe grant of an Award pursuant to the Plan. Additionally, any shares of Stock tendered or withheld to satisfy the
grant or exercise price or tax withholding obligation pursuant to any Award shall again be available for the grant of an Award pursuant to the Plan. To
the extent permiued by applicable law or any exchange iule, shares of Stock subject to Substitute Awards shall not be counted against shares of Stock
available for grant pursuant to this Plan nor shall shares of Stock subject to a Substitute Award be added to the shares of Stock available for Awards
under the Plan as provided above in this paragrnph. Additionally, in the event that a company acquired by the Company or any Subsidiary or with
which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by shareholders and not adopted in
contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the
extent appropriate, using the exchange ratio or other adjustment or valuation ratio or fommla used in such acquisition or combination to determine
the consideration payable to the holders of stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and
shall not reduce the shares of Stock authorized for grant under the Plan (and shares of Stock subject to such Awards shall not be added to the shares of
Stock available for Awards under the Plan as provided above in this paragraph; provided that Awards using such available shares shall not be made
after the date awards or grants could have been made under the te1ms of the pre-existing plan, absent the acquisition or combination, and shall only be
made to individuals who were not Employees or a member of the Board p1ior to such acquisition or combination. The payment of Dividend
Equivalents in conjunction with any outstanding Awards shall not be counted against the shares available for issuance under the Plan.
3.2 S/ock Distributed. Any Stock distributed pursuant to an Award may consist, in whole or in part, of authorized and unissucd Stock, treasury Stock
or Stock purchased on the open market.

I.ti)

3.3 Limitation on Number of Shares Subject to Awards. Notwithstanding any provision in the Plan to the contrary, and subject to Article 11, (a) the
maximum number of shares of Stock with respect to one or more Options or Stock Appreciation Rights that may be granted lo any one Participant during a
one-year period (measured from the date of any grant) shall be 500,000, (b) the maximum number of shares of Stock with respect to one or more PerformanceBased Awards that may be granted to any one Participant during a one-year period (measured from the date of any grant) shall be 500,000 and (c) the
maximum dollar value payable to any one Participant during a one-year period with respect to awards of Performance Units shall be $3,000,000.
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3.4 Limit on Awards to l11depe11de11t Directors. Notwithstanding any other provision oft he Plan to the contrasy. the aggregate grant date fair value
(computed as of the date of grant in accordance with applicable financial accounting rules) of all Awards granted to any Independent Director during any
single calendar year shall not exceed $500,000.

ARTICLE4
ELIGIBILITY AND PARTICIPATION

4.1

Eligibility.

Each Eligible Individual shall be eligible to be granted one or more Awards pursuant to the Plan.

4.2 Par!icipation. Subject to the provisions of the Plan, the Committee may, from time to time, select from among all Eligible Individuals, those to
whom Awards shall be granted and shall determine the nature and amount of each Award. No Eligible Individual shall have any right to be granted an Award
pursuant to this Plan.
4.3 Foreign Participa111s. In order to assure the viability of Awards granted to Pai1icipants employed in foreign countries, the Committee may provide
for such special tcm1s as it may consider necessary or appropriate to accommodate differences in local law, tax policy, or custom. Moreover, the Committee
may approve such supplements to, or amendments, restatements. or allemative versions of, the Plan as it may consider necessary or appropriate for such
pu1poses without the1d,y affecting Ilic lenns ufthe Plan as in t:ITccL fur any other purpose; pro11ided, however, that no such supplements, amendments,
restatements, or alternative versions shall increase the share limitations contained in Sections 3. I and 3.3 of the Plan.

ARTICLE 5
STOCK OPTIONS
5.1

Ge11eral.

The Committee is authorized to grant Options to Pas1icipants on the following tenns and conditions:

(a) Exercise Price. The exercise price per share of Stock subject to an Option (other than in connection with Substitute Awards) shall be not
less than I 00% of the Fair Market Value ofa share of Stock on the date of the grant. Other than pursuant to Section 11.1, the Committee shall not
without the approval of the Company's shareholders (a) lower the exercise price per share of Stock ofan Option after it is granted, (b) cancel an Option
when the exercise price per share of Stock exceeds the Fair Market Value of one share of Stock in exchange for cash or another Award (other than in
connection with a Change in Control), or (c) take any other action with respect to an Option that would be treated as a repricing under the mies and
regulations of the principal U.S. national securities exchange on which the shares of Stock arc listed.
(b) Time a11d Co11di1io11s of Exercise. Each Option shall be fully exercisable at any time within the period beginning not earlier than six
months after the date of the option grant and ending nut later than len years afier the date of such grant, unless the Committee specifies otheiwise (the
"Option Term"). ln no event, however, shall the Option Term extend beyond ten years after the date of the grant. No Option shall be exercisable after
the expiration of the Option Term. The Committee shall also determine the performance or other conditions, if any, that must be satisfied before all or
part ofan Option may be exercised. Notwithstanding the foregoing, in the event that on the last business day of the term ofan Option (otherthan an
Incentive Stock Option) (i) the exercise of the Option is prohibited by applicable law or (ii) shares of Stock may not be purchased or sold by certain
employees or directors of the Company due to the ''black-out period" of a Company policy or a "lock-up" agreement undertaken in connection with
an issuance of securities by the Company, the term of the Option shall be extended for a period of
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thiny (30) days following the end of the legal prohibition, black-out period or lock-up agreement. Notwithstanding the foregoing, an Award
Agreement may provide that if on the last day of the tcml of an Option the Fair Market Value of one share of Stock exceeds the option price per share
of Stock, the Pa1ticipant has not exercised the Option (or a tandem Stock Appreciation Right, if applicable) and the Option has not expired, the
Option shall be deemed to have been exercised by the Panicipant on such day with payment made by withholding shares of Stock otherwise issuable
in connection with the exercise of the Option. In such event, the Company shal I deliver to the Participant the number of shares of Stock for which the
Option was deemed exercised, less the number of shares of Stock required to be withheld for the payment of the total purchase price and required
withholding taxes; provided, however, any fractional share of Stock shall be settled in cash.
(c) Payment The Committee shall determine the methods by which the exercise p1ice ofan Option may be paid, the form of payment,
including. witholll limitation: (i) cash, (ii) promissory note bearing interest at no less than such rate as shall preclude the imputation of interest under
the Code, (iii) shares of Stock having a Fair Market Value on the date of dclive1y equal to the aggregate exercise price of the Option or exercised
ponion thereof, or (iv) other property acceptable to the Committee {including through the delivery of a notice that the Participant has placed a market
sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option. and that the broker has been directed to pay a
sufficient po1tion of the net proceeds of the sale to the Company in satisfaction of the Option exercise p1ice; provided that payment of such proceeds
is then made to the Company upon settlement of such sale), and the methods by which shares of Stock shall be delivered or deemed to be delivered to
Participants. Notwithstanding any other provision of the Plan to the contrary. no Participant who is a member of the Board or an "executive officer" of
the Company within the meaning of Section 13(k) of the Exchange Act shall be permitted to pay the exercise price ofan Option by means ofa
personal loan or other credit extended by the Company or in any other method which would violate Section l 3(k) of the Exchange Act.
(d) Evidence of Grant. All Options shall be evidenced by an Award Agreement between the Company and the Participant. The Award
Agreement shall include the number of shares of Stock subject to the Option, the exercise date, the Option Term, and such additional provisions as
may be specified by the Committee.
5.2 Incentive Stock Op/ions. The terms of any Incentive Stock Options granted pursuant to the Plan must comply with the conditions and limitations
contained Section 13.2 and this Section 5.2.
(a) £/igihility. The Committee may grant one or more Incentive Stock Options to employees of the Company or any "subsidiary corporation"
thereof (within the meaning of Section 424(f) of the Code and the applicable regulations promulgated thereunder). The date an Incentive Stock
Option is granted shall mean the date selected by the Committee as of which the Committee shall allot a specific number of shares to a Participant
pursuant to the Plan.
(b) Individual Dollar Limitation. The aggregate Fair Market Value (determined as of the time the Option is granted) of all shares of Stock with
respect to which Incentive Stock Options are first exercisable by a Participant in any calendar year may not exceed $100,000 or such other limitation
as imposed by Section 422(d) of the Code, or any successor provision. Multiple Incentive Stock Options may be granted to an Optionee in any
calendar year.
(c) Ten Percent Owners. The Committee may determine to grant an Incentive Stock Option to an Employee who is also an individual who
owns, at the date of grant, directly or indirectly according to the stock ownership attribution rules of Section 424(d) of the Code, Stock possessing
more than ten percent of the total combined voting power of all classes of Stock of the Company. However, the exercise price of such Option granted
shall not be less than I I 0% ofFair Market
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Value on the elate of gr.int. Fu1thcn11ore, the Option may be exercisable for no more than five years from the date of grnnl.
(d} Notice of Disposition. The Participant shall give the Company prompt notice of any disposition of shares of Stock acquired by exercise of
an Incentive Stock Option within (i) two years from the date of grant of such Incentive Stock Option or (ii) one year after the transfer of such shares of
Stock to the Participant. In order to obtain the favorable tax treatment available for Incentive Stock Options under Section 422 of the Code, the
Optionee is prohibited from lhe sale. exchange, transfer, pledge, hypothecation, gift or other disposition of the shares of Stock underlying the
Incentive Stock Options until the later of either two (2) years after the date of grant of the lncemive Stock Option, or one (I) year after the transfer to
the Optionee of such underlying Stock after the Optionee's exercise of such Incentive Stock Option. Should Optionee choose to make a premature
disposition of such underlying shares of Stock contrary to such rest1ictions, the Options related to such share of Stock shall be treated as Nonqualified Stock Options pursuant to the tenns of the Plan.
(c)

Right to Exercise.

Dur1ng a Participant's lifetime, an Incentive Stock Option may be exercised only by the Participant.

5.3 S11hstit11tio11 ofSrock Appreciation Rigl11s. The Committee may provide in the Award Agreement evidencing the grant ofan Option that the
Commiuee, in its sole discretion, shall have the right to substitute a Stock Appreciation Right for such Option at any time prior to or upon exercise of such
Option, subject to the provisions of Section 7 .2 hereof; provided that such Stock Appreciation Right shall be exercisable with respect to the same number of
shares of Stock for which such substituted Option would have been exercisable.
5.4 Pupedess E.ten-ise. In the event that the Company establishes, for itself or using the se,vices of a third paity, an automated system for the exercise
of Options, such as a system using an inlcmct website or inleractive voice response, then the paperless exercise of Options by a Panicipant may be permitted
through the use of such an automated system.
5.5
Plan:

Gra11ti11g of Options lo /11depe11dent Directors.

The Committee may from time to time, in its sole discretion, and subject to the limitations of the

(a) Select from among 1he Independent Directors (including Independent Directors who have previously been granted Options under the Plan)
such of them as in its opinion should be granted Options;
(b) Subject to SecllOn 3.3. determine the number of shares of Stock that may be purchased upon exercise of the Options granted to such selected
Independent Directors; and
(c) Subject to the provisions of this Article 5, determine the terms and conditions of such Options, consistent with the Plan.
Options granted to Independent Directors shall be Non-Qualified Stock Options.

ARTICLE6
RESTRICTED STOCK AWARDS
6.1 Grant of Restricted Stock. The Committee is authorized to make Awards of Restricted Stock to any Participant selected by the Committee in such
amounts and subject to such tem1s and conditions as determined by the Committee. All Awards of Restricted Stock shall be evidenced by a written Restricted
Stock Award Agreement.
6.2 Issuance and Restrictions. Restricted Stock shall be subject to such restrictions on transferability and other restrictions as the Committee may
impose (including, without limitation.
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limitations on the right to vote Rcstrietcd Stock or the right to receive dividends on the Restricted Stock). These restrictions may lapse separately or in
combination at such limes, pursuant to such circumstances, in such installments, or othe1wise, as lhc Committee determines at the time of the grant of the
Award or thereafter. Notwithstanding the provisions of this Seel ion, cash dividends, Stock and any other propeny (other than cash) dist1ibuted as a dividend
or otheiwisc with respccl to any Restricted Stock that vests based upon Pcrfonnanee Crilcria or other specific perfonnance criteria (a) shall either (i) not be
paid or credited or (ii) be accumulated, (b) shall be subject to restrictions and risk of forfeiture to the same extent as the Restricted Stock with respect to which
such cash, stock or other propcr1y has been distributed and (c) shall be paid at the time such restrictions and risk of forfeiture lapse.
6.3 Forfeiture. Except as otherwise determined by the Committee at the time of the grant of the Award or thereafter, upon te1mination of employment
or service during the applicable restriction period, Rcst1icted Stock that is at that time subject to restrictions shall be forfeited; provided, however, that the
Committee may (a) provide in any Restricted Stock Award Agreement that restrictions or forfeiture conditions relating to Restricted Stock will be waived in
whole or in pan in the event oftc1minations resulting from specified causes, and (b) in other cases waive in whole or in part restrictions or forfeiture
conditions relating to Restricted Stock.
6.4 Certificates for Resrricred Stock. Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Committee shall
determine. If certi fie ates representing shares of Restricted Stock are registered in the name of the Participant, certificates must bear an appropriate legend
referring to the tenns, conditions, and restrictions applicable to such Restricted Stock, and the Company may, at its discretion, retain physical possession of
the certificate until such time as all applicable restrictions lapse.

ARTICLE 7
STOCK APPRECIATION RIGHTS
7 .1 Gra111 o_lStock Appreciatio11 Rights. A Stock Appreciation Right may be granted to any Participant selected by the Committee. A Stock
Appreciation Right may be granted (a) in connection and simultaneously with the grant of an Option, (b) with respect to a previously granted Option, or
(c) independent ofan Option. A Stock Appreciation Right shall be subject to such tenns and conditions not inconsistent with the Plan as the Committee shall
impose and shall be evidenced by an Award Agreement.

1.2

Coupled Srock Appreciario11 Righrs.

(a) A Coupled Stock Appreciation Right ("CSAR") shall be related to a particular Option and shall be exercisable only when and to the extent
the related Option is exercisable,provided, however, that the exercise price for any CSAR shall not be less than I 00% of the Fair Market Value on the
date of grant; and provided.further, that, the Committee in its sole and absolute discretion may provide that the CSAR may be exercised subsequent
to a termination of employment or service, as applicable, or following a Change in Control of the Company, or because of the Participant's retirement,
death or disability, or otherwise.

(b) A CSAR may be granted to a Participant for no more than the number of shares subject to the simultaneously or previously granted Option to
which it is coupled.
(c) A CSAR shall entitle the Participant (or other person entitled to exercise the Option pursuant to the Plan) to surrender to the Company the
unexereised ponion of the Option to which the CSAR relates (to the extent then exercisable pursuant to its tenns) and to receive from the Company in
exchange therefor an amount determined by multiplying the difference obtained by subtracting the Option exercise price from the Fair Market Value
ofa share of Stock on the date
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of exercise oft he CSAR by the number of shares of Stock with respect to which the CSAR shall have been exercised, subject to any limitations the
Committee may impose.
7.3

Jndependenl S10ck Apprecialio11 Rigllls.

(a) An Independent Stock Appreciation Right ("/SAR") shall be unrelated to any Option and shall have a tenn set by the Committee. An ISAR
shall be exercisable in such installments as the Committee may detennine. An !SAR shall cover such number of shares of Stock as the Committee may
determine. The exercise p1ice per share of Stock subject to each ISAR shall be set by the Committee; provided, however, that the exercise p1icc for any
(SAR shall not be less than l 00% ofthe Fair Market Value on the date of grant; and provided.further, that, the Committee in its sole and absolute
discretion may provide that the ISAR may be exercised subsequent to a tennination of employment or service, as applicable. or following a Change in
Control of the Company, or because of the Participant's retirement, death or disability, or otherwise. Other than pursuant to Section 11.1, the
Commillee shall not, without the approval of the Company's shareholders, (a) iowcr the exercise price per share of Stock subject lo each ISAR after it
is granted, {b) cancel an ISAR when the exercise price per share of Stock exceeds the Fair Market Value of one share of Stock in exchange for cash or
another Award (other than in connection with a Change in Control), or (c) take any other action with respect to an ISAR that would be treated as a
repricing under the rules and regulations of the p1incipal U.S. national securities exchange on which the shares of Stock arc listed.
(b) An ISAR shall entitle the Participant (or other person entitled to exercise the ISAR pursuant to the Plan) lo exercise all or a specified portion
of the ISAR (to the extent then exercisable pursuant to its tcnns) and to receive from the Company an amount detennined by multiplying the
ditlerence obtained by subtracting the exercise p1ice per share of the ISAR from the Fair Market Value ofa share of Stock on the date of exercise oflhc
ISAR by the numbcrofsharcs of Stock with respect lo which the ISAR shall have been exercised, subject to any limitations the Committee may
impose.
(e) Notwithstanding anything to the contrary in this Section 7.3, in the event that on the last business day of the tcnn ofan ISAR (x) the exercise
of the ISAR is prohibited by applicable law or (y) shares of Stock may not be purchased or sold by certain employees or directors of the Company due
to the "black-out period" ofa Company policy or a "lock-up" agreement undertaken in connection with an issuance of securities by the Company, the
term shall be extended for a period of thirty (30) days following the end of the legal prohibition, black-out period or lock-up agreement. In addition,
an Award Agreement for an ISAR may provide that if on the last day of the tenn of the Fair Market Value of one share of Stock exceeds the grant price
per share of Stock of the ISAR, the Participant has not exercised the ISAR, and the ISAR has not otherwise expired, the ISAR shall be deemed to have
been exercised by the Participant on such day. In such event, the Company shall make payment to the Participant in accordance with this Section,
reduced by the number of shares of Stock (or cash) required for withholding taxes; provided, however, any fractional share of Stock shall be settled in
cash.
7.4

Payment and limilalinns on Exercise.
(a) Subject to Section 7.4(b) and (c), payment oflhe amounts detennined under Sections 7.2(c) and 7.J(b) above shall be in cash, in shares of
Stock (based on its Fair Market Value as of the date the Stock Appreciation Right is exercised) or a combination of both, as determined by the
Committee.
·

(b) To the extent payment for a Stock Appreciation Right is to be made in cash, the Award Agreement shall, to the extent necessary to comply
with the requirements of Section 409A of the Code, specify the date of payment, which may be different than the date of exercise of the Stock
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Appreciation Right. If the date of payment for a Stock Appreciation Right is later than the date of exercise, the Award Agreement may specify that the
Participant be entitled to earnings on such amount until paid.
(c) To the extent any payment under Section 7 .2(c) or 7 .3 (b) is effected in Stock 1t shall be made subject to satisfaction of any applicable
provisions of A11iclc 5 above pertaining to Options.

ARTICLE 8
OTHER TYPES OF AWARDS
8.1 Performance Share Awards. Any Participant selected by the Committee may be granted one or more Pe1fonnance Share awards which shall be
denominated in a number of shares of Stock and which may be linked to any one or more of the Perfonnance Criteria or other specific perfonnance criteria
detcnnined appropriate by the Committee, in each case on a specified date or dates or over any period or periods detem1ined by the Committee. In making
such determinations, the Committee shall consider (among such other factors as it deems relevant in light of the specific type of award) the contributions,
responsibilities and other compensation of the particular Participant.
8.2 Performance Uni rs. Any Participant selected by the Committee may be granted one or more Perfonnance Unit awards which shall be denominated
in units of value, including dollar value of shares of Stock, and which may be linked to any one or more of the Perfo1mance C1iteria or other specific
performance criteria determined appropriate by the Committee, in each case on a specified date or dates or over any period or periods determined by the
Committee. In making such detenninations, the Committee shall consider (among such other factors as it deems relevant in light of the specific type of award)
the contributions, responsibilities and other compensation of the particular Participant.

8.3

Dividend Equivalents.

(a) Any Participant selected by the Committee may be granted Dividend Equivalents based on the dividends declared on the shares of Stock that
arc subject to any Award, to be credited as of dividend payment dates, du1ing the pc1iod between the date the Award is granted and the date the Award
is exercised, vests or expires. as detennined by the Committee. Such Dividend Equivalents shall be converted to cash or additional shares of Stock by
such formula and at such time and subject to such limitations as may be determined by the Committee. Notwithstanding the foregoing, Dividend
Equivalents credited in connection with an Award that vests based on the achievement of Perfonnance Crite1ia or other specific performance criteria
shall be subject to restrictions and risk of forfeiture to the same extent as the Award with respect to which such Dividend Equivalents have been
credited.

(b) Dividend Equivalents granted with respect to Options or SARs shall be payable, with respect to pre-exercise periods, regardless of whether
such Option or SAR is subsequently exercised.
8.4 Stock Payments. Any Participant selected by the Committee may receive Stock Payments in the manner detennined from time to time by the
Committee. The number of shares of Stock shall be determined by the Committee and may be based upon the Performance Criteria or other specific
performance criteria determined appropriate by the Committee, determined on the date such Stock Payment is made or on any date thereafter.
8.5 Deferred Stock. Any Participant selected by the Committee may be granted an award ofDeferred Stock in the manner determined from time to
time by the Committee. The number of shares of Deferred Stock shall be determined by the Committee and may be linked to the Performance Criteria or other
specific performance criteria detcnnined to be appropriate by the Committee, in each case on a specified date or dates or over any period or periods
determined by the Committee. Shares
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of Stock underlying a Deferred Stock award will not be issued until the Deferred Stock award has vested, pursuant to a vesting schedule or performance
crite1ia set by the Committee. Unless otherwise provided by the Commillee, a Pa11icipant awarded Deferred Stock shall have no 1ights as a Company
shareholder with respect to such Defen-ed Stock until such time as the Deferred Stock Award has vested and the shares ofSwck underlying the Deferred Stock
Award have been issued.
8.6 Restricted Stock U,rits. The Committee is authorized to make Awards ofRest1icted Stock Units to any Participant selected by the Committee in
such amounts and subject to such tem1s and conditions as determined by the Committee. At the time of grant, the Committee shall specify the date or dates
on which the Rest1icted Stock Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as it deems appropiiate. At the
time of grant, the Committee shall specify the maturity date applicable to each grant ofRcst1ictcd Stock Units which shall be no earlier than the vesting date
or dates of the Award and may be determined at the election of the grantee. On the maturity date, the Company shall, subject to Section I 0.S(b), transfer to the
Participant one unrestricted, fully transferable share of Stock for each Restricted Stock Unit scheduled to be paid out on such date and not previously
forfeited. Tnc Committee shall specify the purchase price, if any, to be paid by the grantee to the Company for such shares of Stock.
8.7 Other Stock-Based Awards. Any Participant selected by the Committee may be granted one or more Awards that provide Pa11ieipants with shares
of Stock or the right to purchase shares of Stock or that have a value de1ived from the value of, or an exercise or conversion privilege at a price related to, or
that arc otherwise payable in shares of Stock and which may be Iinked to any one or more of the Performance Criteria or other speci fie performance criteria
determined appropriate by the Committee, in each case on a specified date or dates or over any period or periods determined by the Committee. In making
such determinations, the Committee shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions,
responsibilities and other compensation of the particular Participant.
8.8 Term. Except as otherwise provided herein, the te1m of any Award of Pe1formance Shares, Perfo1mance Units, Dividend Equivalents, Stock
Payments, Deferred Stock, Rest1icted Stock Units or Other Stock-Based Award shall be set by the Committee in its discretion.
8.9 Exercise or Purchase Price. The Committee may establish the exercise or purchase price, if any, of any Award of Performance Shares, Performance
Units, Deferred Stock, Stock Payments, Restricted Stock Units or Other Stock-Based Award; provided, however, that such p1ice shall not be less than the par
value of a share of Stock on the date of grant, unless otherwise pem1itted by applicable state law.
8.10 Exercise Upon Termination of Employmenl or Service. An Award of Performance Shares, Performance Units, Dividend Equivalents, Deferred
Stock, Stock Payments, Restricted Stock Units and Other Stock-Based Award shall only be exercisable or payable while the Participant is an Employee, a
Consultant, or a member of the Board, as applicable; provided, however, that the Committee in its sole and absolute discretion may provide that an Award of
Performance Shares, Performance Units, Dividend Equivalents, Stock Payments, Deferred Stock, Restricted Stock Units or Other Stock-Based Award may be
exercised or paid subsequent to a termination of employment or service. as applicable, or following a Change in Control of the Company, or because of the
Participant's retirement, death or disability, or otherwise; provided, however, that any such provision with respect to Performance Shares or Performance Units
shall be subject to the requirements of Section l 62(m) of the Code that apply to Qualified Performance-Based Compensation.
8.11 Form of Payment. Payments with respect to any Awards granted under this A11icle 8 shall be made in cash, in shares of Stock or a combination of
both, as determined by the Committee.
8.12 Award Agreeme,rt. All Awards under this Article 8 shall be subject to such additional terms and conditions as determined by the Committee and
shall be evidenced by an Award Agreement.
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ARTICLE 9
PERFORMANCE-BASED AW ARDS

9.1 Pu,pose. The purpose of this Article 9 is to provide the Committee the ability to qualify Awards other than Options and SARs and that are granted
pursuant to Articles 6 and 8 as Qualified Performance-Based Compensation. If the Committee, in its discretion, decides to grant a Performance-Based Award
to a Covered Employee, the provisions of this Article 9 shall control over any contrary provision contained in A1ticles 6 or 8; provided, however, that the
Committee may in its discretion grant Awards to Covered Employees that are based on Pe1formance Crite1ia or Perfmmance Goals but that do not satisfy the
requirements of this Article 9.
9.2 Applicability. This Article 9 shall apply only to those Covered Employees selected by the Committee to receive Perfonnance-Based Awards. The
designation of a Covered Employee as a Participant for a Performance Period shall not in any manner entitle the Participant to receive an Award forthe
period. Moreover, designation ofa Covered Employee as a Participant fora particular Pe1fo1mance Period shall not require designation of such Covered
Employee as a Pa1ticipant in any subsequent Performance Period and designation ofone Covered Employee as a Participant shall not require designation of
any other Covered Employees as a Participant in such period or in any other period.
9.3 Procedures with Respect to Perfonnance-Bused Awards. To the extent necessary to comply with the Qualified Perfonnance-Based Compensation
requirements of Section I 62(m)(4)(C) of the Code, with respect to any Award granted under Articles 6 and 8 which may be granted to one or more Covered
Employees, no later than ninety (90) days following the commencement of any fiscal year in question or any other designated fiscal period or period of
service (or such other time as may be required or permitted by Section I 62(m) of the Code), the Committee shall, in writing, (a) designate one or more
Covered Employees, (b) select the Performance Crite1ia applicable to the Performance Period, (c) establish the Performance Goals, and amounts of such
Awards, as applicable, which may be earned for such Perfonnance Period, and (d) specify the relationship between Performance Criteria and the Performance
Goals and the amounts of such Awards, as applicable, to be earned by each Covered Employee for such Performance Period. Following the completion of
each Performance Period, the Committee shall certify in w1iting whether the applicable Performance Goals have been achieved for such Performance Period.
In dctennining the amount earned by a Covered Employee, the Committee shall have the right to reduce or eliminate (but not to increase) the amount
payable at a given level of performance to take into account additional factors that the Committee may deem relevant to the assessment of individual or
corporate perfonnance for the Pe1formance Period.
9.4 Payment of Pe,formance-Based Awards. Unless otherwise provided in the applicable Award Agreement, a Participant must be employed by the
Company or a Subsidiary on the day a Performance-Based Award for such Performance Period is paid to the Participant. Furthermore, a Participant shall be
eligible to receive payment pursuant to a Performance-Based Award for a Perfonnance Period only if the Performance Goals for such period are achieved.
9.5 Additional Limitations. Notwithstanding any other provision of the Plan, any Award which is granted to a Covered Employee and is intended to
constitute Qualified Performance-Based Compensation shall be subject to any additional limitations set forth in Section l 62(m) of the Code (including any
amendment to Section I 62(m) of the Code) or any regulations or rulings issued thereunder that are requirements for qualification as qualified performancebased compensation as described in Section 162(m)(4)(C) of the Code, and the Plan shall be deemed amended to the extent necessary to confonn to such
requirements.
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ARTICLE 10
PROVISIONS APPLICABLE TO A WARDS

I 0.1 Stand-Alo11e and Tandem Awards. Awards granted pursuant to the Plan may, in the discretion of the Committee, be granted either alone, in
addition to, or in tandem with, any other Award granted pursuant to the Plan. Awards granted in addition to or in tandem with other Awards may be granted
either at the same time as orat a different time from the grant of such other Awards.
I 0.2 Award Agreement. Awards under the Plan shall be evidenced by Award Agreements that shall set forth the tenns, conditions, limitations and
award type for each Award which may include the te1m ofan Award, the provisions applicable in the event the Participant's employment or service
tenninates, and the Company's authority to unilaterally or bilaternlly amend, modify, suspend, caned ur n:scind an Award.
I 0.3 limits 011 Transfer. Except as provided below, no right or interest ofa Participant in any Award may be pledged, encumbered, or hypothccated to
or in favor of any pa11y otherthan the Company or a Subsidiary, or shall be subject to any lien, obligation, or liability of such Participant to any other pa11y
other than the Company or a Subsidiary. Except as otherwise provided by the Committee, during the life of the recipient, such award shall be exercisable
only by such person or by such person's guardian or legal representative. To the extent and under such terms and conditions as determined by the Committee,
a Participant may assign or transfer an Award without consideration (each transferee thereof, a "Permitted Assignee") (a) to the Participant's spouse, children or
grandchildren (includmg any adopted and step children or grandchildren), parents, grandparents or siblings, (b) to a trust for the benefit of one or more of the
Participant or the persons referred to in clause (a), (c) to a partnership, limited liability company or corporation in which the Participant or the persons referred
to in clause (a) are the only partners, members or shareholders or (d) for cha1itable donations; provided that such Pennitted Assignee shall be bound by and
subject to all of the tenns and conditions of the Plan and the Award Agreement relating to the transfe1Ted Award and shall execute an agreement satisfactory
to the Company evidencing such obligations; and provided further that such Participant shall remain bound by the tenns and conditions of the Plan.

I 0.4

Death of Optionee.

(a) Options. Notwithstanding Section I 0.3, upon the death of the Optionee while either in the Company's employ or within six months after
tennination ofOptionee's employment, any 1ights to the extent exercisable on the date of death may be exercised by the Optionee's estate, or by a
person who acquires the right to exercise such Option by bequest or inheritance or by reason of the death of the Optionee,provided that such exercise
occurs within both the remaining effective term of the Option and one yearafterthe Optionee's death. A beneficiary, legal guardian, legal
representative, or other person claiming any rights pursuant to the Plan is subject to all tenns and conditions of the Plan and any Award Agreement
applicable to the Participant, except to the extent the Plan and Award Agreement otherwise provide, and to any additional restrictions deemed
necessa1y or appropriate by the Committee. If no beneficiary has been designated or survives the Participant, payment shall be made to the person
entitled thereto pursuant to the Participant's will or the laws of descent and distribution. Subject to the foregoing. a beneficiary designation may be
changed or revoked by a Participant at any time provided the change or revocation is filed with the Committee.

(b) Incentive Stock Options. Upon the death of the Optionee while in the Company's employ or within not more than six months after
tcnnination ofOptionee's employment, any Incentive Stock Option exercisable on the date of death may be exercised by the Optionee's estate or by a
person who acquires the right to exercise such Incentive Stock Option by bequest or inheritance or by reason of the death of the Optioncc, provided
that such exercise occurs within
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both the remaining Option Term of the Incentive Stock Option and one year after the Optioncc's death.

I 0.5

Retirement or Disability.

(a) Options. Upon termination of the Optionce's employment by reason of retirement or permanent disability, the Optionee may, within
36 months from the date of termination, exercise any Options to the extent such Options are exercisable during such 36-month period.
(b) Incentive Stock Options. Upon tennination of the Optionee's employment by reason ofretirement orpennanent disability, the Optionee
may, within 36 months from the date of termination, exercise any Incentive Stock Options to the extent such Incentive Stock Options are exercisable
during such 36-month period. However, the tax treatment available pursuant to Section 422 of the Code will not be available to an Optionee who
exercises any Incentive Stock Option more than (i) l 2 months after the date of termination of employment due to permanent disability, or (ii) three
months after the date oftennination of employment due to retirement.
10.6 Termina1io11Jor Other Reasons. Except as provided herein or except as otherwise determined by the Committee, all Options shall terminate
ninety (90) days after the termination of the Optionee's employment with the Company.
l 0.7 Leaves oJA.hsence and Pe1formance Targets. The Committee shall be entitled to make such rules, regulations and determinations as it deems
appropriate under the Plan in respect of any leave of absence taken by the recipient of any Award. Without limiting the generality of the foregoing, the
Committee shall be entitled to determine (a) whether or not any such leave of absence shall constitute a termination of employment within the meaning oft he
Plan and (b) the impact, if any, of such leave of absence on Awards under the Plan theretofore made to any recipient who takes such leave of absence. The
Committee shall also be entitled to make such determination of performance targets, if any, as it deems appropriate.
I 0.8 Newly Eligible Employees. The Committee shall be entitled to make such rules, regulations, determinations and Awards as it deems appropriate
in respect of any Employee who becomes eligible to participate in the Plan or any portion thereof, after the commencement of an Award or incentive pe1iod.
I 0.9 Stock Certificates; Book Entry Procedures. As soon as practicable after receipt of payment, the Company shall deliver to the Optionee a
certificate(s) for such shares of Stock. Upon receipt of such certificate(s), the Optionee shall become a shareholder of the Company with respect to shares of
Stock represented by share ce1tificates so issued and as such shall be fully entitled to receive dividends. to vote and to exercise all other rights ofa
shareholder. All Stock certificates delivered pursuant to the Plan are subject to any stop-transfer orders and other restrictions as the Committee deems
necessary or advisable to comply with federal, state, or foreign jurisdiction, securities or other laws, rules and regulations and the rules of any national
securities exchange or automated quotation system on which the shares of Stock are listed, quoted, or traded. The Committee may place legends on any Stock
certificate to reference restrictions applicable to the shares of Stock. In addition to the terms and conditions provided herein, the Board may require that a
Participant make such reasonable covenants, agreements, and representations as the Board, in its discretion, deems advisable in order to comply with any
such laws. regulations, or requirements. The Committee shall have the right to require any Participant to comply with any timing or other rest1ictions with
respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Committee.
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ARTICLE I I
CHANGES IN CAPITAL STRUCfURE
I I.I

Adj11stme11ts.

(a) In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation, spin-off, recapitalization,
distribution of Company assets to shareholders (other than normal cash dividends), or any other corporate event affecting the shares of Stock or the
share price of the shares of Stock, the Committee shall make such proportionate adjustments, if any, as the Committee in its discretion may deem
approp1iate to reflect such changes with respect to (i) the aggregate number and type of shares of Stock that may be issued under the Plan (including,
but noi limited to, adjustments of the limitations in Sections 3.l and 3.3); (ii) the tenns and conditions of any outstanding Awards (including, without
limitation, any applicable performance targets or criteria with respect thereto); and (iii) the grant or exercise price per share for any outstanding
Awards underthe Plan. Any adjustment affecting an Award intended as Qualified Perfo1mance-Based Compensation shall be made consistent with the
requirements of Section I 62(m) of the Code.
(b) In the event of any transaction or event described in Section I I. I (a) or any unusual or nonrccuning transactions or events affecting the
Company, any affiliate of the Company, or the financial statements of the Company or any affiliate (including without limitation any Change in
Control), or of changes in applicable laws, regulations or accounting principles, and whenever the Committee determines that action is appropriate in
order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any
Award und~rthe Plan, to facilitate such transactions or events orto give effect to such changes in laws, regulations or principles, the Committee, in its
sole discretion and on such terms and conditions as it deems appropriate, either by amendment of the terms of any outstanding Awards or by action
taken prior to the occurrence of such transaction or event and either automatically or upon the Participant's request, is hereby authorized to take any
one or more of the following actions:
(i) To provide for either(A) termination of any such Award in exchange for an amount of cash and/or other property, if any, equal to the
amount that would have been attained upon the exercise of such Award or realization of the Participant's rights (and, for the avoidance of
doubt, if as of the date of the occurrence of the transaction or event described in this Section I I .I (b) the Committee determines in good faith
that no amount would have been attained upon the exercise of such Award or realization of the Participant's rights, then such Award may be
terminated by the Company without payment) or (B) the replacement of such Award with other rights or property selected by the Committee in
its sole discretion;
(ii) To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be
substituted for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof,
with appropriate adjustments as to the number and kind of shares and prices; and
(iii) To make adjustments in the number and type of shares of Stock (or other securities or property) subject to outstanding Awards, and in
the number and kind of outstanding Restricted Stock or Deferred Stock and/or in the terms and conditions of (including the grant or exercise
price), and the criteria included in, outstanding options, rights and awards and options, rights and awards which may be granted in the future;
(iv) To provide that such Award shall be exercisable or payable or fully vested with respect to all shares covered thereby, notwithstanding
anything to the contrary in the Plan or the applicable Award Agreement; and
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(v} To provide that the Award cannot vest, be exercised or become payable after such event.
11.2 Outstanding Awards-Other Changes. In the event of any other change in the capitalization of the Company or corporate change other than
those specifically referred to in this Article 11. the Committee may, in its absolute discretion, make such adjustments in the number and kind of shares or
other securities subject to Awards outstanding 011 the date on which such change occurs and in the per share grant or exercise price of each Award as the
Committee may consider appropriate to prevent dilution or enlargement of rights.
I 1.3 No Other Rights. Except as expressly provided in the Plan, no Pa11icipant shall have any rights by reason of any subdivision or consolidation of
shares of stock of any class. the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution,
liquidation, merger, or consolidation of the Company or any other cotporation. Except as expressly provided in the Plan or pursuant to action of the
Committee under the Plan, no issuance by the Company of shares of stock of any class, or securities conve11ible into shares of stock of any class, shall affect,
and no adjustment by reason thereof shall be made with respect to, the number of shares of Stock subject to an Award or the grant or exercise price of any
Award.

ARTICLE 12
ADMINISTRATION
12. l Committee. Pursuant to Utah Code Annotated Section 16-1 0a-624, and consistent with the provisions of Section 12.3 below, the Board may
appoint a Committee consisting of two or more Non-Employee Directors to administer the Plan, as constituted from time to time.
12.2 Committee Appointee Duration. Once appointed, the Committee shall continue to serve until otherwise directed by the Board. From time to
time, the Board may increase or change the size of the Committee, and appoint new members thereof, remove members (with or without cause) and appoint
new members in substitution, fill vacancies, however caused, or remove all members of the Committee: provided. however, that at no time shall any person
administer the Plan who is not otherwise a Non-Employee Director.
12.3 Action by the Board. Unless and until the Board delegates administration of the Plan to a Committee as set forth below, the Plan shall be
administered by the full Board, and for such putposes the term "Committee'' as used in this Plan shall be deemed to refer to the Board. The Board, at its
discretion or as otherwise necessary to comply with the requirements of Section I 62(m) of the Code, Rule l 6b-3 promulgated under the Exchange Act orto
the extent required by any other applicable rule or regulation. shall delegate administration of the Plan to a Committee. The Committee shall consist solely of
two or more members of the Board each of whom is an "outside director," within the meaning of Section l 62(m) of the Code and any other applicable mies
and regulations, a Non-Employee Director and an "independent director" for pu1pose of the mies of the principal U.S. national secmities exchange on which
the Shares are traded, to the extent required by such rules. Notwithstanding the foregoing: (a) the full Board, acting by a majority of its members in office,
shall conduct the general administration of the Plan with respect to all Awards granted to Independent Directors and, for puiposes of such Awards, the term
"Committee" as used in this Plan shall be deemed to refer to the Board and (b) the Committee may delegate its authority hereunder to the extent petmitted by
Section I 2.5. Appointment of Committee members shall be effective upon acceptance of appointment. The Board may abolish the Committee at any time and
revest in the Board the administration of the Plan. Committee members may resign at any time by delivering written notice to the Board. Vacancies in the
Committee may only be filled by the Board.
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12.4 Action by the Commiuee. A majority of the Committee shall constitute a quomm. The acts ofa majority of the members present at any meeting at
which a quorum is present, and acts approved in writing by a majority of the Committee in lieu ofa meeting, shall be deemed the acts of the Committee. Each
member of the Committee is entitled to, in good faith, rely or act upon any repo11 or other infonnation fumished to that member by any officer or other
employee of the Company or any Subsidiary, the Company's independent certified public accountants, or any executive compensation consultant or other
professional retained by the Company to assist in the administration of the Plan.
12.5

A11thori~v of Committee.

Subject to any specific designation in the Plan, the Committee has the exclusive power, authority and discretion to:

(a) Designate Participants to receive Awards;
(b) Determine the type or types of Awards to be granted to each Participant;
(c) Determine the number of Awards to be granted and the number of shares of Stock to which an Award will relate;

(cl) Dete1mine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the exercise p1ice, grant price,
or purchase price, any restrictions or limitations on the Award, any schedule for lapse of fo1feiture restrictions or restrictions on the exercisability of an
Award, and accelerations or waivers thereof, any provisions related to non-competition and recapture of gain on an Award, based in each case on such
considerations as the Committee in its sole discretion detemtines;
(e) Detennine whether, to what extent, and pursuant to what circumstances an Award may be settled in, or the exercise price ofan Award may be
paid in, cash, Stock, other Awards, or other propc11y, or an Award may be canceled, forfeited, or suii-endered;

(t) Prescribe the form of each Award Agreement, which need not be identical for each Participant;
(g) Decide all other matters that must be determined in connection with an Award;
(h) Establish, adopt, or revise any rules and regulations as it may deem necessary or advisable to administer the Plan;
(i)

Interpret the terms of, and any matter arising pursuant to, the Plan or any Award Agreement; and

(i) Make all other decisions and determinations that may be required pursuant to the Plan or as the Committee deems necessary or advisable to
administerthe Plan.
The Committee may delegate to one or more of its members or to one or more agents such administrative duties as it may deem advisable.
12.6 Decisions Binding. The Committee's interpretation of the Plan, any Awards granted pursuant to the Plan, any Award Agreement and all decisions
and determinations by the Committee with respect to the Plan arc final, binding, and conclusive on all pa11ics.
12.7 Delegation ofAuthority. To the extent permitted by applicable law, the Committee may from time to time delegate to a committee ofone or
more members ofthe Committee or the Board or one or more officers of the Company the authority to grant or amend Awards to Participants other than
(a) senior executives and Independent Directors of the Company who are subject to Section 16 of the Exchange Act, {b) Covered Employees, or (c) officers of
the Company (or members of the Board) to whom authority to grant or amend Awards has been delegated hereunder. Any delegation hereunder shall be
subject to the restrictions and limits that the Committee specifies at the time of such delegation, and the Committee may at any time rescind the authority so
delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 12.7 shall se1ve in such capacity at the pleasure of the
Committee.
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12.8 Commillee Admi11islratio11. One mcmbcrofthe Committee shall be clccled by lhe Roard as chainnan. The Commillce shall hold its meetings al
such times and places as it shall deem advisable. The Commillcc may appoint a secretary and make such rules and regula1ions for the conduct of its business
as it shall deem advisable, and shall keep minutes of its meetings.
12.9 Liability. No member of the Board or Committee shall be I iable for any action taken or decision or determination made in good faith with respect
to any Option, the Plan, or any award thereunder.

ARTICLE 13
EFFECTIVE AND EXPIRATION DATE
13.1 Effeclive Dare. The Plan is effective as of the date the Plan is approved by a majority of the Board (the "Ejfeclive Dare"). The Plan, however, shall
be subject to approval by the shareholders. The Plan will be deemed to be approved by the shareholders ifit receives the affinnative vote of the holders ofa
majority of the shares of stock of the Company present or represented and entitled to vote at a meeting duly held in accordance with the applicable
provisions of the Company's Bylaws, but, in any event, held no later than 12 months afler the Effective Date.
13.2 Expiralion Date. The Plan will expire on, and no Incentive Stock Option or other Award may be granted pursuant to the Plan after, the tenth
anniversary of the Effective Date. Any Awards that arc outstanding on the tenth anniversary of the Effective Date shall remain in force according to the terms
of the Plan and the applicable Award Agreement.

ARTICLE 14
AMENDMENT, MODIFICATION, AND TERMINATION
14. I Amendment. Modification, And Termination. The Commi11ee may at any time and from time to time tenninate or modify or amend the Plan in
any respect, except that (a) to the extent necessary and desirable to comply with any applicable law, regulation, or stock exchange rule, the Company shall
obtain shareholder approval of any Plan amendment or any modification of any Options or ISARs that would (i) cancel the Award in exchange for cash or
another Award, (ii) reduce the exercise price of the Award, or (iii) otherwise be deemed a re-pricing under applicable rules, in such a manner and to such a
degree as required, and (b) without shareholder approval the Committee may not (i) increase the maximum number of shares of Stock which may be issued
under the Plan (other than increases pursuant to Section 11.1 ), (ii) increase the limitations in Sections 3.3 and 3.4 (other than increases pursuant to
Section I I .I), (iii) amend to the Plan to permit the Committee to grant Options or ISARs with an exercise price that is below Fair Market Value on the date of
grant, (iv) extend the term of the Plan, or (v) add Perfo1mance Criteria to Section 2.25 . The termination or any modification or amendment of the Plan, except
as provided in subsection (a), shall not without the consent of a Participant, affect his or her other rights under an Award previously granted to him or her.
14.2 Awards Previously Granred. No termination, amendment. or modification of the Plan shall adversely affect in any material way any Award
previously granted pursuant to the Plan without the prior written consent of the Participant.

ARTICLE 15
COMPLIANCE WITH SECTION 409A OF THE CODE
15.1 Awards subjeel to Code Sec/ion 409A. Any Award that constitutes, or provides for, a deferral of compensation subject to Section 409A of the
Code (a "Section 409A Award") shall satisfy the requirements of Section 409A of the Code and this Article 15, to the extent applicable. The Award
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Agreement with respect to a Section 409A Award shall incorporate the tcnns and conditions required by Section 409A oflhc Code and this Article 15.

I 5.2

Dislrib111io11s IJll(/er a Sec1io11 409A Award.

(a) Subject to subsection (b), any shares of Stock or other property or amounts to be paid or dist1ibuted upon the grant, issuance. vesting,
exercise or payment of a Section 409A Award shall be distributed in accordance with the requirements of Section 409A(a)(2) of the Code, and shall
not be distributed earlier than:
(i) the Pa11icipant's separation from service;
(ii) the date the Participant becomes disabled;
(iii) the Pa111cipant's death;
(iv) a specified time (or pursuant lo a fixed schedule) specified under the Award Agreement al the date of the deferral compensation;
(v) a change in the ownership or effective control of the Company or a Parent or Subsidiary, or in the ownership ofa substantial portion
of the assets of the Company or a Parent or Subsidiary; or
(vi) the occurrence of an unforeseeable emergency with respect to the Participant.
(b) In the case of a Paiticipant who is a "specified employee," the requirement of paragraph (a)(i) shall be met only if the distributions with
respect to the Section 409A Award may not be made before the date which is six months after the Participant's separation from seivice (or, if earlier,
the date of the Participant's death). For purposes of this subsection (b), a Participant shall be a "specified employee" if such Participant is a key
employee (as defined in Section 4 I 6(i) of the Code without regard to paragraph (5) thercot) of a corporation any stock of which is publicly traded on
an established securities market or otheiwise, as detennined under Section 409A(a)(2)(B)(i) of the Code and the Treasury Regulations thereunder.
(c) The requirement of paragraph (a)(vi) shall be met only if, as determined under Treasury Regulations under Section 409A(a)(2)(B)(ii) of the
Code, the amounts distributed with respect to the unforeseeable emergency do not exceed the amounts necessary to satisfy such unforeseeable
emergency plus amounts necessary to pay taxes reasonably anticipated as a result of the distribution, after taking into account the extent to which
such unforeseeable emergency is or may be relieved through reimbursement or compensation by insurance or otheiwise or by liquidation of the
Participant's assets (to the extent the liquidation of such assets would not itself cause severe financial hardship).
(d) For purposes of this Section, the terms specified therein shall have the respective meanings ascribed thereto under Section 409A of the Code
and the Treasuiy Regulations thereunder.
15.3 Prohibition on Ac:c:eleratio11 o_f Benefits. The time or schedule of any distribution or payment of any shares of Stock or other property or amounts
under a Section 409A Award shall not be accelerated, except as otherwise permitted under Section 409A(a)(3) of the Code and the Treasury Regulations
thereunder.

15.4 Elections 1mder Section 409A Awards.
(a) Any deferral election provided under or with respect to an Award to any Eligible Individual, or to the Participant holding a Section 409A
Award, shall satisfy the requirements of Section 409A(a)(4)(B) of the Code, to the extent applicable, and, except as othelWise permitted under
paragraph (i) or (ii) below, any such deferral election with respect to compensation for
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services perfom1cd during a taxable year shall be made not later than the close of the preceding taxable year, or at such other time as provided in
Treasury Regulations.
(i} ln the case of the first year in which an Eligible Individual or a Participant holding a Section 409A Award, becomes eligible to
pa11icipate in the Plan, any such deferral election may be made with respect to setvices to be perfo1med subsequent to the election with thi11y
days after the date the Eligible Individual, or the Participant holding a Section 409A Award, becomes eligible to pai1icipa1e in the Plan, as
provided under Section 409A(a)(4)(B)(ii) of the Code.
(ii) In the case of any perfo1manee-based compensation based on setvices pe1fo1med by an Eligible Individual, or the Pai1icipant holding
a Section 409A Award, over a period of at least twelve months, any such deferral election may be made no later than six months before the end
of the pe1iod, as provided under Section 409A(a)(4)(B)(iii) of the Code.
(b) In the event that a Section 409A Award permits, under a subsequent election by the Participant holding such Section 409A Award, a delay in
a distriburion or payment of any shares of Stock orothcr prope11y or amounts under such Section 409A Award, or a change in the form of distribution
or payment, such subsequent election shall satisfy the requirements ofSection 409A(a)(4)(C) of the Code. and:
(i) such subsequent election may not take effect until at least twelve months after the date on which the election is made,
(ii) in the case such subsequent election relates to a distribution or payment not described in Section I 0.2(a)(ii), (iii) or (vi), the first
payment with respect to such election may be deferred for a period of not less than five years from the date such distribution or payment
otherwise would have been made, and
(iii) in the case such subsequent election relates to a distribution or payment described in Section I 0.2(a)(iv), such election may not be
made less than twelve months prior to the date of the first scheduled distribution or payment under Section I 0.2(a)(iv).
15.5 Compliance in Form and Operation. A Section 409A Award, and any election under or with respect to such Section 409A Award, shall comply
in fo1m and operntion with the requirements of Section 409A ofthe Code and the Treasuiy Regulations thereunder.

ARTICLE 16
GENERAL PROVISIONS
16.1 No Rights to Awards. No Eligible Individual or other person shall have any claim to be granted any Award pursuant to the Plan, and neither the
Company nor the Committee is obligated to treat Eligible Individuals, Participants or any other persons uniformly.
16.2 No Shareholders Rights. The recipient of any Award under the Plan shall have no rights as a shareholder with respect thereto unless and until
certificates for shares of Stock are issued to him or her.
I 6.3 Withholding. The Company or any Subsidiary shall have the authority and the right to deduct or withhold, or require a Participant to remit to the
Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant's FICA obligation) required by law to be withheld
with respect to any taxable event concerning a Participant arising as a result of this Plan. The Committee may in its discretion and in satisfaction of the
foregoing requirement allow a Participant to elect to have the Company withhold shares of Stock otherwise issuable under an Award (or allow the return of
shares of Stock) having a Fair Market Value equal to the sums required to be
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withheld. Notwithstanding any other provision of the Plan, the number of shares of Stock which may be withheld with respect to the issuance, vesting,
exercise or payment of any Award (or which may be repurchased from the Pai1icipant of such Award within six months (or such other pc1iod as may be
detennined by the Committee) after such shares of Stock were acquired by the Participant from the Company) in order to satisfy the Participant's federal, stale,
local and foreign income and payroll tax liabilities with respect to the issuance, vesting, exercise or payment of the Award shall be limited to the number of
shares which have a Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of such liabilities based on the minimum
statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income.

16.4 No Right to Employment or Services. Nothing in the Plan or any Award Agreement shall interfere with or limit in any way the right of the
Company or any Subsidiary to terminate any Participant's employment or services at any time, nor con fer upon any Participant any right to continue in the
employ orserviceofthe Company or any Subsidiary.
l G.5 Unjimded Siaiu:>· of Awards. The Plun is inh:mh:d lube an "unfunded" pian for incentive compensation. With respect to any payments not yet
made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Participant any rights that arc greater than
those ofa general creditorofthe Company or any Subsidiary.

16.6 Jndemnijication. To the extent allowable pursuant to applicable law, each member of the Committee or of the Board shall be indemnified and
held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with
or resulting from any claim, action, suit, or proceeding to which he or she may be a pa11y or in which he or she may be involved by reason of any action or
failure to act pursuant to the Plan and agamst and from any and all amounts paid by him or her in satisfaction ofjudgment in such action, suit, or proceeding
against him or her; provided he or she gives the Company an opportunity, at its own expense, lo handle and defend the same before he or she undertakes to
handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which
such persons may be entitled pursuant to the Company's Certificate of Incorporation or Bylaws, as a matter oflaw, or otherwise, or any power that the
Company may have to indemnify them or hold them harmless.
16.7 Relationship to other Ben~/its. No payment pursuant to the Plan shall be taken into account in determining any benefits pursuant to any
pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise
expressly provided in writing in such other plan or an agreement thereunder.

16.8 Expenses.

The expenses of administering the Plan shall be borne by the Company and its Subsidiaries.

16.9 Titles and Headings. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict,
the text of the Plan, rather than such titles or headings, shall control.
16.10 Fractional Shares. No fractional shares of Stock shall be issued and the Committee shall determine, in iL" discretion, whether cash shall be
given in lieu offractional shares or whether such fractional shares shall be eliminated by rounding up or down as appropriate.
16.11 LimUations Applicable to Section 16 Persons. Notwithstanding any other provision ofthe Plan, the Plan, and any Award granted or awarded to
a!1y Participant who is then subject to Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive
rule under Section 16 of the Exchange Act (including any amendment to Rule l 6b-3 of the Exchange Act) that arc requirements for the application of such
exemptive rule. To the extent permitted by
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applicable law, the Plan and Awards granted or awarded hereunder shall be deemt:d amended to the extent necessary to confonn to such applicable exemptive
rule.
16.12 Financial Restatements. In the event ofa restatement of the Company's financial statt:ments, the Committee shall have the right to review any
Award, the amount, payment or vesting of which was based on an entry in the financial statements that arc the subject of the restatement. If the Committee
dcte1mines that based on the results of the restatement, a lesser amount or portion of an Award should have been paid or vested, it may (i) cancel all or any
portion of any outstanding Awards and (ii) require the Participant or other person to whom any payment has been made or shares or other property have been
transferred in connection with the Award to forfeit and pay over to the Company. on demand, all or any portion oft he gain (whether or not taxable) realized
upon the exercise of any Option or Stock Appreciation Right and the value realized (whether or not taxable) on the vesting or payment of any other Award
during the period beginning twelve months preceding the date of the restatement and ending with the date of cancellation of any outstanding Awards
16.13 Government and Other Reg11lations. The obligation of the Company to make payment of awards in Stock or otherwise shall be subject to all
applicable laws, rules, and regulations, and to such approvals by government agencies as may be required. The Company shall be under no obligation to
register pursuant to the Securities Act of 1933, as amended, any of the shares of Stock paid pursuant to the Plan. If the shares paid pursuant to the Plan may in
certain circumstances be exempt from registration pursuant to the Securities Act of 1933, as amended. the Company may restrict the transfer of such shares in
such manner as it deems advisable to ensure the availability of any such exemption.
16.14

Governing Law.

The Plan and all Award Agreements shall be constmed in accordance with and governed by the laws of the State of Utah.

• • * • •
• 2015.

I hereby certify that the foregoing Plan was duly adopted by the Board of Directors ofUSANA Ilea Ith Sciences, Inc. on

• * * • •
I hereby certify that the foregoing Plan was approved by the shareholders ofUSANA Health Sciences. Inc. on
Executed on this

day of

, 2015.

, 2015.
Corporate Secretary
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UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)

lRI QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended June 28, 2014
OR

•

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the transition period from

to

Commission file number: 001-35024

USANA HEALTH SCIENCES, INC.
(Exact name ofregistrant as specified in its charter)

Utah
(State or other jurisdiction
of incorporation or organization)

87-0500306
(1.R.S. Employer
Identification No.)

3838 West Parkway Blvd., Salt Lake City, Utah 84120
(Address of principal executive offices, Zip·Code)

(801) 954-7100
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (I) has filed all reports required to be filed by Section 13 or l 5(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Y cs [R) No 0
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Ruic 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months ( or for such
shorter period that the registrant was required to submit and post such files). Yes [R) No 0
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of"largc accelerated filer," "accelerated filer" and "smaller reporting company" in Ruic 12b-2 of the Exchange Act.
Large accelerated filer 0
Non-accelerated filer

•

Accelerated filer [RI
Smaller reporting company D

Indicate by check mark whether the registrant is a shell company (as defined in Rule l 2b-2 of the Exchange Act). Ycs D No 00
The number of shares outstanding of the registrant's common stock as of August I, 2014 was 12,984,073.
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PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
(unaudited)

~

As of
December 28,
2013

As of
June 28,
2014

ASSETS
Current assets
Cash and cash equivalents
Securities held-to-maturity, net
Inventories
Prepaid expenses and other current assets
Total current assets

~
$

Property and equipment, net
Goodwill
Intangible assets, net
Deferred tax assets
Other assets
$
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137,343
8,642
47,242
35,818
229,045

$

118,267
3,374
44,528
35,756
201,925

59,180

65,859

18,243
42,329
5,519
14,154
368,470

17,919
41,015
5,515
22,688
354,921

$

~

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable
Other current liabilities
Total current liabilities

$

9,502
86,369
95,871

Deferred tax liabilities
Other long-term liabilities
Stockholders' equity
·common stock, $0.001 par value; Authorized-50,000 shares, issued and outstanding 13,886 as of
Pecember 28, 2013 and 13,404 as of June 28, 2014
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income
Total stockholders' equity
$

6,408
82,297
88,705

$

10,866
1,211

10,672
1,290

14
54,691
200,023
5,794
260,522
368,470

13
51,925
196,992
5,324
254,254
=$==3=5=4'=92=1

The accompanying notes are an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)
(unaudited)
Six Months Ended
June 29,
June 28,
2014
2013

Quarter Ended
June 28,
June 29,
2014
2013

'$

_N~(s~l~ '.:.
Cost of sales

189,136
31,905

$

188,256 '$.
34,865

.:· .j_ss;2 is
..•.'

157,231

gross_profit

_"$' ":' , _-·-. "?JJQ:6.s.'t

62,166

153,391

,.,,·, ....

-.

68,693

-~ , ..

•.: .- ... ...

,·

~-

:::..\~: ~(\(-~· ..·~---~

296,052
;_,

3P!!~-~4
. .;;";.:.

'

~

,' ' ~ -.- .-

~ ~

' i ' ..-

Opernting expenses:
: Associate incentives
Selling, general and administrative

77,801
42,978

81,098
43,206

147,656
85,382

'J59,972
87,783

Total operating expenses

120,779

124,304

233,038

247,755

36,452

29,087

63,014

54,209

81

215

159

( 164)

82

(268)

I

(83)

297

~ 109)

422

Earnings from operations
Other income (expense):
Interest income.
Interest expense
Other, net
Other income (expense), net

427
(6)

Earnings before income taxes

36,369

29,384

62,905

54,631

Income taxes

12,159

10,083

20,916

18,793

Net earnings
Earnings per common share
Basic
Diluted

$

24,210

$

19,301

$

41,989

$

35,838

s

1.79
1.72

s

1.40

s

3,09

$

$

1.36

$

2.99

$

2.59
2.50

$

Weighted average common shares outstanding
Basic

13,513

13,768

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
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13,578

13,843

Diluted

14,235

14,099

14,034

14,315

Comprehensive income:
Net earni ngs

24,210

$

Other comprehensive income (loss), n<!t of tax:
Foreign currency translation adjustment
Tax benefil (expense) related to foreign currency
translati on adjustment

19,301

$

(2,472)

802

798

Other comprehensive income (loss), net of lax
$

22,536

540
19,84 1

$

35,838

$

(860)

(2,441)

{262)

(1,674)

Comprehensive income

41,989

$

732

390

( I ,709)

(410)

40,280

$

$

35,368

The accompany ing notes arc an integra l part of these statements.
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USANA HEALTH SCIENCES, INC. AND SU IJSID IAIUES
CUNDl<:NSE D CONSOLI DAT ED STATEM ENT OF STOCKH OLDERS' EQUITY
Six Months Ended .Ju ne 28, 20 14
(in thousands)
(unaudited)
Accumula ted
Oth er
Comprehensive
Inco me {Loss}

Acl clitiona l
Common Stock
Shares
Valu e
Balance a! December 28, 20 13
Net earnings
Other comprehensive income (loss),
ne1.Q.f tax
Equity-based compensation expense
Common stock repurc hased and
relired
Common stock issued under equity
award plans, includ ing tax benefit
of $3,387

13,886

Balance at June 28, 201 4

13,404

$

Retained
Earnings

Pa id•i n

Ca(! ital
14

$

54,691

$

200,023
35,838

$

Total

5,794

$

260 522
35,838

(470)

('170)
4,07 1

4,071
(I)

(682)

( I 0,224)

200

(38,869)

(49,094)

3,387

s

13

s

51,925

3,387

s

196,992

5,324

$

$

254,254

The accompa nying notes arc an integ ra l part of these statements .
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USANA II EA LT II SCIENCES, INC. AND SU BSID IARJES
CO ' DENSED CONSO LIDAT ED STAT EM ENTS OF CAS II FLOWS
(in thousands)
(una udit ed)
Six Months Ended
,lun e 29,
J un e 28,
20 14

20 13

Cash flows from operating activi ties
Net ea rnings
Adj us11ncnts to reconcile net ea rnings to net cash provided by (used in) operating act ivities
Depreciation and amortization
(Gain) loss on sale of property and equipment

$
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4 1,989
4,63 1
(6)

$

35,838
4,408
16

•

Equity-based compensation expense
Excess tax benefits from equity-based payment arrangements
Deferred income taxes
Changes in operating assets and liabilities:
Inventories
Prepaid expenses and other assets
Accounts payable
Other liabilities
Net cash provided by (used in) operating activities
Cash.flows from investing activities
Additions to notes receivable
· Purchases of investment securities held-to-maturity
Maturities of investment securities
Proceeds from-sale of property and equipment
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from equity awards exercised
Excess tax benefits from equity-based payment arrangements
Repurchase of common stock
Net cash provided by {use·d in) financing activities

\d)

Effect of exchange rate changes on cash and cash equivalents

4,427
(1,734)
843

4,071
(3,387)

(6,123)
{3,295)
155
6,409

3,034
{5,144)
(3,085)
{3,896)

47,296

31,250

(2,232)

15
(2,961)

(2,520)
,·(3,871)
9,137
8
(10,103)

(5,178)

(7,349)

454
1,734
(18,085)

3,387
(46,109)

(15,897)

(42,722)

(1,004)

{255)

(605)

25,217

Net increase (decrease) in cash and cash equivalents

(19,076)

_ .. ·-'_.._._:7_.0,__
83_9. /;::/ .· ·:,'3; .-:137-~343-Cash amf cash equivalents, end of period

..

':~- ~

'

~

'

. ~ ':'.

,_

..

Suppl~m~ritaj(dis.~h>!iµr¢s_ofcash:flow,.infonnation·
C~jb'.P-a.149pri,Qg-;tji~;pen9_d_ (Qt::: ·
Interest

-:·: ~;Jit~Qgi_(@i~E·~~·

. '·.·.

-.·-··.,,,.

~· ·: ~; .

.:_·,::,

$

$

_.. )l~~O:::>L

,, .·, ..

Non-cash financing activities:
Unsettled trades for repurchase of common stock

6

-~ :·; :-9~963
(2,985)

The accompanying notes are an integral part of these statements.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited)
NOTE A - ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION
USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care products that are sold internationally
through a global network marketing system, which is a form of direct selling. The Consolidated Financial Statements include the accounts and
operations ofUSANA Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the "Company" or"USANA") in two geographic
regions: Americas and Europe and Asia Pacific, which is further divided into three sub-regions; Southeast Asia Pacific, Greater China, and North
Asia. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands.
Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand; Greater China includes Hong Kong,
Taiwan and China; and North Asia includes Japan and South Korea. All significant intercompany accounts and transactions have been eliminated
in this consolidation.
The condensed consolidated balance sheet as of December 28, 2013, derived from audited financial statements, and the unaudited interim
consolidated financial information of the Company have been prepared in accordance with Article IO of Regulation S-X promulgated by the
Securities and Exchange Commission. Certain information and footnote disclosures that are normally included in financial statements that have
been prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted
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pursuant to such mies and regulations. In the opinion of management, the accompanying interim consolidated financial information contains all
adjustments, consisting of normal recurring adjustments that are necessary to state fairly the Company's financial position as of June 28, 2014 and
results of operations for the quarters and six months ended June 29, 2013 and June 28, 2014. These financial statements should be read in
conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form I 0-K
for the year ended December 28, 2013. The results of operations for the quarter and six months ended June 28, 2014, may not be indicative of the
results that may be expected for the fiscal year 2014 ending January 3,2015.
Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued an Accounting Standard Update ("ASU") No. 2014-09,
"Revenue from Contracts with Customers (Topic 606)." ASU 2014-09 includes a five-step process by which entities will recognize revenue to
depict the transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled to in
exchange for those goods or services. The standard also will require enhanced disclosures to enable users of financial statements to understand
the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual
and interim reporting periods beginning after December 15, 2016, with early adoption prohibited. Accordingly, the Company will adopt this ASU on
January I, 2017. ASU 2014-09 permits companies the use of either a full retrospective or a modified retrospective approach to adopt this ASU, and
the Company is currently evaluating which transition approach to use. The Company is currently evaluating the impact ASU 2014-09 will have on
its consolidated financial statements
7
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
NOTE B- FAJR VALUE MEASURES

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that
prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and
best use of the asset or liability. The levels of the fair value hierarchy are:
•
•
•

Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement
date.
Level 2 inputs are from other than quoted market prices included in Level I that are observable for the asset or liability, either
directly or indirectly.
Level 3 inputs are unobservable and arc used to measure fair value in situations where there is little, if any, market activity for the
asset or liability at the measurement date.

As of December 28, 2013 and June 28, 2014, the following financial assets and liabilities were measured at fair value on a recurring basis
using the type of inputs shown:
Fair Value Measurements Using:
Level I Inputs
Level 2 Inputs
Level 3 Inputs

December 28, 2013

Money market funds included in cash equivalents
Term deposits included in cash equivalents

$

9,249
348

$

$

14,412

$

$

348
Fair Value Measurements Using:
Level I Inputs
Level 2 Inputs
Le,·el 3 Inputs

June 28, 2014

Money market funds included in cash equivalents

9,249

$

14,412

$

$

There were no transfers of financial assets or liabilities between Level I and Level 2 inputs for the periods indicated.
The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, arc not
required to be carried at fair value on a recurring basis. However, if certain triggering events occur (or tested at least annually for goodwill and
indefinite-lived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impaim1ent is recorded to reduce the
carrying value to the fair value, if the carrying value exceeds the fair value. At December 28, 2013 and June 28, 2014, there were no non-financial
assets measured at fair value on a non-recurring basis.
At December 28, 2013 and June 28, 2014, the Company's financial instruments include cash equivalents, restricted cash, securities heldto-maturity ("HTM"), and notes receivable. The recorded values of cash equivalents and restricted cash approximate their fair values, based on
their short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest rates in the notes reflect
current market rates. HTM securities consist of certificates of deposits. The fair value of a certificate of deposit is determined based on the
pervasive interest rates in the market, which is considered to be a Level 2 input. The carrying values of these certificates of deposit approximate
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~

their fair values due to their short-term maturities.

8
Table of Contents

USANA HEALTH SCIENCES, INC. ANO SUBSIDJARJES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)

NOTE C - INVESTMENTS
The carrying amount, gross unrealized holding gains, gross unrealized holding losses, and fair value of HTM securities by major security
type and class of security were as follows:
As of December 28, 2013
Unrecognized
Unrecognized
Holding Gains
Holding Losses

Amortized Cost
~

Estimated Fair
Value

Certificates of Deposit

$

82642

$

$

$

8,642

Total HTM Securities

$

8,642

$

$

$

8,642

As of June 28, 2014
Unrecognized
Unrecognized
Holding Gains
Holding Losses

Amortized Cost

Estimated Fair
Value

Certificates of Deposit

$

.. 3;374

·$'

$

$

3,374

Total HTM Securities

$

3,374

$

$

$

· 3,374

NOTED - INVENTORIES
Inventories consist of the following:

Raw materials
Work in progress
Finished ·goods
$

NOTE E -

December 28,

June 28,

2013

2014

13,824
8,147
.. 25,271

$

12,301
8,361
.. 23,866

47,242

$

44,528

OTHER ASSETS

The Company has extended non-revolving credit to its supplier of nutrition bars to allow this supplier to acquire the necessary equipment
to manufacture the USANA nutrition bars. Notes receivable are valued at their unpaid principal balance plus any accrued but unpaid interest,
which approximates fair value. Interest accrues at an annual interest rate of LIB OR plus 400 basis points. The note has a maturity date of
February I, 2024 and will be repaid by a combination of cash payments and credits for the manufacture of USA NA 's nutrition bars. There is no
prepayment penalty. Notes receivable from this supplier as of December 28, 2013, and June 28, 2014, were $4,942 and $7,447, respectively.
The Company is building a state-of-the-art manufacturing and production facility in China, which is expected to become operational
during the latter halfof 2015. As part of this project, land use rights totaling $1,483, and $7,364 as of December 28, 2013 and June 28, 2014,
respectively, have been purchased and will be amortized over 50 years. Land-use rights are classified within the "Other assets" line item in the
Company's consolidated balance sheets.

9
Table of Contents

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO COND~NSEO CON SO LIDA TED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
NOTE F -

CONTINGENCIES
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The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of
conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships,
employees and other matters. While complete assurance cannot be given to the outcome of these proceedings, management does not currently
believe that any of these matters, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results
of operations.

NOTE G - EQUITY BASED COMPENSATION
The Company utilizes a share-based compensation plan, which is more fully described in Note K to the Consolidated Financial Statements
in Fonn 10-K for the year ended December 28, 2013.
Equity-based compensation expense for the quarters ended June 29, 2013, and June 28, 20 I 4, was $2,058 and $2,235, respectively. The related
tax benefit for these periods was $697 and $743, respectively. Expense for the six months ended June 29, 2013, and June 28, 2014, was $4,427 and
$4,071, respectively. The related tax benefit for these periods was $1,509 and $1,359, respectively.

~

The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of unvested equity awards
outstanding as of June 28, 2014. This table does not include an estimate for future grants that may be issued.
2014
2015
2016
2017

4,643
7,382
5,504
3,399

$

(t.

541

2018+
$

21,469

The cost above is expected to be recognized over a weighted-average period of 2.1 years.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awards. The weighted-average fair
value of stock-settled stock appreciation rights that were granted during the six months ended June 29, 2013, and June 28, 2014, was $13.86 and
$17. 73, respectively. Following is a table that includes the weighted-average assumptions that the Company used to calculate fair value of equity
awards that were granted during the periods indicated.

~
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
NOTE G-EQUITY BASED COMPENSATION-CONTINUED
Six Months Ended
June 29,
June 28,
2013

Expected volatility.(l) ...
Risk-free interest rate (2)
Expected life (3)
Expected dividend yield (4)
Weighted-average exercise price (5)

(I)
(2)
(3)

(4)
(5)

$

2014

43.1%
0.6%
3.97 yrs
0.0%
40.84
$

39.9%
1.2%
3.54 yrs
0.0%
57.62

The Company utilizes historical volatility of the trading price of its common stock.
Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
Depending upon the tenns of the award, expected life may be a weighted-average that includes historical settlement data of the
Company's equity awards and a hypothetical holding period for outstanding awards, or it may be calculated under the
simplified method.
The Company historically has not paid dividends.
Exercise price is the closing price of the Company's common stock on the date of grant.

A summary of the Company's stock option and stock-settled stock appreciation right activity is as follows:
Weighteda\·erage
exercise erice

Shares

Outstanding at December 28, 2013
Granted

1,827
686

$

Weighted-average
remaining
contractual term

37.37
57.62
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2.6

Aggregate
intrinsic
value*
$

74,160

~

~

(362)
(20)

Exercised
Forfeited
Expirt:u
Outstanding at June 28, 2014

1$

32.26
27.33

2,131

$

44.85

2.8

$

70,555

412

$

38.40

1.6

$

16,207

Exercisable at June 28, 2014

* Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the Company's
common stock on the last trading day of the period) and the exercise price of awards that were in-the- money. The closing price of the Company's
common stock at December 28, 2013, and June 28, 2014, was $77.72 and $77.76, respectively.
~

The total intrinsic value of stock options and stock-settled stock appreciation rights exercised during the six months ended June 29, 2013,
and June 28, 2014, was $10,429 and $14,404, respectively.
The total fair value of equity awards that vested during the six months ended June 29, 2013, and June 28, 2014, was $1,553 and $3,506,
respectively. This total fair value includes equity-based awards issued in the form of stock options and stock-settled stock appreciation rights.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
NOTE H - COMMON STOCK AND EARNINGS PER SHARE
Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been
repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that
are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per
common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in
the diluted earnings per share calculations under the treasury stock method include equity awards that arc in-the-money but have not yet been
exel'cised.
The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per
share for the periods indicated:
Quarter Ended
June 29,
June 28,
2013
2014

Net earnings available to common shareholders

$

24!210

$

Six Months Ended
June 29,
June 28,
2013
2014

19,301

$

41,989

$

35,838

Basic EPS
Shares
Common shares outstanding entire period
Weighted average common shares:
Issued during period
Canceled during period

13,821
106
(414)

Weighted average common shares outstanding
during period
Earnings per common share from net earnings - basic

13,886
131
{249)

13,513
$

1.79

1.40

13,886

58

81
il24)

pot)

13,768

s

13,821

13,578
$

3.09

13,843
$

2.59

Diluted EPS
Shares
Weighted average common shares outstanding
during period - basic
Dilutive effect of in-the-money equity awards
Weighted average common shares outstanding
durin_g period - diluted

13,513

13,768

13,578

13,843

586

467

456

472

14.099

14,235

14,034

14,315
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Machine-generated OCR, may contain errors.

Earnings per common share from net earnings - diluted

_$_ _ _ _ _1_.7_2

_$_ _ _ _ _1_.3_6

2.99

$

$
- - - -2.50
-

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be antidilutive:
Quarter Ended
.June 29,
June 28,

Six Months Ended

2014

2013

234

June 29,

June 28,

2013

2014

383

328

560
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
NOTE H - COMMON STOCK AND EARNINGS PER SHARE- CONTINUED
During the six months ended June 29, 2013 and the quarter and six months ended June 28, 2014, the Company repurchased and retired 414
shares and 682 shares, for $18,085 and $49,094 respectively, under the Company's share repurchase plan. The excess of the repurchase price over
par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces
the number of shares outstanding in the above calculations.
Subsequent to the period ended June 28, 2014 and through August I, 2014, the Company repurchased and retired 430 shares under the
Company's share repurchase plan for a total of $30,932. As of August 1, 2014, the remaining approved repurchase amount under the plan was
$119,953.

NOTE I -SEGMENT JNFORMATION
USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care
products that are sold through a global network marketing system of independent distributors {"Associates"). As such, management aggregates
its operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial
performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate
accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product
revenue that has been contributed by the Company's nutritional and personal care products for the periods indicated.
Quarter Ended
June 29,
June 28,

Six Months Ended

2014

2013

USANA*Nutritiohals
USANA Foods
Sense- beautiful science®

81%
12%
6%

78%
14%

7%

June 29,

June 28,

2013

2014

., . '.80%-·
12%

····6%

79%
13%
7%

Selected financial information for the Company is presented for two geographic regions: Americas and Europe and Asia Pacific, with three
sub-regions under Asia Pacific. Individual markets are categorized into these regions as follows:
•

Americas and Europe -

•

Asia Pacific -

United States, Canada, Mexico, Colombia (I), the United Kingdom, France, Belgium, and the Netherlands..

•

Southeast Asia Pacific -

•

Greater China -

•

North Asia -

Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand

Hong Kong, Taiwan and China(2)

Japan and South Korea

(I) The Company commenced operations in Colombia in the third quarter of 2013.
(2) The Company's business in China is that of BabyCare, its wholly-owned subsidiary.
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USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(in thousands, except per share data)
(unaudited)
~

NOTE I-SEGMENT INFORMATION-CONTINUED

Selected Financial Information
Financial information by geographic region is presented for the periods indicated below:
Quarter Ended
June 28,
June 29,
2014
2013

Six Months Ended
June 29,
June 28,
2013
2014

Net Sales to External Customers
$

Americas and Europe
Asia Pacific
Southeast Asia Pacific
Greater China
North Asia
Asia Pacific Total

$

37,475
77,388
7,504
122,367

s

Consolidated Total

v.,

66,769

189,136

63,661

130,921

$

42,689
74,091
. 7,815
124,595
$

188,256

127,476

$

72,784
140,373
14il40..
227,297
358,218

$

83,137
144,938
.15 11.06
243,181
370,657

$

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived
assets, respectively:
Quarter Ended
June 28,
June 29,
2014
2013

Net sales:
China

·~- Uii1ted States

$
:,.-,:,.

Hong Kong

23,559
40,087.
45,938

s

51,223

Six Months Ended
June 29,

June 28,

2013

2014

36,984

$

89,983

$

-~p~~l.$.L._-.. :_:~~-~:-~.: ·•. i·73,l:83

.. 3~;57().:;:
NIA

87,535

38,926

As of

Long-lived Assets:··'
China

$

United States

December 28,

June 28,

2013

2014

61,716 $
· 51~60' ::·.

73,026
53,004
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Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of USA NA 's financial condition and results of operations is presented in six sections:
•
•
•
•
•
•

Overview
Customers
Current Focus and Recent Developments
Results of Operations
Liquidity and Capital Resources
Forward-Looking Statements and Certain Risks

This discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes
thereto that are contained in this quarterly report, as well as Management's Discussion and Analysis of Financial Condition and Results of
Operations that are included in our Annual Report on Form l 0-K for the year ended December 28, 2013, and our other filings, including Current
Reports on Form 8-K, that have been filed with the Securities and Exchange Commission ("SEC") through the date of this report.

Overview
We develop and manufacture high-quality, science-based nutritional and personal care products that arc distributed internationally
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through a network marketing system, which is a form of direct selling. Our customer base comprises two types of customers: "Associates" and
"Preferred Customers." Associates are independent distributors of our products who also purchase our products for their personal use. Preferred
Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. As of June 28, 2014,
we had approximately 283,000 active Associates and approximately 79,000 active Preferred Customers worldwide. For purposes of this report, we
only count as active customers those Associates and Preferred Customers who have purchased from us at any time during the most recent threemonth period, either for personal use or for resale.
We have ongoing operations in the following markets, which arc grouped and presented as follows:
•

Americas and Europe - United States, Canada, Mexico, Colombia( l ), the United Kingdom, France, Belgium, and the Netherlands

•

Asia Pacific
•

Southeast Asia Pacific - Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand

•

Greater China - Hong Kong, Taiwan, and China (2)

•

North Asia - Japan and South Korea

(l) We commenced operations in Colombia in the third quarter of 2013.
(2) Our business in China is that of BabyCare, our wholly-owned subsidiary.
Our primary product lines consist ofUSANA® Nutritionals, USANA Foods, and Sense - beautiful science® (Sense), which is our line of
personal care products. The USANA Nutritionals product line is further categorized into two separate classifications: Essentials and Optimizers.
The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our
top-selling products for the current and prior-year periods as indicated:
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Six Months Ended
June 29,
June 28,
2013

2014

Product-L°Ine
USANA® Nutritionals
... Essentials-- Optimizers

USANA Fb'o'ds_: :
· Sense - beautiful science®
All Other

27% ..
53%
12%

25%
54%

2%

13%
7%
1%

18%
12%

16%
13%

6%

Key Product
USANA® Essentials
Proflavanol®

We believe that our ability to attract and retain Associates and Preferred Customers to sell and consume our products is positively
influenced by a number of factors, some of which include: the general public's heightened awareness and understanding of the connection
between diet and long-tenn health, and the growing desire for a secondary source of income and small business ownership.
We believe that our high-quality products and our financially rewarding Associate Compensation Plan arc the key components to
attracting and retaining Associates. We strive to ensure that our products are formulated with the latest science in nutrition research and to keep
our product lines relatively compact, which we believe simplifies the selling and buying process for our Associates and Preferred Customers. We
also periodically make changes to our Compensation Plan in an effort to ensure that our plan is among the most rewarding in the industry, to
encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to
grow sales and earnings.
To further support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer
information about our products and our network marketing system. These meetings arc designed to assist Associates in their business
development and to provide a forum for interaction with our Associate leaders and members of our management team. We also provide low cost
sales tools, including on line sales, business management, and training top ls, which we believe are an integral part of building and maintaining a
successful home-based business for our Associates. Although we provide training and sales tools, we ultimately rely on our Associates to sell
our products, attract new customers to purchase our products, and educate and train new Associates.
Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our
reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. ln general, net sales and gross
profit are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. Associate incentives and
selling, general and administrative expenses, however, arc affected negatively by a weakening of the U.S. dollar and positively by a strengthening
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of the U.S. dollar. During the six months ended June 28, 2014, net sales outside of the United States represented 80.3% of consolidated net sales.
In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the
average exchange rates in effect during the comparabie periods of the prior year.

Customers
Because we utilize a direct selling model for the distribution of our products, the success and growth of our business is primarily based
on our ability to attract new Associates and retain existing Associates to sell and consume our products. Notably, sales to Associates account for
the majority ofour product sales, representing approximately 90% of product sales during the six months ended June 28, 2014. Additionally, it is
important to attract and retain Preferred Customers as consumers of our products. Increases or decreases in product sales are typically the result
of variations in product sales volumes relating to fluctuations in the number of active Associates and Preferred Customers purchasing our
products. The number of active Associates and Preferred Customers is, therefore, used by management as a key non-financial measure.
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The tables below summarize the changes in our active customer base by geographic region. These numbers have been rounded to the
nearest thousand as of the dates indicated.
~

Active Associates Bv Region
As of
As of
June 29 2 2013
June 28 2 2014

Americas and Europe

~

Asia Pacific:
Southeast Asia Pacific
Greater China
North Asia
Asia Pacific Total

82,000

32.3%

82,000

29.0%

60,000
l03,000
9,000
172,000

23.6%
40.6%
3.5%
67.7%

67,000
125,000
9,000
201,000

23.7%
44.1%
3.2%
71.0%

29,000

100:0%·

283 1000

100.0%

29,000

. is4~oof ~

'ii

IJj

' . .: ! ' ~'

.- .

'

Preferred Customers B;r Region
As of
As of
June 29 2 2013
June 28 1 2014

fi,oijif_:-.

Americas and Europe

~

Change from
Prior Year

Asia Pacific:
Southeast Asia Pacific
Greater China
North Asia
Asia Pacific Total

_:/8L4% -

75.9%

3,000

2,000
13;000··

10.0%
<·.)sj%,
2.9%
:,,·1s.6%

11,000
MOO
5,000
19,000·

13.9%
3.8%
6.4%
24.1%

4,000
(1,000}
3,000
6,000

10:000·-

:•.ioo.0%

79,000

·100.0%

9,000

'•.

'

. ._'.. (

Change from
Prior Year

60,000

7,000

~

7,000
22,000

-:• _··..4,opo;:,.;::<.

..

. : ~- ..

-.

Current Focus and Recent Developments
Our primary objective, both on a short- and long-term basis, is to strengthen and grow our active customer counts throughout the world.
To this end, in August 2013 we announced and implemented several strategic changes to our business, which we refer to as the .. 2013 strategic
changes" throughout this report. These changes are aimed at simplifying our business model for our Associates and promoting customer loyalty,
enjoyment and success with USANA. The 2013 Strategic Changes included: (i) simplification of our pricing structure, which included an overall
IO% price reduction, while maintaining a price discount on products ordered through our monthly Auto Order program (collectively "price
discounts"), (ii) a new reward based on the amount of a customer's initial product order to then be credited on their subsequent two Auto Orders,
and (iii) increased payout under and simplification of our Compensation Plan.
We increased the payout under our Compensation Plan in several ways, including: (i) paying higher compensation to newer Associates,
(ii) increasing compensation for Associates who grow their business through our Auto Order program, and (iii) simplifying the commission
qualification requirements under the plan, resulting in a greater number of Associates earning compensation. Additionally, we simplified our rank
advancement system to make it easier for Associates to advance in our business, and we added new recognition benefits for Associate leaders.
During the second quarter, we continued training our Associates on the benefits of the 2013 Strategic Changes and emphasized
Associate recognition. We also continued to achieve progress on several business indicators that we monitor to measure the success of the 2013
Strategic Changes. These indicators include: active customer counts; world-wide unit volume; percent of sales processed through our Auto Order
program; and the number of Associates earning a commission check. On a year-over-year basis, we achieved double-digit growth for most of
these indicators.
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The positive impact to net sales, however, from improvements in these indicators will, in the short-term, be partially offset by the
aforementioned price discounts. For instance, overall customers grew by nearly 12% during the second quarter of2014, compared to the prior year
quarter, while net sales were essentially flat. This difference can, in most part, be attributed to the price discounts and is manifest more greatly in
markets with higher Auto Order penetration. Our annual pricing update, which takes effect during the first quarter of the year, softened the impact
of the price discounts as we increased prices in several markets.
Results of Operations

Summary of Financial Results
Although the number of active Associates and Preferred Customers increased 11.4% and 12.9%, respectively, in the second quarter of
2014 when compared with the second quarter of2013, net sales were essentially flat at $188.3 million. Net sales, on a comparative basis, were
negatively impacted by: (i) $7.0 million of incremental sales that occurred ahead ofa worldwide policy change that we implemented during the
second quarter of 2013 (restricing Associate purchases to in-market purchases only), which did not recur in 2014; (ii) $3.3 million from unfavorable
changes in currency exchange rates, and (iii) the price discounts noted above.
Net earnings for the second quarter of 2014 decreased 20.3%, to $19.3 million, compared with the second quarter of 2013. This decrease
was primarily the result of higher relative Associate incentives expense and lower gross margins, which arc discussed further below.
Quarters Ended June 29, 2013 and June 28, 2014

Net Sales
The following table summarizes the changes in our net sales by geographic region for the quarters ended as of the dates indicated:
Net Sales by Region
(in thousands)
Quarter Ended
June 29 1 2013
June 28, 2014

Americas and Europe

$

Asia Pacific:;,·::., . :Southeast Asia Pacific

Ore.aier china

66,769

63,661

35.3% $

37,475

n~i~~-

7,504
122;367::·. · ·

North Asia
. J\sia·PacificTotal$ ..

.. 189;'i36.;.,

33.8%

$

Percent
Change

(3,108)

(4.7)%

5,214
(3,297)

13.9%
(4:3)%
4.1%
-1_ 18%

·;.-..

• r J • ~:··

·

Change from
Prior Year

19.8%

42,689

•·-~A¢~¾:. - ··14MC.'~ ·
4.0%

.

7,815

•- -.:_;,-o4a«ro~: .:_; ·, :-: _1.24is9s>_ ·

.. :~i:oo.o¾:s . -. 188,256:.i:,.

22.7%
•-

39A%

4.1%
,_:_-_66:2%
100.0%$

311

-2,228
{880)

(0.5)%

Americas and Europe: The decline in net sales in this region was due to a decrease in net sales in the United States and to changes in
currency exchange rates, which reduced net sales by $1.4 million. Net sales in the United States decreased $4.5 million, or I 1.3%, due to pressure
from price discounts, combined with a decrease in the number of active Associates and Preferred Customers of7.0% and 2.7%, respectively. The
decreases in the United States, however, were partially offset by net sales growth in other markets within the region. Most notably, local currency
sales increased 4.8% in Canada and 12.2% in Mexico due to continued growth in the number of active Associates and Preferred Customers in
these markets. Our newest market, Colombia, also contributed $0.9 million to net sales during the quarter.

~

Asia Pacific: The increase in net sales in this region was driven primarily by growth in Southeast Asia Pacific, partially offset by a
decrease in sales in Greater China.
The increase in Southeast Asia Pacific was driven by growth in every market within this region, despite a $1.7 million reduction from
changes in currency exchange rates. The strongest growth in this region came from the Philippines and Singapore, where net sales
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increased 20.2% and 24.2%, respectively. On a local currency basis, sales in these two markets increased 27.1 % and 24.4%, respectively. The
number of active Associates in the Philippines and Singapore increased I I .1 % and 40.0%, respectively. Sales in Singapore benefited from another
year-over-year increase in sales of our MyHealthPak product to our Associates in other Asia Pacific markets, as sales of this item started gaining
traction late in the second quarter of2013.
The decline in net sales in Greater China was the result of a 66.5% decrease in net sales in Hong Kong, which was partially offset by
triple-digit sales growth in mainland China. Notably, the decrease in Hong Kong includes an estimated $7.0 million in incremental sales generated
ahead of a worldwide policy that we implemented during the second quarter of 2013 (restricting Associate purchases to in-market purchases only),
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~

which makes for a difficult year-over-year comparable.

Gross Profii

~

Gross profit decreased to 81.5% of net sales for the second quarter of 2014, from 83.1 % for the second quarter of 2013. This decline can
be attributed to price discounts, unfavorable currency fluctuations, production inefficiencies, and an increase in relative freight costs. This
decrease was partially offset by favorable changes in product and market mix and from our annual pricing update.

Associate Incentives
Associate incentives increased to 43.1 % of net sales for the second quarter of 2014, from 41.1 % for the second quarter of 2013. This
increase was the result of the 2013 Strategic Changes, and was partially offset by changes from our annual pricing update.
~

Selling. General and Administrative Expenses
In absolute terms, our selling, general and administrative expense was essentially flat when compared with the second quarter of 2013.
Selling, general and administrative expense as a percentage of net sales increased 23 basis points in the second quarter of2014 compared with the
second quarter of 20 I 3, which can primarily be attributed to the impact from the price discounts introduced in 2013.

Income Taxes
Our effective income tax rate during the second quarter of2014 was 34.3%, compared with 33.4% in the second quarter of 2013. This
increase was due to a reduction in our United States manufacturing deduction benefit as a result of increased sales in China where products are
manufactured in-market, and a reduction in tax benefits from lower tax rate jurisdictions, where sales have decreased.

Diluted Earnings Per Share
Diluted earnings per share decreased 20. 9% in the second quarter of 2014 when compared with the prior year quarter. This decrease was
the result of reduced net earnings as discussed above.
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Six Months Ended June 29, 2013 and June 28, 2014

Net Sales
The following table summarizes the changes in our net sales by geographic region for the periods ended as of the dates indicated:
Net Sales by Region
(in thousands)
Six Months Ended

$

Americas and Europe

Change from
Prior Year

June 28, 2014

June 29 1 2013

Percent
Change

130,921

36.5% $

127,476

34.4%$

(3,445)

(2.6)%

72,784
140,37314,140
227,297

20.3%
39.2%
4.0%
63.5%

83,137
144,938
15,106
243,181

22.4%
39.1%
4.1%
65.6%

10,353
4,565
15,884

14.2%
3.3%
6.8%
7.0%

358,218

100.0% $

370,657

100.0%$

12,439

3.5%

Asia Pacific:
Southeast Asia Pacific
Greater China
North Asia
Asia Pacific Total
$

966

Americas and Europe: The decrease in net sales in this region was due to a decrease in net sales in the United States and to changes in
currency exchange rates, which reduced net sales by $3.3 million. Net sales in the United States decreased $7.1 million, or 8.9%, due to pressure
from price discounts, combined with a decrease in the average number of active Associates and Preferred Customers. The decreases in the United
States, however, were partially offset by net sales growth in other markets within the region. Most notably, local currency sales increased 9.7% in
Canada and 13.4% in Mexico due to continued growth in the number of active Associates and Preferred Customers in these markets. Our newest
market, Colombia, also contributed $1.5 million to net sales for the six month period.
Asia Pacific: The increase in net sales in this region was driven mostly by growth in Southeast Asia Pacific and Greater China, which
was primarily the result of an increase in the average number of active Associates.
The increase in Southeast Asia Pacific was driven by growth in every market within this region despite a $5.3 million reduction from
changes in currency exchange rates. The strongest growth in this region came from the Philippines and Singapore, where net sales increased
18.5% and 43.0%, respectively. On a local currency basis, sales in these two markets increased 27 .9% and 44.9%, respectively. Sales in Singapore
benefited from a year-over-year increase in sales of our MyHealthPak product to our Associates in other Asia Pacific markets, as sales of this item
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started gaining traction late in the second quarter of 2013.
Sales in Australia and New Zealand during the first six months of2014 increased 3.0% even with a $2.0 million reduction from changes in
currency exchange rates. On a local currency basis, net sales in this market increased I 0.5%.
The increase in net sales in Greater China included a 143.3% increase in net sales in mainland China, offset in great part by a 55.5%
decrease in Hong Kong. Notably, the decrease in Hong Kong includes an estimated $7.0 million in incremental sales generated ahead of a
worldwide policy that we implemented during the second quarter of 2013 (restricting Associate purchases to in-market purchases only), which
makes for a difficult year-over-year comparable. We have also experienced a change in the trend of our unearned revenue as a result of these
policy changes and anticipate being able to begin recognizing breakage in the near future.

Gross Profit
Gross profit declined to 81.5% oi net sales for the first six months of 2014, compared with 82.6% in the prior year period. This decline can
be attributed to price discounts and unfavorable currency fluctuations. This decrease was partially offset by favorable changes in product and
market mix.

~
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Associate Incentives
Associate incentives increased to 43.2% of net sales for the first six months of 2014, from 41.2% in the prior year period. This increase
was the result of the 2013 Strategic Changes, and was partially offset by changes from our annual pricing update.

Selling, General and Administrative Expenses
In absolute terms, our selling, general and administrative expense increased $2.4 million during the first six months of2014 when compared
with the same period of the prior year. This increase is the result of costs associated with supporting a higher sales base, spending on new
markets, and spending to support our personalization initiative. Relative to net sales, selling, general and administrative expense remained
relatively flat in the first six months of2014 compared with the same period of the prior year, due to leverage gained on a higher sales base.

Income Taxes
Our effective income tax rate during the first six months of2014 was 34.4%, compared with 33.3% in same period of 2013. This increase
was primarily the result of a reduction in our United States manufacturing deduction benefit due to increased sales in China where products are
manufactured in-market, and a reduction in tax benefits from lower tax rate jurisdictions, where sales decreased.

Diluted Earnings Per Share
Diluted earnings per share decreased 16.4% in the first six months of 20 I 4 when compared with the prior year period. This decrease was
the result of reduced net earnings as discussed above.

Liquidity and Capital Resources
We have historicaHy met our working capital and capital expenditure requirements by using both net cash flow from operations and by
drawing on our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with
banks in some of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets.
The hypothetical repatriation of$ I 0.2 million that relates to earnings considered indefinitely reinvested in certain ofour markets at June 28, 2014,
would result in a tax liability to the Company.

~

We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled
$31.3 million in the first six months of 2014, compared with $47.3 million in the first six months of 2013. Items affecting year-over-year changes in
cash flow from operating activities include the impact of our 2013 Strategic Changes on operating income, and the overall change in operating
assets and liabilities. Included in the change in operating assets and liabilities were: (i) an increase in other assets, related mostly to the purchase
of land use rights for our new facility in China, (ii) an overall decrease in other liabilities resulting primarily from changes in accrued compensation,
accrued commissions, and deferred convention revenue, and (iii) a decrease in accounts payable in the current year quarter due to the timing of
invoices and payments. These items were partially offset by lower spending on inventory in the current year compared with the prior year.

~

Net cash flow from operating activities in the first six months of 20 I 4 was offset by share repurchases as discussed below. As a result,
cash and cash equivalents decreased to $118.3 million at June 28, 2014, from $137.3 million at December 29, 2013. Of the $118.3 million cash and
cash equivalents held at June 28, 2014, $47.5 million was held in the United States and $70.8 million was held by international subsidiaries. Of the
$137.3 million.held at December 28, 2013, $65.8 million was held in the United States and $71.5 million was held by international subsidiaries. Net
working capital decreased to $113.2 million at June 28.2014. from S 133.2 million at December 28, 2013.

~

We have extended non-revolving credit to the supplier of our nutrition bars to allow this supplier to acquire the necessary equipment to
manufacture our bars. Notes receivable from this supplier as of June 28, 2014, were $7.4 million.
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We are building a state-of-the-art manufacturing and production facility in China, which we anticipate will become operational during the
latter half of 2015. We anticipate that this project will require a total investment of approximately $40 million, of which
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approximately $24 million will be incurred in 2014. During the first six months of 2014, we incurred$ I 1.8 million on this project of which $5.9 million
was for land use rights.

line ofcredit
We have a long-standing relationship with Bank of America. We currently maintain a $75.0 million credit facility pursuant to a credit
agreement with Bank of America, which expires in April 2016. Bank guarantees are considered a reduction of the overall availability of credit. As
of June 28, 2014, such normal course of business bank guarantees reduced our available borrowing limit by $3.9 million. We did not otherwise
draw on this line of credit at any time during the quarter and, as of June 28, 2014, there was no actual outstanding balance on our line of credit.
The agreement for this credit facility contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter
adjusted earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA") equal to or greater than $60.0 million, and a ratio of
consolidated funded debt to adjusted EBITDA of 2.0 to 1.0 at the end of each quarter. The adjusted EBITDA under this agreement is modified for
certain non-cash expenses. As of June 28, 2014, we were in compliance with these covenants. Management is not aware of any issues currently
impacting Bank of America's ability to honor their commitment to extend credit under this facility.

Share repurchase

I@

ivJ

We have a share repurchase plan that has been ongoing since the fourth quarter of2000. The objective of this plan is to return value to
our shareholders. Our Board of Directors has periodically approved additional dollar amounts for share repurchases under that plan. Share
repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of our
cash balances, general business opportunities, and other factors. During the quarter ended June 28, 2014, our Board of Directors authorized an
increase in the amount available for repurchase under this plan to a total of$200 million. During the quarter and six months ended June 28, 2014,
we repurchased and retired 681,719 shares of common stock for a total investment of $49.1 million, at an average market price of $72.02 per share.
Additionally, subsequent to the quarter ended June 28, 2014, and through August 1, 2014, we repurchased and retired 429,774 shares of common
stock for a total investment of$30.9 million, at an average market price of $71.97 per share pursuant to a preset trading plan meeting the
requirements of Rule 1Ob5- l under the Securities Exchange Act of 1934 as amended. As of August I, 2014, there was $120.0 million remaining
under the current share repurchase authorization and there is currently no expiration date on the remaining approved repurchase amount and no
requirement for future share repurchases.
Summary

We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be
sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse
operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be
given, however, that additional financing, if required, would be available or on favorable terms. We might also require or seek additional financing
for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may include the use of
additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are
convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.
Forward-Looking Statements and Certain Risks
The statements contained in this report that arc not purely historical are considered to be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and Section 21 E of the Securities Exchange Act of 1934. These statements
represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by
the use of words or phrases such as "believes," "expects," "anticipates," "should," "plans," "estimates," and "potential," among others. Forwardlooking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and
Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to
fund our future operations and capital spending needs. Readers are
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cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking
statements for the reasons that arc detailed in our most recent Annual Report on Form l 0-K. The fact that some of these risk factors may be the
same or similar to those in our past SEC reports means only that the risks arc present in multiple periods. We believe that many of the risks
detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods
reported. The fact that certain risks arc common in the industry does not lessen their significance. The forward-looking statements contained in
this report are made as of the dale of this report, and we assume no obligation to update them or to update the reasons why our actual results
could differ from those that we have projected. Among others, risks and uncertainties that may affcct our business, financial condition,
performance, development, and results of operations include:
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•

Our ability to attract and maintain a sufficient number of Associates;

•

Our dependence upon a network marketing system to distribute our products and the activities of our independent Associates;

a

The integration of BabyCare's operations and expansion ofour business in China through BabyCarc;

•

Unanticipated effects of changes to our Compensation Plan;

•

Our planned expansion into international markets, including delays in commencement of sales or product offerings in any new
market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;

•

General economic conditions, hoth domestically and internationally;

•

Potential political events, natural disasters, or other events that may negatively affect economic conditions;

•

Potential effects of adverse publicity regarding the Company, nutritional supplements, or the network marketing industry;

•

Reliance on key management personnel;

•

Extensive government regulation of the Company's products, manufacturing, and network marketing system;

•

Potential inability to sustain or manage growth, including the failure to continue to develop new products;

•

An increase in the amount of Associate incentives;

•

Our reliance on the use of information technology;

•

The effects of competition from new and established network and direct selling organizations in our key markets;

•

The adverse effect of the loss of a high-level sponsoring Associate, together with a group ofleading Associates, in that person's
downline;

•

The loss of product morket shore or Associates to competitors;

•

Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions
between and Company responsibilities to employees and independent contractors;

•

The fluctuation in the value of foreign currencies against the U.S. dollar;

•

Our reliance on outside suppliers for raw materials and certain manufactured items;

•

Shortages of raw materials that we use in certain of our products;

•

Significant price increases of our key raw materials;

•

Product liability claims and other risks that may arise with our manufacturing activity;

•

Intellectual property risks;

o

Liability claims that may arise with our "Athlete Guarantee" program;

a

Continued compliance with debt covenants;

•

Disruptions to shipping channels that arc used to distribute our products to international warehouses;
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•

The introduction of new laws or changes to existing laws, both domestically and internationally; or

•

The outcome of regulatory and litigation matters.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have bee~ no material changes to information presented from that presented for the year ended December 28, 2013.
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Item 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures

~

va

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our
Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and
that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures,
management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives.
As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of
the design and operation of our disclosure controls and procedures (as defined in Rule l 3a- I S(e) under the Exchange Act). Based on this
evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of
June 28, 2014.
Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 28, 2014 that have
materially affected, or arc reasonably likely to materially affect, our internal control over financial reporting.
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PART 11. OTHER INFORMATION
Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c) Repurchases
The following table presents information with respect to purchases of USA NA common stock made by the Company during the three
months ended June 28, 2014:
Issuer Purchases of Equity Securities
(amounts in thousands, except per share data)

Total
Number
of Shares
Purchased

Period

Average
Price
Paid per
Share

Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs *

Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs

Fiscal April
(Mar.:30~2014 through May 3,2014)

44·

$

69.31

44

$

196,948 ·

Fiscal May
(May 4, 2014 through May 31, 2014)

378

$

69.92

378

$

170,542

Fiscal June
(Jun. I, 2014 through Jun. 28, 2014)

260

$

75.52

260

$

150,905

682

$

72.02

682

* The Company's share repurchase plan has been ongoing since the fourth quarter of 2000, with the Company's Board of Directors periodically
approving additional dollar amounts for share repurchases under the plan. The Company began the second quarter of 2014 with $13,622 remaining
under the plan. As announced in a publicly issued press release on April 29, 2014, the Board of Directors authorized an increase in the amount
available for repurchase under the plan to a total of$200,000. Subsequent to the quarter ended June 28, 2014, and through August I, 2014, the
Company repurchased 430 shares for a total of $30,932, at an average market price of $71.97 per share pursuant to a Ruic I 0b5-l trading plan. As of
August l, 2014, the Company had$ I 19,953 available under the share repurchase plan. There currently is no expiration date on the approved
repurchase amount.

Item 5.

OTHER INFORMATION

On July 23, 2013, the Company disclosed that the Securities and Exchange Commission ("SEC") was conducting a formal investigation,
which appeared to involve possible issues regarding trading in the Company's stock during late 2012 by certain of the Company's directors,
including the Chairman. On May 28, 2014, the Company received a letter from the SEC which indicated that the SEC had concluded its
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investigation as to the Company and, as of the date of the letter, did not intend to recommend any enforcement action against the Company.
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Item 6.

EXHIBITS

Exhibit
Number

Dcscri tion

3.1

Amended and Restated Articles of Incorporation (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)

3.2

Bylaws (Incorporated by ref~rence to Report on Form 8-K, filed April 25, 2006)

4.1

Specimen Stock Certificate for Common Stock, no par value (Incorporated by reference to Registration Statement on Fann I 0, File
No. 0-21116, effective April I 6, 1993)

10.1

?.002 USANA Health Sciences, Inc. Stock Option Plan (Incorporated by reference to Registration Statement on Fann S-8, filed
July 18, 2002)*

I0.2

Form of employee or director non-statutory stock option agreement under the 2002 Stock Option Plan (Incorporated by reference
to Report on Form 10-K, filed March 6, 2006)*

10.3

Fann of employee incentive stock option agreement under the 2002 Stock Option Plan (Incorporated by reference to Report on
Fonn I0-K, filed March 6, 2006)*

10.4

Credit Agreement, dated June 16, 2004, by and between Bank of America, N.A. and USANA Health Sciences, Inc. (Incorporated by
reference to Report on Fonn 10-Q for the period ended July 3, 2004)

I0.5

Amendment dated May 17, 2006 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form I 0-Q for
the period ended September 30, 2006)

10.6

Amendment dated April 24, 2007 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form I 0-Q for
the period ended March 31, 2007)

10.7

USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 25,
2006)*

10.8

Fann of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc.
2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

I0.9

Fonn of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA
Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

I0.10

Fann of Incentive Stock Option Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award
Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

JO.I I

Fann of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2006
Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

10.12

Fonn of Stock-Settled Stock Appreciation Rights Award Agreement for directors who are not employees under the USANA Health
Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Fom1 8-K, filed April 26, 2006)*

10.13

Form of Defc1Ted Stock Unit Award Agreement for grants of deferred stock units to directors who arc not employees under the
USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Fonn 8-K, filed April 26,
2006)*

10.14

Fonn of Indemnification Agreement between the Company and its directors (Incorporated by reference to Report on Form 8-K,
filed May 24, 2006)*

10.15

Fonn of Indemnification Agreement between the Company and certain of its officers (Incorporated by reference to Report on
Fonn 8-K, filed May 24, 2006)*
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10.16

Share Purchase Agreement, dated as of August 16, 2010, among USANA Health Sciences, Inc., Petlanc, Inc., Yaolan Ltd., and
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BabyCare Holdings Ltd. (Incorporated by Reference to Report on Form 8-K, filed August 16, 2010)
10.17

Arm:mlc<l an<l Rcslall.:d Credit Agrccrm:nl, c.late<l as uf Aprii 27,201 i (Im:urporatcd by reference to Report on Fonn 8-K. filed
April 28. 2011)

10.18

Fonn of Executive Confidentiality, Non-Disclosure and Non-Solicitation Agreement {Incorporated by reference to Quarterly Report
on Form l 0-Q for the period ended October l, 20 l l, filed November 9, 20 l l )*

I0.19

Separation and Release of Claims Agreement dated as of December 21, 2012 by and between USA NA Health Sciences, Inc. and
Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*

I 0.20

Amendment to Confidentiality, Non-Disclosure and Non-Solicitation Agreement dated as of December 21, 2012 by and between
USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*

l 0.21

Amendment to Amended and Restated Credit Agreement, dated as of July 18, 2013 (Incorporated by reference to Report on
Fonn 8-K, filed July 23, 2013)

31.1

Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

32.2

Certification ofChiefFinancial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

IOI.INS

XBRL Instance Document

IOI.SCH

XBRL Taxonomy Extension Schema Document

IOI.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

IOI.DEF

XBRL Taxonomy Extension Definition Linkbase Document

IOI.LAB

XBRL Taxonomy Extension Label Linkbase Document

IOI.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

* Denotes a management contract or compensatory plan or arrangement.
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SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.

USA NA HEALTH SCIENCES, INC.

Isl Paul A. Jones

Date: August 5, 2014

Paul A. Jones
Chief Financial Officer
(Principal Financial and Accounting Officer)
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EXHIBIT 31.1
CHIEF EXECUTIVE OFFICER CERTIFICATION

I, David A. Wentz, certify that:
I.

1 have reviewed this Quarterly Report on Form I 0-Q of USA NA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this report docs not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.

The Registrant's other certifying officer and I arc responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-l 5(e) and I 5d-l 5(e)) and internal control over financial reporting (as defined in Exchange Act
Rules l 3a-15(f) and I 5d-l 5(f)) for the Registrant and have:

5.

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and

d)

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materialJy affected, or is
reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent
functions):
a)

AIJ significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's
internal control over financial reporting.

Date: August 5, 2014

Isl David A. Wentz
David A. Wentz
Chief Executive Officer
(Principal Executive Officer)
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EXHIBIT 31.2
CHIEF FINANCIAL OFFICER CERTIFICATION
I, Paul A. Jones, certify that:

I.

I have reviewed this Quarterly Report on Form l 0-Q of USANA Health Sciences, Inc. (the "Registrant");

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.

The Registrant's other certifying officer and I arc responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules l3a-l 5(e) and I 5d-l 5(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f)and 15d-15(f)) for the Registrant and have:

5.

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and

d)

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent
functions):
a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's
internal control over financial reporting.

Date: August 5, 20 I4

Isl Paul A. Jones
Paul A. Jones
Chief Financial Officer
(Principal Accounting and Financial Officer)
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EXHIBIT 32.l
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARHANES-OXLEY ACT OF 2002

The undersigned hereby certifies that the Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. for the period ended June 28,
2014 as filed August 5, 2014 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The
Securities Exchange Act of 1934 ( 15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of USA NA Health Sciences, Inc.

Date: August 5, 2014

Isl David A. Wentz

David A. Wentz
Chief Executive Officer
(Principal Executive Officer)
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EXHJBJT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
The undersigned hereby certifies that the Quarterly Report on Form l 0-Q of USANA Health Sciences, Inc. for the period ended June 28,
2014 as filed August 5, 2014 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or l S(d) of The
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the
financial condition and results ofoperations of USANA Health Sciences, Inc.

Date: August 5, 2014

Isl Paul A. Jones
Paul A. Jones
Chief Financial Officer
(Principal Accounting and Financial Officer)
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Segment Information
(Consolidated Net Sales And
Long Lived Assets By
Percent) (Details) (USD $)
In Thousands, unless
otherwise specified
Revenues from External Customers and Long-Lived
Assets [Line Items]
Net sales
China [Member]
Revenues from External Customers and Long-Lived
· Assets [Line Items]

Net sales
Long-lived Assets
United States [Member]
Revenues from External Customers and Long-Lived
Assets [Line Items]
Net sales
Long-lived Assets
Hong Kong [Member]
Revenues from External Customers and Long-Lived
Assets [Line Items)
Net sales

3 Months Ended

6 Months Ended
Jun. 28,
2014

Jun. 29,
2013

$ 188,256 $ 189,136 $ 370,657

$ 358,218

51,223

36,984

Jun. 28,
2014

Jun. 29,
2013

23,559

73,026

73,026

35,570

89,983

40,087

53,004

73,183

61,716

80,325
51,260

53,004

$45,938

$ 38,926
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Dec. 28,
2013

$ 87,535

~

Equity-Based Compensation
(Schedule Of Stock Option
Activity) (Details) (USD $)
In Thousands, except Share
data, unless otherwise
specified
Equity-Based Compensation [Abstract]
Shares, Outstanding
Shares, Granted
Shares, Exercised
Shares. Forfeited
Shares, Outstanding
Shares, Exercisable
Weighted-average grant price, Outstanding
Weighted-average grant price, Granted
Weighted-average grant price, Exercised
Weighted-average grant price, Forfeited
Weighted-average grant price, Outstanding
Weighted-average grant price, Exercisable
Weighted-average remaining contractual term, Outstanding
Weighted-average remaining contractual term, Exercisable
Aggregate intrinsic value, Outstanding

6 Months Ended

12 Months Ended

Jun.28,2014

Dec. 28, 2013

1,827
686
(362)
(20)
2,131

1,827

412
$ 37.37
$ 57.62
$ 32.26
$ 27.33
$ 44.85
$ 38.40
2 years 9 months 18
days
I year 7 months 6 days

$

37.37

2 years 7 months 6
days

$74,160

[I]

Aggregate intrinsic value, Outstanding

70,555

fl]

Aggregate intrinsic value, Exercisable

$ 16,207

(I]

Closing price of common stock

$ 77.76

74,160

$

[I}

77.72

[ 1] Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price
of the Company's common stock on the last trading day of the period) and the exercise price of awards that were in-themoney. The closing price of the Company's common stock at December 28, 2013, and June 28, 2014, was $77.72 and
$77.76, respectively.
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Fair Value Measures
(Narrative) (Details) (USD $)

Mar.29,2014Dec.28,2013

Fair Value Measures [Abstract]

Transfers of financial assets or liabilities $ 0
Non-financial assets
$0

$0
$0

@
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Segment Information
(Percentage Of Total Product
Revenue Contributed By
Company's Nutritional And
Care Products) (Details)

3 Months Ended

6 Months Ended

Jun. 28, 2014 Jun. 29, 2013 Jun. 28, 2014 Jun. 29, 2013

USANA Nutritionals [Member]
Revenue from External Customer [Line Items)

Percentage of product revenue

78.00%

81.00%

80.00%

79.00%

14.00%

12.00%

12.00%

12.00%

7 .00%

6.00%

6.00%

7.00%

USANA Foods [Member]
Revenue from External Customer [Line Items l

Percentage of product revenue
Sense - Beautiful Science [Member]
Revenue from External Customer [Line Items)

Percentage of product revenue
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6 Months Ended
jun.28,2014

Fair Value Measures
Fair Value Measures
[Abstract I
Fair Value Measures

NOTE B- FAIR VALUE MEASURES
The Company measures at fair value certain of its financial and non-financial assets and liabilities by
using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date, essentially an exit p1ice, based on the highest and best
use of the asset or liability. The levels of the fair value hierarchy arc:
•
•
•

Level I inputs arc ciuorcd market prices in active markets for identical assets or liabilities that
arc accessible at the measurement date.
Level 2 inputs arc from other than quoted market prices included in Level 1 that are
observable for the asset or liability, either directly or indirectly.
Level 3 inputs arc unobservable and arc used to measure fair value in siniations where there is
little, if any, market activity for the asset or liability at the measurement date.

NOTE B - FAIR VALUE MEASURES - CONTINUED
As of December 28, 2013 and June 28, 2014, the folJowing financial assets and liabilities were
measured at fair value on a recurring basis using the type of inputs shown:

Fair Value Measurements Using:
December 28,
2013
Money market funds included in cash
equivalents

$

Term deposits included in cash equivalents

Level 1 Inputs Level 2 Inputs Level 3 Inputs

9,249$

9,249$

348

-$

348

Fair Value Measurements Using:

Iune 28, 2014
Money market funds included in cash
equivalents

$

Level 1 Inputs Level 2 lnputs Level 3 Inputs

14,412$

14,412$

-$

There were no transfers of financial assets or liabilities between Level 1 and Level 2 inputs for the
periods indicated.
The majority of the Company's non-financial assets, which include goodwill, intangible assets, and
property and equipment, arc not required to be carried at fair value on a recurring basis. However, if certain
triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a
non-fmancial asset is required to be evaluated for impairment, an impairment is recorded to reduce the
carrying value to the fair value, if the ca~-rying value exceeds the fair value. i\ t December 28, 2013 and March 29,
20i4, there were no non-financial assets measured at fair value on a non-rec:urring hasis.

1\1 Deu.:111Ler 28, 2013 aml J unc 28, 2014, the Company's financial instruments include cash
equivalents, restricted cash, securities hckl-to-maturity ("I-ITM"), and notes receivable. The recorded values of
cash ec1uivalcnrs and restricted cash approximate their fair values, based on their short-term nature. The
carrying value of the notes receivable approximate fair value because the variable interest rares in the notes
reflect current market rates. I ITM securities consist of certificates of deposits. The fair value of a certificate of
deposit is determined based on the pervasive interest rates in the market, which is considered to be a Level 2
input. The carrying values of these certificates of deposit approximate their fair values due to their short-term
maturities.
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Other Assets (Details) (USD
$)
In Thousands, unless
otherwise specified

6 Months Ended 12 Months Ended
Jun. 28, 2014

Dec.28,2013

Other Assets (Line Items 1

Credit facility issued
Receivable
Land-use rights
Amortization period
London Interbank Offered Rate (LIBOR) [Member]

$7,000
7,447
$7,364
50 years

4,942
$ 1,483

Other Assets [Line Items]

Variable rate

4.00%
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Inventories (Details) (USD $)
In Thousands, unless
Jun. 28, 2014 Dec. 28, 2013
otherwise specified
Inventories [Abstract]

Raw materials
Work in Qrogress
Finished goods
Inventories

$ 12,301

8,361
23,866
$44,528

$13,824
8,147
25,271
$-47,242
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•

Equity-Based Compensation
(Narrative) (Details) (USD $)
In Thousands, except Per
Share data, unless otherwise
specified

3 r,-fonths Ended
Jun. 28, Mar. 29, Jun. 29,
2014
2014
2013

6 Months Ended

~ii:o,

Jun. 28, 2014

Jun. 29,
2013

Equity-Based Compensation fAbstract)

Equity-based compensation expense
Equity-based compensation related tax benefit
Unrecognized compensation expense weighted average
period of recognition
Weighted-average grant date fair value
Total intrinsic value of stock options and stock-settled
stock appreciation rights exercised
Total fair value of equity awards vested

$2,235

$2,058

$4,071

$4,427

743

697

1,359

1,509

2 years 1
month 6 days
$ 17.73

$ 13.34
14,404

10,429

$3,506

$ 1,553
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Equity-Based Compensation
{Schedule Of Remaining
Unrecognized Compensation
Expense For Unvested
Awards) (Details) (USD $)
In Thousands, unless
otherwise specified
Equity-Based Compensation (Abstract)

6 Months Ended

Jun.28,2014

2014

$4,643

2015

7,382

2016

5,504

2017

3,399

2018+

541

$21,469
Total
Unrecognized compensation expense weighted average period of recognition 2 years 1 month 6 days
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6 Months F.ndcd

Organization, Consolidation,
And Basis Of Presentation
~

Jun.28,2014

Organization, Consolidation,
And Basis Of Presentation
(Abstract)

Organization, Consolidation, And
Basis Of Presentation

NOTE A- ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION
USANJ\ I Iealth Sciences, Inc. develops and manufactures high-quality nutritional and personal
care products that arc sol<l internationally through a global network marketing system, which is a form of
direct selling. The Consolidated Financial Statements include the accounts and operations of US,\N1\
Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the "Company" or "USANJ\") in two
geographic regions: Americas and Europe and Asia Pacific, which is further divided into three sub-regions;
Southeast Asia Pacific, Greater China, and North t\sia. 1\mericas and Europe includes the United States,
Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands. Southeast t\sia
Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand; Greater Chma
includes I long Kong, Taiwan and China; and North 1\sia includes Japan and South Korea. ,\II significant
intcrcompany accounts and transactions have been eliminated in this consolidation.
The condensed balance sheet as of December 28, 2013, derived from audited financial statements,
and the unaudited interim consolidated financial information of the Company have been prepared in
accordance with 1\ rricle 10 of Regulation S-X promulgated by the Securities and Exchange Commission.
Certain information and footnote disclosures that are normally included in financial statements that have
been prepared in accordance with accounting principles generally accepted in the United States of America
have been condensed or omitted pursuant to such rules and regulations. In the opinion of management,
the accompanying interim consolidated financial information contains all adjustments, consisting of
normal recurring adjustments that arc necessary to state fairly the Company's financial position as of June
28, 2014 and results of operations for the quarters and six months ended June 29, 2013 and June 28,
2014. These financial statements should be read in conjunction with the audited consolidated financial
statements and notes thereto that arc included in the Company's Annual Report on Form 10-K for the
year ended December 28, 2013. The results of operations for the quarter and six months ended June 28,
2014, may not be indicative of the results that may be expected for the fiscal year 2014 ending January 3,
2015.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board ("FASB") issued an Accounting
Standard Update ("J\SU") No. 2014-09, "Revenue from Contracts with Customers (fopic 606)." ASU
2014-09 includes a five-step process by which entities will recognize revenue to depict the transfer of goods
or services to customers in amounts that reflect the consideration to which an entity expects to be entitled
to in exchange for those goods or services. The standard also will require enhanced disclosures to enable
users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and
cash flows arising from contracts with customers. J\SU 2014-09 is effective for annual and interim reporting
periods beginning after December 15, 2016, with early adoption prohibited. Accordingly, the Company will
adopt this t\SU on January 1, 2017. :\SU 2014-09 permits companies the use of either a full retrospective
or a modified retrospective approach to adopt this t\SU, and the Company is currently evaluating which
transition approach to use. The Company is currently evaluating the impact ASU 2014-09 will have on its
consolidated financial statements.
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Equity-Based Compensation
(Schedule Of Fair Value
Assumptions) (Details) (USD

6 Months Ended

Jun.28,2014

$)

Jun.29,2013

Equity-Based Compensation [Abstract)
Expected volatility

39.90%

(I]

43.10%

[I)

Risk- free interest rate

1.20%

[2]

0.60%

[2]

Expected life

3 years 6 months 15 days

[J]

3 years 11 months 19 days

[3]

Expected dividend yield

0.00%

[4]

0.00%

[4]

Weighted-average grant price

$ 57.62

[5]

$ 40.84

[5]

[I] The Company utilizes historical volatility of the trading price of its common stock.
[2] Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
[3] Depending upon the terms of the award, expected life may be a weighted-average that includes historical settlement data of
the Company's equity awards and a hypothetical holding period for outstanding awards, or it may be calculated under the
simplified method.
[4] The Company historically has not paid dividends.
[5] Exercise price is the closing price of the Company's common stock on the date of grant.
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Condensed Consolidated
Balance Sheets (USD $)
In Thousands, unless
otherwise specified

l&I

ASSETS
Cash and cash equivalents
Securities held-to-maturity. net
Inventories
Prepaid expenses and other current assets
Total current assets
Property and equipment. net
Goodwill
Intangible assets. net
Deferred tax assets
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable
Other current liabilities
Total current liabilities
Deferred tax liabilities
Other long-term liabilities
Stockholders' equity
Common stock, $0.00 I par value; Authorized -- 50.000 shares, issued and outstanding 13,886 as of
December 28, 2013 and I 3,404 as of June 28, 20 I4
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income
Total stockholders' equity
Total liabilities and stockholder's equity
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Jun. 28,

Dec. 28,

2014

2013

$ 118,267

$ 137,343

3,374

8,642

44,528

47,242

35,756

35,818

201,925

229,045

65,859

59,180

17,919

18,243

41,015

42,329

5,515

5,519

22,688

14,154

354,921

368,470

6,408

9,502

82,297

86,369

88,705

95,871

10,672

10,866

1,290

1,211

13

14

51,925

54,691

196,992

200,023

5,324

5,794

254,254

260,522

$354,921

$ 368,470

Condensed Consolidated
Statement Of Stockholders'
Equity (Parenthetical) (USO
$)
In Thousands, unless
otherwise specified

6 Months Ended

Jun. 28, 2014

Condensed Consolidated Statement Of Stockholders' Equity (Abstract)

Common stock issued under equity award plans, including tax benefit {expense)$ 3,387
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Common Stock And Earnings
Per Share (Schedule Of
Common Stock And Earnings
Per Share) (Details) (USD $)
In Thousands, except Per
Share data, unless otherwise
specified
Common Stock And Earnings Per Share
[Abstract}
Net earnings available to common shareholders

Common shares outstanding entire Qeriod
Weighted average common shares issued during
period
Weighted average common shares cancelled
during period
Weighted average common shares outstanding
during period
Earnings Qer common share from net earnings basic
Weighted average common shares outstanding
during period - basic
Dilutive effect of in-the-money eguity awards
Weighted average common shares outstanding
during period - diluted
Earnings per common share from net earnings diluted
Eguity awards for the following shares were not
included in the their effect would be anti-dilutive:

3 Months Ended 6 Months Ended

Jun. 28, Jun. 29, Jun. 28, .Jun. 29, Mar. Dec. 28, Mar. Dec. 29,
2014
2013
2014
2013 29,2014 2013 30,2013 2012

$
19,30 l

$
24,210

$
35,838

$
41,989

13,404

13,404

13,886

131

106

81

58

(249)

(414)

(124)

(301)

13,768

13,513

13,843

13,578

$ 1.40

$ 1.79

$ 2.59

$ 3.09

13,768

13,513

13,843

13,578

467

586

472

456

14,235

14,099

14,315

14,034

$ 1.36

$ 1.72

$ 2.50

$ 2.99

383

234

328

560

13,886

~

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

13,821

13,821

6 Months Ended
Jun. 28, 2014

Common Stock And Earnings
Per Share (Tables)
Common Stock And Earnings Per
Share [Abstract)
Schedule Of Common Stock And
Earnings Per Share

<it)
Six Months Ended

Quarter Ended
June 29,
2013

June 28,
2014

June 29,
2013

June 28,
2014

~
Net earnings available to common shareholders

$

24,210$

19,301 S

41,989S

35,838

Basic EPS
Shares
Common shares outstanding entire period
Weighted average common shares:
I ssue<l <luring period

13,821

13,886

13,821

13,886

106

131

58

81

{414}

{249}

{301}

{124}

13,513

13,768

13,578

13,843

~

Canceled during period
Weighted average common shares
outstanding during
period

G1:;,

Earnings per common share from net earnings
- basic

s

1.79$

1.40$

3.09$

2.59

Diluted EPS
Shares
Weighted average common shares
outstanding during
period - basic

~

Dilutive effect of in-the-money equity awards

13,513

13,768

13,578

13,843

586

467

456

472

14 099

14,235

14,034

14,315

Weighted average common shares
outstanding during
period - diluted

Earnings per common share from net earnings
- diluted

$

1.72$

1.36$

2.99S

~

2.50

l•:t1uity awards for the following shares were
not included in the computation of diluted
EPS due to the fact that
their effect would be anti-dilutive:

~·

Quarter Ended
Ju~e 29,
2013

Six Months Ended

June 28,
2014

June 29,
2013

June 28,
2014

~
234
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383

560

328

Segment Information
(Narrative) (Details)

6 Months Ended

Jun.28,2014

Segment-Information [Abstract]
Percentage of revenue from major customers. maximum I 0.00%
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Organization, Consolidation,
And Basis Of Presentation
(Details)

6 Months Ended

Jun.28,2014
item

·

Organization, Consolidation, And Basis Of Presentation [Abstract]

Geographic regions
Sub-geographical regions

2
3
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Condensed Consolidated
Statements Of Cash Flows
(USD $)
In Thousands, unless
othenvise specified
Cash flows from operating activities
Net earnings
Adjustments to reconcile net earnings to net cash provided by (used in) operating
activities
Depreciation and amortization
(Gain) loss on sale of property and equipment
Equity-based compensation expense
Excess tax benefits from equity-based payment arrangements
Deferred income taxes
Changes in operating assets and liabilities:
Inventories
Prepaid expenses and other assets
Accounts payable
Other liabilities
Net cash provided by (used in) operating activities
Cash flows from investing activities
Additions to notes receivable
Purchases of investment securities held-to-maturity
Maturities of investment securities
Proceeds from sale of property and equipment
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from equity awards exercised
Excess tax benefits from equity-based payment arrangements
Repurchase of common stock
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosures of cash flow information
Interest
Income taxes
Non-cash financing activities:
Unsettled trades for repurchase of common stock

6 Months Ended
Jun. 28,

Jun. 29,

2014

2013

$ 35,838

$41,989

4,408

4,631

16

(6)

4,071

4,427

(3,387)

(1,734)

(605)

843

3,034

(6,123)

(5,144)

(3,295)

(3,085)

155

(3,896)

6,409

31,250

47,296

(2,520)

(2,232)

(3,871)
9,137

8

15

(10,103)

(2,961)

(7,349)

(5,178)
454

3,387

1,734

(46,109)

(18,085)

(42,722)

(15,897)

(255)

(1,004)

(19,076)

25,217

137,343

70,839

118,267

96,056

6
9,963
$ (2,985)
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21,040

Condensed Consolidated
Balance Sheets
(Parenthetical) (USD $)
In Thousands, except Per
Share data, unless otherwise
specified

Jun. 28, 2014 Dec. 28, 2013

Condensed Consolidated Balance Sheets [Abstract)

Common stocki 12ar value
Corrnnon stocki shares authorized
Common stockl shares issued
Common stocki shares outstanding

$ 0.001

$ 0.001

50,000

50,000

13,404

13,886

13,404

13,886
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Organization, Consolidation,
And Basis Of Presentation
(Policy)
Organization, Consolidation,
And Basis Of Presentation
(Abstract]
Recent Accounting
Pronouncements

6 Months Ended

Jun.28,2014

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued an Accounting
Standard Update ("1\SU") No. 2014-09, "Revenue from Contracts with Customers (fopic 606)." ASU
2014-09 includes a five-step process by which entities will recognize revenue to depict the transfer of goods
or services to customers in amounts that reflect the consideration to which an entity expects to be entitled
to in exchange for those goods or services. The standard also will relJUire enhanced disclosures to enable
users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and
cash flows arising from contracts with customers. 1\SU 2014-09 is effective for annual and interim
reporting periods beginning after December 15, 2016, with early adoption prohibited. Accordingly, the
Company will adopt this ASU on January 1,2017. t\SU 2014-09 permits companies the use of either a
full retrospective or a modified retrospective approach to adopt this ASU, and the Company is currently
evaluating which transition approach to use. The Company is currently evaluating the impact ASU 201409 will have on its consolidated financial statements.
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6 Months Ended
Jun.28,2014

Document And Entity
Information

Aug. 01, 2014

Document And Entity Information (Abstract)
Document Type
I 0-Q

Amendment Flag
Document Period End Date
Document Fiscal Period Focus
Entity Central Index Key
Entity Registrant Name
Current Fiscal Year End Date
Document Fiscal Year Focus
Entity Filer Category
Entity Common Stock, Shares Outstanding

false

Jun.28,2014
Q2

0000896264
USANA HEALTH SCIENCES INC

--01-03
2014
Accelerated Filer

12,984,073
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6 Months Ended

Fair Value Measures
(Tables)

Jun.28,2014

Fair Value Measures (Abstract]
Schedule Of Assets And Liabilities Measured
· At Fair Value

Fair Value Measurements Using:
December 28,
2013
Money market funds included
in cash equivalents
$
·Term deposits included in
cash equivalents

Level 1 Inputs Level 2 Inputs Level 3 Inputs

9,249$

9,249~

348

-s
348

Fair Value Measurements Using:
June 28, 2014

Level 1 Inputs Level 2 Inputs LeveJ.3 Inputs

Money market funds included

in cash equivalents

S

14,412$

14,412$
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Condensed Consolidated
Statements Of
Comprehensive Income (USO

3 Months Ended

6 Months Ended

$)

In Thousands, except Per
Share data, unless otherwise
specified
Condensed Consolidated Statements Of Com~rehensive Income
[Abstract]
Net sales
Cost of sales
Gross Qrofit
0Qerating exQenses:
Associate incentives
Selling, general and administrative
Total OQerating exQenses
Earnings from OQerations
Other income (expense}:
Interest income
Interest ex12ense
Other, net
Other income (ex12ense), net
Earnings before income taxes
Income taxes
Net earnings
Earnings per common share
Basic
Diluted
Weighted average common shares outstanding
Basic
Diluted
ComQrehensive income:
Net earnings
Other comprehensive income (loss} 2 net of tax:
Foreign currency translation adjustment
Tax benefit (ex12ense) related to foreign currency translation adiustrnent
Other com12rehensive income (loss). net of tax
ComQrehensive income

Jun. 28,

Jun. 29,

Jun. 28,

Jun. 29,

2014

2013

2014

2013

$ 188,256

$189,136

$370,657

$358,218

34,865

31,905

68,693

62,166

153,391

157,231

301,964

296,052

81,098

77,801

159,972

147,656

43,206

42,978

87,783

85,382

124,304

120,779

247,755

233,038

29,087

36,452

54,209

63,014

215

81

427

159

~

~

~

(6)
(268)

82

(164)

297

(83)

422

(109)

29,384

36,369

54,631

62,905

10,083

12,159

18,793

20,916

19,301

24,210

35,838

41,989

$ 1.40
$ 1.36

$ 1.79
$ 1.72

$ 2.59
$ 2.50

$ 3.09
$ 2.99

13,768

13,513

13,843

13,578

14,235

14,099

14,315

14,034

19,301

24,210

35,838

41,989

802
(262)

(2,472)

(860)

(2,441)

540

798
(1,674)

390
(470)

732
(1,709)

$19,841

$22,536

$35,368

$40,280
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6 Months Ended

Other Assets

~

Jun.28,2014

Other Assets [Abstract)
Other Assets

NOTE E - OTHER ASSETS
The Company has extended non-revolving credit to its supplier of nutrition bars of up to $7,000 to
allow this supplier to acquire the necessary equipment to manufacture the USANA nutrition bars. Notes
receivable arc valued at their unpaid principal balance plus any accrued but unpaid interest, which
approximates fair value. Interest accrues at an annual interest rate of LI BO R plus 400 basis points. The note
has a matutity date of February 1, 2024 and will be repaid by a combination of cash payments and credits for
the manufacture of US1\NA's nutrition bars. There is no prepayment penalty. Notes receivable from this
supplier as December 28, 2013, and June 28, 2014 were $4,942 and $7,447, respectively.
The Company is building a state-of-the-art manufacturing and production facility in China, which is
expected ro become operational during the latter half of 2015. As part of this project, land use rights totaling
$1,483, and S7,364 as of December 28, 2013 and June 28, 2014, respectively, have been purchased and will be
amortized over 50 years. J,and-use rights arc classified within the "Other assets" line item in the Company's
consolidated balance sheers.

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

6 Months Ended

Inventories
Inventories [Abstract]
Inventories

Jun.28,2014

NOTED- INVENTORIES
Inventories consist of the
following:

Raw materials

December 28,

June 28,

2013

2014

s

Work in progress
Finished goods·

s

13,824$

12,301

8,147

8,361

25,271

· 23,866

47,242S

44,528
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6 Months Ended

Segment Information (Tables)

Jun.28,2014

Segment Information IAbstract)
Schedule Of Revenue Percentage By Product

Six Months Ended

Quarter Ended
June 29,

June 28,

2013

2014

June 29,
2013

June 28,
2014

USt\Nt\ 8' Nutritionals

81%

78%

79%

80%

USt\NJ\ Foods

12%

14%

12%

12%

6%

7%

7%

6%

Sense - beautiful scicnCl.-i

Schedule Of Revenues From External Customers By
Geographical Areas

Quarter Ended
June 29,
2013

Six Months Ended

June 28,
2014

June 29,
2013

June 28,
2014

Net Sales to External
Customers
Americas and Europe

s

Asia Pacific
Southeast Asia Pacific
Greater China
North Asia
Asia Pacific Total
Consolidated Total

$

Consolidated Net Sales And Long Lived Assets

63,(16

66,769S

ls

130,921 S

127,476

37,475

42,689

72,784

83,137

77,388

74,091

140,373

144,938

7,504

7,815

14,140

15 106

122,367

124,595

227,297

243,181

189,136$

188,256$

Quarter Ended
June 29,
2013

358,218$

370,657

Six Months Ended

June 28,
2014

June 29,
2013

June 28,
2014

Net sales:
China

$

23,559$

51,223$

36,984$

89,983

United States

40,087

35,570

80,325

73,183

Hong Kong

45,938

N/1\

87,535

38,926

As of

December 28,
2013

June 28,
2014

J,ong-lived Assets:
China

s

United States
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61,7165
51,260

73,026
53,004

6 Months Ended

Investments (Tables)

Jun.28,2014

Investments (Abstract]

Schedule Of Held-To-Maturity
Securities

As of December 28, 2013
J\morri;,.ed Cost

Unrecognized
Holding Gains

Umccoh111 izcd

Estimated Fair
Value

Holding Losses

Certificates of Deposit

s

8,6 112$

-$

-$

8,642

Total I ITM Securities

$

8,642S

-S

-S

8,642

&.

As of June 28, 2014

Unrecognized
:\morci;,.cd Cost

Certificates of Deposit
Total I ITivl Securities

s
s

Estimated Fair
Value

Unrecognized
Holding I .osses

1-Iolding·c;ains

3,374$

·S

-S

3,374

3,374$

-S

-S

3,374
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6 Months Ended

Common Stock And Earnings
Per Share

Jun. 28,2014

Common Stock And Earnings
Per Share [Abstract)

Common Stock And Earnings Per
Share

NOTE H -

COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share arc based on the weighted-average number of shares outstanding for each
period. Shares that have been repurchased and retired during the periods specified below have been included
in the calculation of the number of weighted-average shares that arc outstanding for the calculation of basic
earnings per share based on the time they were outstanding in any period. Diluted earnings per common
share arc based on shares that are outstanding (computed under basic EPS) and on potentially dilutive
shares. Shares that arc included in the diluted earnings per share calculations under the treasury stock
method include equity awards that are in-the-money but have not yet been exercised.
The following is a reconciliation of the numerator and denominator used to calculate basic earnings
per share and diluted earnings per share for the periods indicated:

Quarter Ended
June 29,
2013

"'
~

Net earnings available to common shareholders

s

24,210$

Six Months Ended

June 28,
2014

19,301S

June 29,
2013

June 28,
2014

41,989S

35,838

13,821

13,886

Basic EPS
Shares
Common shares outstanding entire period
Weighted average common shares:
Issued during period

13,821

Canceled during period

13,886

106

131

{414}

{249}

{301}

{124}

81

13,513

13 768

13,578

13 843

58

Weighted average common shares outstanding
during
period

~
Earnings per common share from net earnings - basic

$

1.79$

1.40$

3.09$

2.59

Diluted EPS

~

Shares
\Veighted average common shares outstanding
during
period - basic

13,513

13,768

13,578

13,843

586

467

456

472

14,099

14,235

14,034

14,315

Dilutive effect of in-the-money equity awards
Weighted average common shares outstanding
during
period - diluted

~
Earnings per common share from net earnings ·
diluted

vJ

s

1.72S

1.36S

2.50

ElJUity awards for the following shares wen· 1101
included in the computation of diluted EPS due to
the fact that
their effect would be anti-dilutive:
Quarter Ended
June 29,

2013

Vil

2.99S

June 28,
2014
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Six Monchs Ended
June 29,
2013

June 28,
2014

234

383

560

328

NOTE H - COMMON STOCK AND EARNINGS PER SHARE - CONTINUED
During the six months ended June 29, 2013 and the quarter and six months ended June 28, 2014, the
Company repui-chased and retired 414 shares and 682 shares, for $18,085 and $49,094, respectively, under the
Company's share repurchase plan. The excess of the repurchase price over par value is allocated between
additional paid-in capital and retained eaminbrs on a pro-rata basis. The purchase of shares under this plan
reduces the number of shares outstanding in the above calculations.
Subsequent to the period ended June 28, 2014 and through August 1, 2014, the Company repurchaser
and retired 430 shares under the Company's share repurchase plan for a total of $30,932 As of August 1, 2014, t
remaining approved repurchase amount under the plan was $119,953.
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6 Months Ended
Jun.28,2014

Contingencies
Contingencies {Abstract]
Contingencies

NOTE F - CONTINGENCIES
The Company is involved in various lawsuits, claims and other legal matters from time to time that
arise in the ordinary course of conducting business, including matters involving our products, intellectual
property, supplier relationships, distributors, competitor relationships, employees and other matters. While
complete assurance cannot be given to the outcome of these proceedings, management does not currently
believe that any of these matters, individually or in the aggregate, will have a material adverse effect on our
financial condition, liqui9ity or results of operations.
.
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6 Months Ended

Equity-Based Compensation

Jun.28,2014

Equity-Based Compensation
[Abstract)

Equity- Based Compensation

NOTE G-EQUITY BASED COMPENSATION
The Company utiliz<.'s a share-based compcmation plan, which is more fully descriht·d in Note K to the
Consolidated rinancial Statements in Form 10-K for the year ended December 28, 2013.
Equity-based compensation expense for the quarters ended June 29, 2013 and June 28, 2014, was $2,058,
and $2,235 respectively. The related tax benefit for these periods was $697, and $743, respectively. Expense for
the six months ended June 29, 2013, and June 28,2014, was $4,427 and $4,071, respectively. The related tax
benefit for these periods was $1,509 and Sl,359, respectively.

The following table shows the rcmain_ing unrecognized compensation expense on a pre-tax basis for
all types of unvested equity awards outstanding as of i\larch 29, 2014. This table docs not include an estimate
for future grants that may be issued.

"'
~

s

2014
2015
2016
2017
2018+

4,643
7,382
5,504
3,399
541

S

21,469

The cost above is expected to be recognized over a weighted-average
period of 2.1 years.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity
awards. The weighted-average fair value of stock-settled stock appreciation rights that were granted during the
three months ended March 30, 2013, and March 29, 2014, was $13.34 and $17.73, respectively. Following is a
table that includes the weighted-average assumptions that the Company used to calculate fair value of equity
awards that were granted during the periods indicated.

Six Months Ended
June 29,
2013
Expected volatility (1) .
Risk-free interest rate (2) .
Expected life (3) .
Expected dividend yield (4).
Weighted-average exercise price (5) .

s

43.1%
0.6%
3.97 yrs
0.0%
40.84

June 28,
2014
39.9%
1.2%

s

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is base<l on rhe U.S. Treasury yield curve with respect to the expected life of
the award.
(3) Depending upon the terms of the award, expected life may be a weighted-average that includes
historical serrlcment cfata of the Company's c4uity awards and a hypothetical holding
period for outstanding awards, or it may be calculated tmdcr the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the ( :ompany's common stock on the date of grant.
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3.54 yrs
0.0%
57.62

NOTE G- EQUITY-BASED COMPENSATION - CONTINUED
A summary of the Company's stock option and stock-settled stock appreciation right activity is as
follows:

~

Shares
Outstanding at December 28. 20·13

1.827

Weightedaverage
exercise encc

s

37.37

Granted

686

57.62

Exercised

(362)

32.26

Forfeited

(20)

27.33

Weightedaverage
remaining
contractual
term

Aggregate
intrinsic
value*

2.6

$

74,160

~.

Expired
Outstanding atjune 28, 2014
Exercisable at June 28, 2014

2,131
412

s

44.85

2.8

$

70,555

s

38.40

1.6

$

16,207

~

* Aggregate intrinsic value is defined as the difference between the current market value at the reporting date
(the closing price of the
Company's common stock on the last trading dar of the period) and the exercise price of awards that were inthe- money. The
closing price of the Company's common stock at December 28, 2013, and June 28, 2014, was '$77.72 and
S77.76, respectively.

The total intrinsic value of stock options and stock-settled stock appreciation rights exercised during
the six months ended June 29, 2013, and June 28, 2014, was $10,429 and S14,404, respectively.
The total fair value of equity awards that vested during the six months ended June 29, 2013, and June
28, 2014, was S1,553 and $3,506, respectively. This total fair value includes equity-based awards issued in the
form of stock options and stock-settled stock appreciation rights.
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6 Months Ended

Segment Information
Segment Information
(Abstract)
Segment lnfonnation

Jun.28,2014

NOTE I - SEGMENT INFORMATION
USJ\NJ\ operates as a direct selling company that develops, manufactures, and distributes high-c1uality
nutritional and personal care products that arc sold through a global network marketing system of independent
distributors (" Associates"). As such, management aggregates its operating segments into one reportable
segment as management believes that the Company's segments exhibit similar long-term financial performance
and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No
single Associate accounted for 10% or more of net sales for the periods presente<l. The table below summarizes
the approximate percentage of total product revenue that has been contributed by the Company's nutritional and
personal care products for the periods indicated.

Quarter Ended
June 29,
2013
USJ\NJ\ 11 Nutritionals
USJ\NA Foods
Sense - beautiful sciencex

Six Months Ended

June 28,
2014

June 29,
2013

June 28,
2014

81%
12%

78%
14%

79%
12%

80%
12%

6%

7%

7%

6%

Selected financial information for the Company is presented for two ge<>!,>raphic regions: Americas and
Europe and t\sia Pacific, with three sub-regions under 1\sia Pacific. Individual markets are categorized into these
regions as follows:
Americas and Europe - United States, Canada, Mexico, Colombia<•>. the United Kingdom,
France, Belgium, and the Netherlands.

•
•

Asia Pacific •

Southeast Asia Pacific - Australia, New Zealand, Singapore, Malaysia, the Philippines, and
Thailand

•

Greater China - Hong Kong, Taiwan and China<2l

•

North Asia - Japan and South Korea

<•> The Company commenced operations in Colombia in the third quarter of 2013.
<2J
The Company's business in China is that of BabyCare, its wholly-owned subsidiary.
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NOTE I - SEGMENT INFORMATION - CONTINUED
Selected Fi11a11tial foformatio11
Financial information by geographic region is presented f?r the periods indicated below:

Quarter Ended
June 29,
2013

Six Months Ended

June 28,
2014

June 29,
2013

June 28,
2014

Net Sales to External Customers
1\mericas and I~urope

s

66,769

S

63,661

s

130,921

s

127,476

Asia Pacific
Southeast 1\sia Pacific

37,475

42,689

72,784

83,137

Greater China

77,388

74,091

140,373

144,938

North 1\sia
Asia Pacific Total
Consolidated Total

s

7 504

7,815

14140

15,106

122,367

124,595

227,297

243,181

189,136 $

188,256

s

358,218 S

370,657

The following table provides further information on markets representing ten percent or more of consolidated
net sales and long-lived assets, respectively:

Quarter Ended
June 29,
2013
Net sales:
China
United States

23,559 $
40,087

Hong Kong

45,938

$

Six Months Ended

June 28,
2014

June 29,
2013

51,223 $

June 28,
2014

36,984

s

89,983

35,570

80,325

73,183

N/A

87,535

38,926

Asof
December 28,
2013

June 28,
2014

Long-lived Assets:
China

s

United States
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61,716
51,260

s

73,026
53,004

~

((dl)

~

Common Stock And Earnings
3 Months Ended
6 Months Ended
Per Share (Narrative)
(Details) (USD $)
Jun. 28, Jun. 29, Jun. 28, Jun. 29,
In Thousands, except Share
2014
2013
2014
2013
data, unless otherwise
specified
Eguit:y~ Class of Treasury Stock (Line
Items]
Eguity awards of stock excluded in
383,000 234,000 328,000 560,000
com12utation of diluted EPS
414
Shares re12urchased and retired
682
Value of shares repurchased and retired
$49,094 $ 18,085
Remaining apQroved repurchase amount

0 Months Ended 1 Months Ended
Aug. 01, 2014
Aug. 01, 2014
Subsequent
Subsequent
Event [Member) Event [Member)

430
$30,932
$ 119,953

~
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6 Months Ended

Equity-Based Compensation
(Tables)

jun.28,2014

Eguitv-Based Compensation [Abstract)

Schedule Of Remaining Unrecognized
Compensation Expense For Unvested Awards

~

s

2014

4,643

2015
2016

7,382
5,504

2017

3,399

2018+

541

s

21,469

~

The cost above is expected to be recognized over a weighted-average
period of 2.1 years.

Schedule Of Fair Value Assumptions
Six Months Ended
June 29,
2013
Expected volatihry ( 1) .
Risk-free interest rare (2) .
Expected life (3) .

June 28,
2014

43.1%

Expected dividend yield (4).

0.6%

39.9%
1.2%

3.97 yrs
0.0%

3.54 yrs
0.0%

s

Weighted-average exercise price (5) .

40.84

s

57.62

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the
expected life of
the award.
(3) Depending upon the terms of the award, expected life may be a weighted-average that
includes
historical settlement data of the Company's equity awards and a hypothetical holding
period for outstanding awards, or it may be calculated under the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of 1-,l'fant.

Schedule Of Stock Option Activity

Shares
Outstanding at December 28,2013
Granted
J•:xcrcised
1:orfeited

Weightedaverage
exercise price

1,827
686
(362)
(20)

s

2,131

s

412

s

Weightedaverage
remaining
contractual
term

Aggregate
intrinsic
value•

2.6

s

74,160

44.85

2.8

s

70,555

38.40

1.6

s

16,207

37.37
57.62
32.26
27.33

l~xpired
Outstanding at June 28, 2014
1·'.xcrcisable at June 28, :Wl•l

• :\ggrcgate intrinsic value is defined as the difference between the current market value at
the reporting date (the closing price of the
Company's common stock on the last trading day of the period) and the exerci:-e price of
awards that were in-the- money. The
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closing price of the Company's common stock at December 28, 2013, and June 28, 2014,
was S77.72 and $77.76, respectively.

@

•

....
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Fair Value Measures
(Schedule Of Assets And
Jun. 28,
Liabilities Measured At Fair
2014
Value) (Details) (USD $)
In Thousands, unless
otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line
Items)
$ 14,412
Money market funds included in cash equivalents
Term deposits included in cash
Fair Value, Inputs, Level l [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line
Items}
14,412
Money market funds included in cash equivalents
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line
Items)
Term deposits included in cash
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Dec. 28,
2013

$ 9~249

348

9,249

$ 348

vi)

~

v;

~

~

Condensed Consolidated
Statement Of Stockholders'
Equity (USD $)
In Thousands, except Share
data

Common
Stock
[Member)

$ 14
Balance2 value at Dec. 28 2 2013
Balance 2shares at Dec. 28 22013
13,886,000
Net earnings
Other comnrehensive income (losst net
of tax
Eguity-based comnensation ex12ense

Common stock re12urchased and retired2 (
OOO)
682
shares
'
Common stock renurchased and retired 2 ( )
1
value
Common stock issued under eguity
200 000
award 12Ians 2 including tax benefit 2 shares
'
Common stock issued under eguity
award 12lans 2 including tax benefit2value
Balance2 value at Jun. 28 2 2014
$ 13
Balance 2 shares at Jun. 28 2 2014
13,404,000

Additional
Paid-in Capital
[Member)
$ 54,691

Retained
Earnings
[Member)
$200,023

Accumulated Other
Comprehensive Income
(Loss) [Member)
$5,794

Total

$260,522
13,886,000

35,838

35,838
(470)

4,071

(470)
4,071
(682)

(10,224)

(38,869)

(49,094)

3,387
$ 51,925

3,387
$196,992

$5,324
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$254,254
13,404,000

6 Months Ended

Investments

Jun.28,2014

Investments [Abstract)

Investments

NOTE C- INVESTMENTS
The carrying amount, gross unrealized holding gains, gross unrealized holding losses, and fair value
of held-to-maturity securities by major security type and class of security were as follows:

As of December 28, 2013
Amortized Cost

Unrecognized
Holding Gains

Estimated foair
Value

Unrecognized
Holding Losses

Certificates of Deposit

s

8,642$

-S

-S

8,642

Total HTM Securities

s

8,642$

-$

-S

8,642

~

Cill.,
'

As of June 28, 2014
Amortized Cost

Unrecognized
Holding Gains

Estimated Fair
Value

Unrecognized
Holding Losses

Certificates of Deposit

s

3,374S

-$

-S

3,374

Total HTM Securities

s

3,374$

-$

-S

3,374
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Investments (Details) (USD
$)
In Thousands, unless
otherwise specified

Jun. 28, 2014 Dec. 28, 2013

Schedule of Held-to-maturity Securities [Line Items]

Amortized Cost
Estimated Fair Value
Certificates of Deposit [Member]

$3,374
3,374

$8,642
8,642

3,374
$3,374

8,642
$8,642

Schedule of Held-to-maturity Securities (Line Items]

Amortized Cost
Estimated Fair Value
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Segment Information
(Schedule Of Revenues From
External Customers And
Assets By Geographic
Region) (Details) (USD $)
In Thousands, unless
otherwise specified
Revenues From External Customers Bl:: Geograuhic Area (Line
Items)
Net Sales to External Customers
Americas And Europe [Member]
Revenues From External Customers Bl:: GeograQhic Area (Line
Items)
Net Sales to External Customers
Southeast Asia/Pacific [Member]
Revenues From External Customers B:y GeograQhic Area (Line
Items)
Net Sales to External Customers
Greater China [Member]
Revenues From External Customers Bl:: GeograQhic Area (Line
Items)
Net Sales to External Customers
North Asia [Member]
Revenues From External Customers B:y GeograQhic Area (Line
Items)
Net Sales to External Customers
Asia Pacific [Member]
Revenues From External Customers B:y Geograuhic Area (Line
Items)
Net Sales to External Customers

3 Months Ended

6 Months Ended

Jun. 28,
2014

Jun. 29,
2013

Jun. 28,
2014

Jun. 29,
2013

$ 188,256

$189,136

$370,657

$358,218

63,661

66,769

127,476

130,921

42,689

37,475

83,137

72,784

~

•
~

®

74,091

77,388

144,938

140,373
~

7,815

7,504

15,106

14,140

$ 124,595

$ 122,367

$243,181

$227,297

~
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6 Months Ended

Inventories (Tables)
Inventories (Abstract]
Schedule Of Inventories

Jun.28,2014
Inventories consist of the
following:

Raw materials

December 28,

June 28,

2013

2014

$

13,824$
8,147
25,271

12,301
8,361
23~866

$

47,242$

44,528

Work in progress

@,

Finished goods

@
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-------~----- -------·-·-------••---•- ---------- ----------------------------UNITED STA TES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14{a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant R
Filed by a Party other than the Registrant £
Check the appropriate box:

£ Preliminary Proxy Statement
£ Confidential, for Use of the Commission Only (as permitted by Rule l4a-6{e)(2))
R Definitive Proxy Statement

£ Definitive Additional Materials
£ Soliciting Material Pursuant to §240. I 4a- l 2

CytRx Corporation
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
R No fee required.

£ Fee computed on table below per Exchange Act Rules l4a-6(i){I) and 0-11.
(I)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

(4}

(5)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined):

Proposed maximum aggregate value of transaction:

Total fee paid:

£ Fee paid previously with preliminary materials.
£ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11 (a)(2} and identify the filing for which the offsening fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date of its filing.
~

"1JP

(I)

Amount Previously Paid:

(2)

Fonn, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:
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CytRx Corporation
11726 San Vicente Boulevard, Suite 650
Los Angeles, California 90049
May I, 2014
Dear Stockholder:
You are cordially invited to attend the 2014 Annual Meeting of Stockholders ofCytRx Corporation. The meeting will be held at the Hotel Bel Air, 701 Stone Canyon Road, Los Angeles,
California al 10:00 A.M., local lime, on Tuesday, June 24, 2014.
The Notice of Meeting and the Proxy Statement on the following pages cover the fonnal business of the Annual Meeting. At the Annual Meeting, I will also report on CytRx's current
operations and will he available to respond lo appropriate questions from stockholders.
We sincerely hope you will be able 10 attend lhe Annual Meeting. Whether or not you plan to attend, however, and regardless of the oumber of shares you own, ii is important that
your shares be represented at the Annual Meeting. Therefore, please take the time lo vole your shares by compleling and mailing lhe enclosed proxy card to us.
Thank you for your continued support.
Sincerely,

/s/ STEVEN A. KRIEGSMAN
Steven A. Kriegsman
Presidcnl and Chief Executive Officer

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

CytRx Corporation
11726 San Vicente Boulevard, Suite 650
Los Angeles, California 90049

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
to be held on June 24, 2014

i,,J,

Notice is hereby given 10 the holders of common stock, $.001 par value per share, ofCytRx Corporation that the Annual Meeting of Stockholders will be held on Tuesday, June 24, 2014
at the Hotel Bel Air, 701 Stone Canyon Road, Los Angeles, California at 10:00 A.M .• local time, for the following purposes:
(I)

The election of two directors to serve until the 2017 Annual Meeting of Stockholders;

(2)

The advisory approval of the compensation of our named executive officers as disclosed in this proxy statement;

(3)

The ratification of the selection of BOO USA, LLI' as our independent registered public accounting firm for the fiscal year ending December 31, 2014; and

(4)

The transaction of such other business as may properly come before the Annual Meeting and at any postponement or adjournment thereof.

Only those stockholders of record at the close of business on May I, 2014 arc entitled to notice of and lo vote at the Annual Meeting and at any postponement or adjournment thereof.
A complete list of stockholders entitled to vote al the Annual Meeting will be available at the Annual Meeting.

By Order of the board of directors,
Isl BENJAMIN S. LEVIN
Benjamin S. Levin
Corporate Secretary
May 1,2014

WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, PLEASE COMPLETE, SIGN, DATE, AND RETURN THE ENCLOSED PROXY PROMPTLY IN THE
ENCLOSED BUSINESS REPLY ENVELOPE (OR USE TELEPHONE OR INTERNET VOTING PROCEDURES, IF AVAILABLE THROUGH YOUR BROKER). IF YOU ATTEND THE
ANNUAL MEETING AND WISH TO DO SO, YOU MAY REVOKE YOUR PROXY AND VOTE IN PERSON.
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CytRx Corporation
11726 San Vicente Boule,·ard, Suile 650
Los Angeles, California 90049
To Be Held June 24, 2014
PROXY STATEMENT
This Proxy Statement is furnished to holders of common stock, $.00 I par value per share, of Cy1Rx Corporation, a Delaware corporation ("we," "us," "our," "CytRx" or the "company")
in connection with the solicitation of proxies by our board of directors for use at our 2014 Annual Meeting of Stockholders to he held al the Hotel Rel Air, 701 Stone f'anyon Roacl, 1.os Anedt"~,
California at I 0:00 A.M., local time, on Tuesday, June 24, 2014, and at any postponement or adjournment thereof.
This Proxy Statement and lhe accompanying proxy card are first being mailed to our stockholders on or about May 3, 2014.
Our board of directors is asking you to vote your shares by complc1ing, signing and returning the proxy card. If you attend the Annual Meeting in person, you may vote at the Annual
Meeting even if you have previously returned a proxy. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Annual
Meeting, you must obtain a proxy issued in your name from that record holder.
Whal is a proxy?
A proxy is the legal designation of another person to vote the stock you own. That other person is called a proxy. If you designate someone as your proxy in a written document, Ihat
<locumenl i~ also called a proxy or a proxy card. We have designated Steven A. Kriegsman, our President and t'hief Executive Officer, and Benjamin S. Levin, our General Counsel, Senior Vice
President - Legal Affairs and Corporate Secretary, as proxies for the Annual Meeting. By completing, signing and returning the accompanying proxy card, you are authorizing
Messrs. Kriegsman and Levin to vote your shares at the Annual Meeting as you have instrncted them on the proxy card. This way, your shares will be voted whether or not you attend the
Annual Meeting. Even if you plan to attend the Annual Meeting, it is advisable to complete, sign and return your proxy card before the Annual Meeting date just in case your plans change.
You may vote, in person, at the Annual Meeting even if you have previously returned a proxy.
What is a Proxy Statement?
A Proxy Statement is a document that regulations of the Securities and Exchange Commission, or SEC, require us to give you when we ask you to sign a proxy card designating
Messrs. Kriegsman and Levin as proxies to vote on your behalf.
What is in this proxy statement'!
This Proxy Statement describes the proposals on which we would like you, as a stockholder, to vote at the Annual Meeting. It gives you information on the proposals, as well as other
information about us, so that you can make an informed decision.

~

Whal am I voting on?
At the Annual Meeting, stockholders will act upon the proposals referred to in the attached Notice of Meeting and descnbed in detail in this proxy statement. These proposals are:

( l)

the election of two directors to serve until the 2017 annual meeting of stockholders;

(2)

the advisory approval of the compensation of our named executive officers as disclosed in this proxy statement;

(3)
(4)

the ratification of our appointment of independent accountants; and
the transaction of such other business as may properly come before the Annual Meeting and at any postponement or adjournment thereof.

In addition, management will report on our performance during fiscal 2013 and respond to appropriate questions from stockholders.
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Who is entitled to vote at the Annual Meeting?
Only stockholders of record at the close of business on May I, 2014 are en1i1led to nolice of, and lo vole at, the Annual Mee1ing and at any adjournment or postponement !hereof.
What does it mean if I receive more than one proxy card?

vj;

It means that you have multiple accotmls al the transfer agent or wilh siockbrokcrs. Please complete, sign and return all proxy cards lo ensure that all your shares are voted. Unless
you need muhiple accounts for specific purposes, ii may be less confusing if you consolida1e as many of your transfer agent or brokerage accounts as possible under the same name and
address.
What if I change my mind after I return my proxy card?
You may revoke your proxy card and change your vote by:
• signing another proxy card with a later date and returning it before the polls close at 1he Annual Meeting, or
• voting in person at the Annual Meeting.
However, if you hold your shares in street name, you must request a proxy from 1he person in whose name your shares are held, usually your stockbroker, to vole at 1he Annual
Meeting.
Will my shares be voted if I do not return my proxy card?
If your shares are held in street name, your brokerage firm, under certain circumstances, may vote your shares.
Brokerage firms have authority under the rules ofThe NASDAQ Capilal Market to vote customers' unvoted shares on "rou1ine" matters. If you do not give instructions to your broker,
your broker can vote your shares with respect to routine mauers only. Under these rules, Proposals I and 2 are considered non-routine, so if you do not give your broker instructions, your
shares will be treated as broker non-votes with respect to each Proposals I and 2. Proposal 3 is considered a routine mauer.
If you do not return a proxy card to vote your shares, your brokerage finn may ei1her:
• vote your shares on routine matters, or
• leave your shares unvo1ed.
We encourage you to provide instructions to your brokerage firm by returning your proxy card. This ensures that your shares will be voted al 1he Annual Meeting with respect to all of
the proposals described in this proxy statement.
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Whal constitutes a quorum?
Our Restated Bylaws provide that the presence, in person or by proxy, al lhe Annual Meeting or the holders or a majority of outstanding shares of our common stock will constitute a
quorum for the transaction of business.
For the purpose or determining the presence or a quonnn, proxies marked "withhold au1hori1y" or "ahstain" will be counted as present. Shares represented by proxies that include socalled broker non-votes (shares held by a broker or nominee that has no authority to vote upon a particular mailer) also will be counted as shares present for purposes or establishing a quorum.
On the record dale, there were 55,776,523 shares of our common stock issued and ou1s1anding, exclusive of treasury shares.
What are lhe voting rights of the holders of our common stock?
Holders of our common slock arc entitled to one vote per share with respect lo each of the mailers to be presented at the Annual Meeting. Wi1h regard to the election of directors, the
two nominees receiving the greatest number of affinnative votes cast will be elected. Approval of each of the other proposals requires the affinnative vote of a majority of the shares present in
person or represented by proxy and entitled to vole on that proposal at the Annual Meeting.
In the election of directors, you may vote "FOR" or "WITHHOLD AUTHORITY" with respect 10 each of the nominees. In 1abulating the voting results for the election of direclors,
only "FOR" voles will be counted.
With respect to each of Proposals 2 and 3, you may vole "FOR," "AGAINST" or "ABSTAIN." If you elect to abstain, it will have the same effect as an "AGAINST" vote.
Broker non-votes have no effect and will not be counted toward 1he vote lotal for any proposal.
What happens if a nominee is unable to stand for election?
Our board or directors may reduce the number of nominees or select a subs1itute nominee. In the la lier case, if you have completed, signed and returned your proxy card, Messrs.
Kricgsman and Levin can vote your shares for a substitute nominee. They cannot vote for more than two nominees.
What a.-e the board's .-ecommendalions?
The recommendations of our board or direclors are set forth together with the description of each Proposal in this Proxy Slatcment. In summary, our board of directors recommends a
VOie:

"FOR" election of the incumbent direclors named in this Proxy Sta1cmcn1 as described in Proposal I;
"FOR" advisory approval of the compensation of our named executive officers as disclosed in Ihis Proxy Statement as described in Proposal 2; and
"FOR" ratification of the appoinlment ofBDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2014 as described in Proposal 3.
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Proxies
If the enclosed proxy card is executed, returned in time and not revoked, the shares represented thereby will be voted at the Annual Meeting and at any postponement or adjournment
. thereof in accordance with the directions indicated on the proxy card. IF NO DIRECTIONS ARE INDICATED, PROXIES WILL BE VOTED IN ACCORDANCE WITH OUR BOARD OF
DIRECTORS' RECOMMENDATIONS IN THIS PROXY STATEMENT AND, AS TO ANY OTHER MA TIERS PROPERLY BROUGHT BEFORE THE ANNUAL MEETING OR ANY
POSTPONEMENT OR ADJOURNMENT THEREOF, IN THE SOLE DISCRETION OF THE PROXIES.
Is my vote kept confidential?
Proxies, ballots and voting tabulations identifying stockholders are kept confidential and will not be disclosed to third parties except as may be necessary to meet legal requirements.
Where do I find the voting results

or the Annual Meeting?

We will announce preliminary voting results at the Annual Meeting. We will publish the final results in a Form 8-K. We intend to file the Form 8-K no later than June 30, 2014 with the
Securities and Exchange Commission, or SEC. You may obtain a copy of the 8-K report by contacting us at (310) 826-5698 or at an SEC public reference room. For the location ofan SEC public
reference room, please contact the SEC at (800) SEC-0330.
You can also get a copy of the 8-K report that will contain the voting results on the Internet at www.cytrx.com or through the SEC's electronic data system called EDGAR at
www.sec.gov.
How do I receive an annual report?
A copy of our Annual Report on Form I 0-K for the fiscal year ended December 31, 2013 is being <lei ivcred with this proxy statement to each stockholder. A copy of the Annual Report
is also available on our website at www.cytrx.com and on the SEC's website at www.sec.gov. Copies of exhibits to the Annual Report will be made available for a reasonable charge upon
written request to CytRx Corporation, 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049, Attention: Corporate Secretary.
We encourage you to review the Company's disclosures in its period reports filed with the SEC, including, but not limited to, the Company's Fonn I 0-Q, filed on May I, 2014.
Do we have a policy about directors' attendance at the annual meeting?
We do not have a policy regarding attendance of directors at our annual meetings of stockholders. At our last annual meeting, all of our directors were in attendance.
How are proxies solicited, and what is the cost?
We pay all expenses incurred in connection with distributing and soliciting proxies. As part of this process, we reimburse brokers, nominees, fiduciaries and other custodians'
reasonable fees and expenses in forwarding proxy materials to stockholders. Our directors and employees may solicit proxies by mail, telephone or other means. Our directors and employees do
not receive any additional compensation for these activities.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDERS MEETING TO BE HELD ON JUNE 24,
20 I4 - This Proxy Statement, along with the proxy card, and letter of transmittal from our President and Chief Exccmive Officer accompanying our Annual Report on Fonn I 0-K for the year
ended December 31, 20! 3 as filed with the Securities and Exchange Commission are available at our website, http://www.cytrx.com, under "Investor Relations."
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PROPOSAL l
ELECTION OF DIRECTORS

Pursuant to our Restated Bylaws, our board of directors has fixed the number of our directors al seven. Our Restated Certificate of Incorporation and our Restated Bylaws provide for
the classification of our directors into three classes, which we refer to as Class I, Class II and Class 111, with each Class to consist as nearly as possible of an equal number of directors. One
Class of directors is to be elected at each annual meeting of stockholders to serve for a tenn of three years.
We have two incumbent directors in Class II whose term expires al the Annual Meeting. The board of directors has nominated the incumbent Class II directors, Steven A. Kriegiman
and Marvin R. Seiter, for reelection as Class II directors to serve until the 2017 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
Information concerning Messrs. Kricgsman and Seiter, as well as the directors whose tenns of office will continue after the Annual Meeting, is set forth below. Each director's age is
indicated in parentheses after his name.
Class II ___:Nominees to Serve as Directors Until the 2017 Annual Meeting
We believe that Messrs. Kriegsman and Seiter will be available and able to serve as directors. In the event that one of them is unable or unwilling to serve, the proxy holders will vote
the proxies for such other nominee as they may detcnnine.

Steven A. Kriegsman (72) has been Cy1Rx's President and Chief Executive Officer and a director since July 2002. He also serves as a director of Galena Biopharma, a listed public
company, and is Chainnan of its Compensation Committee and a member of its Strategy Committee. Mr. Kriegsman also serves on the Board of Directors of Catasys, Inc. He previously served
as Director and Chainnan of Global Genomics from June 2000 until 2002. Mr. Kriegsman is an inactive Chairman and Founder ofKriegsman Capital Group LLC, a financial advisory firm
specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. During his career, he has advised such companies as
SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. In the past five years, Mr. Kriegsman has also served on the
Board of Directors of Bradley Phannaceuticals, Inc. and Hythiam, Inc. Mr. Kriegsman has a B.S. degree with honors from New York University in Accounting and completed the Execmive
Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors' College
Mr. Kriegsman was fonnerly a Certified Public Accountant with KPMG in New York City. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award
from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr.
Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University, and New York University. Mr. Kriegsman has
been active in various charitable organizations including the Biotechnology Industry Organization, the California Health Institute, the ALS Association, the Los Angeles Venture Association,
the Southern California Biomedical Council, the American Association of Dance Companies and the Palisades-Malibu YMCA.
Mr. Kriegsman 's extensive history as a member of management is vital to the board of directors' collective knowledge of our day-to-day· operations. Mr. Kriegsman also provides great
insight as to how CytRx grew as an organization and his institutional knowledge is an invaluable asset to the board of directors in effecting its oversight of CytRx 's strategic plans.
Mr. Kriegsman 's presence on the board of directors also allows for a flow of information and ideas between the board of directors and management.

Marvin R. Seiter (86) has been a director since October 2003. He has been President and Chief Executive Officer of CMS, Inc. since he founded that finn in 1968. CMS, Inc. is a national
management consulting firm. In 1972, Mr. Seiter originated the concept of employee leasing. He served as a member of the Business Tax Advisory Committee-City of Los Angeles, Small
Business Board-State of California and the Small Business Advisory Commission-State of California. Mr. Seiter also serves on the Valley Economic Development Center as past Chairman
and Audit Committee Chairman, the Board of Valley Industry and Commerce Association as past Chainnan, the Advisory Board oflhe San Fernando Economic Alliance and the California State
University-Northridge as Past Chairman of the Economic Research Center; and President of the Olive View-UCLA Medical Center Foundation. He has served, and continues to serve, as a
member of boards of directors of various hospitals, universities, private medical companies and other organizations. Mr. Seiter attended Rutgers-The State University, majoring in Accounting
and Business Administration, and is the recipient of an honorary Ph.D. from American Jewish University. He was an LPA having served as Controller, Financial Vice President and Treasurer at
distribution, manufacturing and service firms. He has lectured extensively on finance, corporate structure and budgeting for the American Management Association and other professional
teaching associations.
Mr. Seiter has founded, operated, and grown his own successful businesses, which gives him a valuable insight into the financial constraints and operational challenges facing
companies in the development stage and as they mature. He also has many years of involvement in various governmental agencies and charitable organizations, which affords him an important
perspective on the business regulatory process and capital-raising activities. In addition, he has significant education and work experience in accounting and financial matters that he is able to
utilize as the named financial expert on our Audit Committee.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ELECTION
OF MSRRS. KRIEGSMAN AND SELTER AS DIRECTORS.
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Continuing Directors
The following is a dcscriplion of the incumbent Class Ill and Class I directors whose tenns ofoflice will continue after the Annual Meeting:

Class Ill - Term E,piri11g at the lOI 5 Annual Meeting
Max Link, Ph.D. (73), our Chaimrnn of the Board, has been a director since 1996. Dr. Link has been retired from business since 2003. From March 2002 until its acquisition by Zimmer
I loldings, Dr. Link served as Chairman and CEO of Centerpulse, Ltd. From May 1993 to June 1994, Dr. Link served as the Chief Executive Officer of Corange Ltd. {the holding company for
Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy International). From 1992 to 1993, Dr. Link was Chairman of Sandoz Pharma, Ltd. From 1987 to 1992, Dr. Link
was the Chief Executive Officer of Sandoz Phanna and a member of the Executive Board of Sandoz, Ltd., Basel. Prior to 1987, Dr. Link served in various capacities with the United States
operations of Sandoz, including President and Chief Executive Officer. Dr. Link currently serves as a director of Alexion Pharmaceuticals, Inc. and Celsion Corporation, Inc., and has previously
served on the Boards of Directors of Cell Therapeutics, Inc., Columbia Laboratories, Inc., Human Genome Sciences, Inc., Protein Design Laboratories und Discovery Laboratories, Inc .• cuch a
listed public company.
Dr. Link has extensive executive-level experience with a number of large phannaceutical companies, including Sandoz Pharma, Ltd. In these positions, he was responsible for major
strategic and other business initiatives, including new drug development, acquisitions and dispositions of new drug candidates and other technology, licensing, marketing and distribution
agreements and other key contractual strategic arrangements that affect, or are likely to affect, our company's own business effons. As an executive officer and board member of these other
companies, he has experience with the regulatory schemes in foreign jurisdictions and also has been exposed to different approaches 10 corporate governance matters, potential conflicts of
interest, and similar matters, which enables him to offer importance guidance 10 our Board of Directors.

Richard L. Wennekamp (71) has been a director since October 2003. He retired from Community Bank in June 2008 where he was the Senior Vice President-Credit Administration since
October 2002. From September 1980 to July 2002, Mr. Wennekamp was an executive officer of Bank of America Corporation, holding various positions, including Managing Director-Credit
Product Executive for the last four years of his 22-year term with the bank. From 1977 through 1980, Mr. Wennekamp was a Special Assistant to former President of the United States, Gerald R.
Ford, and the Executive Director of the Ford Transition Office. Prior thereto, he served as Staff Assistant 10 the President of the United States for one year, and as the Special Assistant lo the
Assistant Secretary of Commerce of the U.S.
Mr. Wennekamp 's senior executive experience in the banking and financial services industry distinguishes him from our other directors and adds unique capabilities and a different
perspective to the deliberations of our Board of Directors. As a former chief credit officer at Bank of America and Community Bank, he understands the credit needs, financing requirements, and
operational constraints of development-stage and mature businesses.

Class I -Nominees to Serve as Directors Until rhe 20/6 Annual Meeting
Louis lgnarro. Ph.D. {72) has been a director since July 2002. He previously served as a director of Global Genomics since November 20, 2000. Dr. Jgnarro serves as the Jerome J. Belzer,
M.D. Distinguished Professor of Pharmacology in the Depanmenl of Molecular and Medical Phannacoloi,,y at the UCLA School of Medicine. Dr. lgnarro has been at the UCLA School of
Medicine since 1985 as a professor, acting chairman and assistant deun. Dr. lgnarro received the Nobel Prize for Medicine in 1998. Dr. lgnarro received a B.S. in pharmacy from Columbia
University and his Ph.D. in Pharmacology from the University of Minnesota. Dr. lgnarro is a Nobel Laureate and an esteemed medical researcher whose experience enables him to offer imponanl
scientific guidance to our Board of Directors.
Joseph Rubinfeld. Ph.D. {81) has been a director since July 2002. He co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President and as a director
since its inception until December 31, 2003. He resigned as Chairman Emeritus ofSuperGen, Inc. on February 8, 2005. Dr. Rubinfeld was also Chief Scientific Officer ofSuperGen from 1991 until
September 1997. Dr. Rubinfeld is also a founder of JJ Phanna; Dr. Rubinfcld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations
until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director al Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company, International Division
in a variety of positions. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D. in chemistry from Columbia University.
Dr. Rubinfeld served as a senior executive of several large phannaceutical companies before leaving lo co-found SuperGen and served as Chief Executive Officer or in other senior
executive capacities with highly successful companies. Dr. Rubinfeld's academic training and business experience enhances the breadth and scope of our Board's oversight of our company's
management, business, strategic relationships, and other activities, while his vision adds to the long-range planning of our Board of Directors and management.

·~.
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Meetings orrhe Board or Direclors and Committees

Board ofDirectors

'vtJ

The property, affairs and business of CytRx are conducted under the general supervision and management of our board of directors as called for under the laws of Delaware and our
Restated Bylaws. Our board of directors has established a standing Audit Committee, Compensation Commincc, and Nomination and Governance Commince.
The board of directors held five meetings during 2013. Each director ancndcd at least 75% of the total meetings of the board during 2013. Each director who served on a committee of
our board of directors attended at least 75% of all committee meetings during 2013. Board agendas include regularly scheduled executive sessions for the independent directors to meet without
management present. In 2013, the independent directors met two times in executive session.

Director Independence
Our board of directors has determined that Messrs. Link, Seiter, Rubinfeld, lgnarro and Wennekamp arc "independent" under the current independence standards of both The
NASDAQ Capital Market and the SEC, and have no material relationships with us (either directly or as a partner, shareholder or officer of any entity) that arc inconsistent with a finding of their
independence as members of our board of directors. Our board has detennincd that Messrs. Link, Seiter and Wennekamp also met the higher standards of The NASDAQ Capital Market of
"independence" for purposes of service as the members of our Audit Committee and our Compensation Committee.
In making these detenninations, our board of directors has broadly considered all relevant facts and circumstances, recognizing that material relationships can include commercial,
banking, consulting, legal, accounting, and familial relationships, among others.
The following table provides infonnation concerning the current membership of our board committees:

~

~

Class of
Directors

Name

Audit
Committee

Compensation
Committee

Nomination and

Governance
Committee

II

Steven A. Kriegsman
Louis lgnarro, Ph.D.
Max Link, Ph.D.
Joseph Rubinfeld, Ph.D.
Marvin R. Seiter
Richard L. Wennekamp

I
Ill
I
II
Ill

(I)
(I)
(I)

---~-----(I)

Members of our Audit Committee. Mr. Seiter is the Chairman of the committee.

(2)

Members of our Compensation Committee. Dr. Rubinfcld is Chairman of the committee.

(3)

Members of our Nominating and Corporate Governance Commillce. Mr. Wennekamp is Chairman of the committee.
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(2)
{2)
(2)
(2)

(3)
(3)
(3)

A11dil Commillee
Our board of directors has determined that each of the current members of the Audit Commiltee is "independent" under the current independence standards of The NASDAQ Capital
Market and the SEC. Our board of directors has also detennined that Mr. Seher, the Chainnan of the Audit Commiltee, is an audit commiltee financial expert
The Audit Commiuee's responsibilities include oversight activities described below under the "Report of the Audit Commitlee." The Audit Committee reviews our financial stnicture,
policies and procedures, appoints our independent registered public accounting finn, reviews with our independent registered public accounting firm the plans and resuhs of the audit
engagement, approves audit and permitted non-audit services provided by our independent registered public accounting firm. reviews the independence of our independent registered public
accountants and reviews the adequacy of our internal accounting controls.
The Audit Committee has discussed with our independent registered public accounting !inn the Jinn's independence from management and us, including the matters in the written
disclosures required by the Independence Standards board and considered the compatibility of permitted non-audit services with the auditors' independence. The Audit Commillee operates
pursuant 10 a wriuen charter, a copy of which is available on our website at ht1p://www.cytrx.com.
A11dit Committee Report

Ser forth below is 1he Audi! Committee Report:
The following Report does 1101 constitute soliciting material and should not be considered or clecmecl filed. or i11corporatecl by reference into any filing. by us wirh the SEC. excepr
ro rhe exrent we specifically incorporate this Report by reference.
The primary function of the Audit Committee is to assist the board of directors in fulfilling its oversight responsibilities relating to:
The quality and integrity of our financial statements and reports.
Our independent registered public accounting firm's qualifications and independence.
The performance of our internal audit function and our independent auditors.
The Audit Committee operates under a written charter adopted by our board of direc1ors, a copy of which is available on our website at http://www.cytrx.com.

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

i.,

The Audi1 Comminee's primary du1ies and responsibililies arc 10:
Serve as an independent and objective party 10 monitor our financial reporling process and internal control system.
Review and appraise the audit efforts of our independcnl accountants and internal audit function.

Provide an open avenue of communication among the independent accountants, internal auditors, our management and the board of directors.
The Audit Committee provides assislance 10 the board of directors in fulfilling ils oversight rcsponsibili1y to lhe slockholdcrs, potenlial stockholders, the investmcnl community and
olhcrs relating to our financial statements and lhe financial reponing process, lhc sys1ems of i111crnal accounling and financial con1rols, the internal auJi1 function, the annual independenl audit
of our financial statements and the elhics programs when established by our management and lhe board of directors. The Audit Commillee has the sole authorily (subject, if applicable, 10
slockholder ralification) to appoint or replace the outside auditors and is directly responsible for determining the compcnsa1io11 of1he independent auditors.
The Audit Committee must pre-approve all auditing services and all pcrmiucd non-auditing services to be provided by 1he outside audilors. In general, the Audit Commiltee's policy is
lo gr.int such approval where ii detennines lhal the non-audil services are nol incompalible with maintaining the auditors· independence and !here arc cosl or other efficiencies in oblaining
such services from lhe auditors as compared lo other possible providers. During 2013, !he Audit Commillce approved all of 1he audit and non-audi1 services proposals submitted to ii.
The Audit Commi1tee met four limes during 2013. The Audit Commillcc schedules ils meerings with a view lo ensuring that it devores approprialc attenlion 10 all of its tasks. In
discharging its oversight role, the Audit Commiltee is empowered lo investigate any matter brought to its attention, with full access to all of our books, records, facili1ies and personnel, and to
retain its own legal counsel and olher advisers as it deems necessary or appropriate.
As pan of its oversight of our financial statements, the Audit Committee reviews and discusses with both management and its outside auditors our interim financial stalements and
annual audited financial stalements that are included in our Quarterly Reports on Fonn I 0-Q and Annual Report on Fonn I0-K, respectively. Our management advised lhe Audit Committee in
each case that all such financial statements were prepared in accordance wi1h accoun1ing principles generally accepted in the United Stales and reviewed significant accounting issues with 1he
Audit Committee. These reviews included discussion with the outside auditors of mallers required to be discussed pursuant to the Public Company Accoun1ing Oversight Board ("PCAOB")
Statement on Auditing Standards No. 16 (Communication with Audit Committees).
The Audit Commillee retained BDO USA, LLP to audit our financial stalemenls for 2013. The Audit Committee also has selected BDO USA, I.LP as our independent registered public
accounting finn for fiscal 2014.
The Audit Committee discussed with BDO USA, LLP, which audited our annual financial statements for 2013, matters relaring toils independence. including a review of audil and nonaudil fees and the letter and written disclosures made by BDO USA, LLP to the Audit Comminee as required by the PCAOB.
In addition, the Audit Commitlee reviewed initiatives aimed at strengthening the effeclivencss of Cy1Rx 's internal control stmcture. As part of this process, the Audit Committee
continued to monitor and review staffing levels and steps laken lo implement recommended improvements in internal procedures and conlrols.
Taking all of these reviews and discussions into account, the Audit Commi1tee recommended
Report on Fonn 10-K for the fiscal year ended December 31, 2013, filed with lhe SEC.

10 our

board of directors that our audited financial statements be included in our Annual

Respectfully submitted,
Audil Committee:
Marvin R. Seiter, Chainnan
Max Link, Ph.D.
Richard L. Wennekamp
10
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Compensation Committee
The Compensation Committee is authorized to determine the annual salaries and bonuses of our officers and to determine in it sole discretion all grants of stock options, the exercise
price of each option, and the number of shares to be issuable upon the exercise of each option under our various stock option plans. The Committee also is authorized to interpret our stock
option plans, to prescribe, amend and rescind rules and regulations relating to the plans, to determine the term and provisions of the respective option agreements, and to make all other
detenninations deemed necessary or advisable for the administration ofrhe plans. The Compensation Committee operates pursuant to a written charter, a copy of which is available on our
website at www.cytrx.com. Our board of directors has detcnnined that each of the current members of the Compensation Committee, Messrs. Rubinfeld, Link, Seher and Wennckamp, are
"independent" under the current independence standards of The NASDAQ Capital Market for purposes of service as the members of our Compensation Committee.
The Compensation Committee has reviewed our compensation policies and practices for all employees, including our named executive officers, as they relate to risk managemcn1
practices and risk-taking incentives, and has dctennined that there arc no risks arising from these policies and practices that are reasonably likely to have a material adverse effect on us.
The Compensation Committee held five meetings during 2013.

No111inatio11 a11d Gnver11a11ce Cmmnittee
The Nomination and Governance Committee assists our board of directors in discharging its duties relating to corporate governance and the compensation and evaluation of the board.
The Nomination and Governance Committee also operates pursuant to a written charter, a copy of which likewise is available on our website at www.cytrx.com. As indicated above wirh respect
to service on our Audit Commillee, our board of directors has determined that each of the current members of the Nomination and Governance Committee, Messrs. Wennckamp, Rubinldd and
Seher, are "independent" under the current independence standards of The NASDAQ Capital Market.
The principal responsibilities of the Nomination and Governance Committee include:
Overseeing our corporate governance practices and developing and recommending to our board a sci of Corporate Governance Guidelines.
Assisting our board in identifying qualified director candidates, selecting nominees for election as directors at meetings of stockholders and selecting candidates to fill vacancies
on our board.
Creating and recommending to our board a policy regarding the consideration of director candidates recommended by stockholders and procedures for stockholders• submission
of nominees of director candidates.
Reviewing and recommending the compensation for non-employee directors and making recommendations to our boord for its approval.
Establishing criteria for our board and for all committees (including the Nomination and Governance Committee) to use lo evaluate their perfonnance on an annual basis.
Overseeing and advising our board regarding developments related to corporate governance.
The Nomination and Governance Committee has sole authority, in connection with the identification of qualified director candidates, to retain and tenninale any search finn for such
purpose (including the authority to approve any such firm's fees and other retention tenns). We do not currently employ an executive search firm, or pay a fee to any other third party, to locate
qualified candidates for director positions.
The Nomination and Governance Committee held two meetings during 2013.
The Nomination and Governance Committee has not established any specific minimum qualifications for director candidates, or any specific qualities or skills that a candidate must
possess in order to be considered quolilied to be nominated as a director.
Qualifications for consideration as a director nominee may vary according to the particular areas of expertise being sought as a complement to the existing board composition. In
making its nominations, our Nomination and Governance Committee generally will consider, among other things, an individual's business experience, industry experience, financial background,
breadth of knowledge about issues affecting our company, time available for meetings and consultation regarding company matters and other particular skills and experience possessed by the
individual. We have no formal policy of considering diversity in identifying director nominees, but the Nomination and Governance Committee seeks to include on the board of directors a
complementary mix of individuals with diverse backgrounds and skills reflecting the broad set of challenges that the board of directors confronts. These individual qualities can include matters
such as experience in the company's industry, technical experience (i.e., medical or research expertise), experience gained in situations comparable to the company's, leadership experience, and
relevant geographical diversity

II
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Stockholder Recommendations or Director Candidates
The policy of the Nominalion and Governance Commillee is 1hat a s1ockholder wishing to submil recommendalions for director candidales for consideralion by the Nomination and
Governance Commiuee for elcc1ion al an annual mceling or shareholders mus1 do so in wri1ing by December 15 of the previous calendar year. The \\Tillcn recommendation mus1 include 1he
following infonnation:
A statement thal the writer is a slockholder and is proposing a candidale for considera1ion.
The name and conlacl information for 1he candidale.
A s1a1emen1 of the candidate's business and educational experience.
lnfonnation regarding the candidate's qualificalions to be a direclor.
The number of shares of our common stock, if any, owned ci1her beneficially or of record by the candida1e and the length of lime such shares have been so owned.
The wriuen consent of the candidate to serve as a director if nominated and elected.
Information regarding any rda1ionship or underslanding between the proposing s1ockholder and the candidale.
A statemenl 1ha1 lhe proposed candidate has agreed 10 furnish us all information as we deem necessary lo evaluale such candidale's qualificalions to serve as a direclor.
As lo the stockholder giving 1he notice, the wriuen recommendalion mus1 stale the name and address of lhc stockholder and the number of shares ofour common stock which arc
owned beneficially or of record by the shareholder.
Any recommendations in proper fonn received from slockholders will be evaluated in 1he same manner that potenlial nominees recommended by our board members or management are
evaluated.
Stockholder Nominations of Directors
Our Bylaws specify the procedures by which stockholders may nominate director candidates directly, as opposed to merely recommending a director candidate to the Nomination and
Governance Commillee as described above. Any stockholder nominations must comply with 1he requirements of our Bylaws and should be addressed 10: Corporate Secretary, CytRx
Corporation, 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049.
Stockholder Communication with Board Members

v)

Stockholders who wish to communicate with our board members may contact us by telephone, facsimile or regular mail at our principal executive office. Wriuen communications
specifically marked as a communication for our board of directors, or a particular director, except those that are clearly marketing or soliciting materials, will be forwarded unopened to the
Chairman of our board, or to the particular director to which they arc addressed, or presented to the full board or the particular director at the next regularly scheduled board meeting. In addition,
communications sent to us via telephone or facsimile for our board of directors or a particular director will be forwarded to our board or the director by an appropriate officer.

12
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Transactions with Related Persons
General
Our Audil Comminee is responsible for reviewing and approving, as appropriate, all transactions with related persons, in accordance with its Charier and NASDAQ Marketplace Rules.
Transactions between us and one or more related persons may present risks or conflicts of inleresl or the appearance of conflicts of interest. Our Code of Ethics requires all employees,
officers and directors to avoid activities or rclalionships lhat connict, or may be perceived to connicl, wi1h our interesls or adversely affect our reputation. It is understood, however, that certain
relationships or transactions may arise that would be deemed acceptable and appropriate so long as there is full disclosure of the interest of the related parties in the transaction and review and
approval by disinterested directors to ensure there is a legi1ima1e business reason for 1he transaction and 1hat 1he transaction is fair to us and our stockholders.

~

As a resuh, 1he procedures followed by the Audit Committee 10 evaluate 1ransac1ions with related persons require:
that all related person transactions, all material tcnns of the transactions, and all the material facts as to the related person's direct or indirect interest in, or relationship to, the
rcla:cd person transaction must be communicated :o :he Audit Committee; and
that all related person transactions, and any malerial amendment or modification to any related person transaction, be reviewed and approved or ratified by the Audit Comminee, as
required by lhe requirements of The NASDAQ Capi1al Market.
Our Audit Comminee will evalua1e rela1ed person lransactions based on:
infonna1ion provided by members of our board of directors in connection with 1he required annual evaluation of director independence;
pertinent responses 10 the Directors• and Officers• Ques1ionnaircs submined periodically by our officers and directors and provided to the Audit Commiltce by our management;
background information on nominees for director provided by the Nominating and Corporate Govemance Commillee of our board of directors; and
any other relevant informalion provided by any of our direc1ors or officers.
In connection with its review and approval or ratiticalion, if appropriate, of any related person transaction, our Audit Commillee is 10 consider whether the transaction will compromise
standards included in our Code of Ethics. In lhe case of any rclaled person transaclion involving an outside director or nominee for director, the Audi I Commillee also is 10 consider whether the
transaction will compromise lhe director's s1a111s as an independent director as prescribed by The NASDAQ Capital Markel.
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On December 2, 2008, we entered into a wrillen consulting agreement with Joseph Rubinfeld, Ph.D., under which Dr. Rubinfeld agrees lo serve as our Chief Scientific Advisor. In
exchange, we granted lo Dr. Rubinfeld under our 2008 Stock Incentive Plan a ten-year stock option 10 purchase up to 50,000 shares of our common stock at an exercise price of $2.45 per share,
which equaled the market price of our common stock as of the grant date. The fair value of this option grant was SI 16,900. The stock option vested immediately upon grant as 107,143 of the
option shares and vested as to the remaining option shares in 36 equal monthly ins1alhnen1s, and is now fully vested. The consulting agreement is terminable al any time by either party upon
notice to the other party.
On December I0, 2012, we entered into an amendment 10 our written consulting agreement with Dr. Rubinfeld, Ph.D. lo provide for the one-lime grant to Dr. Rubinfeld under our 2008
Plan of an option to purchase 30,000 shares of our common slOck at an exercise price of$) .83 per share, which was equal to the market price of our common stock on the grant date. The option
has a tcnn often years and is fully vested. The fair grant date value of this option grant was $47,400.
Applicable Dennitions
For purposes of our Audit Committee's review:
"related person" has the meaning given to such tcnn in Item 404(a) of Securities and Exchange Commission Regulation S-K ("Item 404(a)"); and
"related person transaction" means any transaction for which disclosure is required under the tenns of Item 404(a) involving the company and any related persons.
Board Member Attendance at Annual .Meetings
Our board of directors has no fonnal policy regarding attendance of directors al our annual stockholder meetings. Our 2013 Annual Meeting of Stockholders was attended by all of our
directors.
Section l6(a) Bcnencial Ownership Reporting Compliance
Each of our executive officers and directors and persons who owns more than I 0% of our outstanding shares of common stock is required under Section I 6(a) of the Securities
Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and to furnish us with copies of those reports. Based solely on our
review of copies of reports we have received and written representations from certain reporting persons, we believe that our directors and executive officers and greater than I 0% shareholders
for 2013 complied with all applicable Section I6(a) filing requirements.
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Security Ownership of Certain Benclidal Owners and Management
Based solely upon infonna1ion made available to us, the following 1able sets forth infonnation wi1h respecl to the beneficial ownership of our common stock as of May I, 2014 by:
( I) each person who is known by us to beneficially own more than five percent of our common stock; (2) each of our directors; (3) our named executive officers listed in the Summary
Compensation Table under the caption "Exccu1ive Compensation"; and (4) all of our executive officers and directors as a group.
Beneficial O\\'llership is detcnnined in accordance with lhe SEC rnlcs. Shares of common stock subject to warrants or options that are presently exercisable, or exercisable within 60 days
of May I. 2014, which arc indicated by footnote, are deemed outstanding in computing the percentage ownership of the person holding the warrants or options, but not in computing the
percentage ownership of any other person. The percentage ownership reflected in the table is based on 55,776,523 shares of our common stock outstanding as of May I, 2014. Except as
other wi~e i11dica1ed, !he hol<lers listed below have sole vo1ing and investment power with respect 10 all shares of common stock shown, subject to applicable community property laws. An
asterisk(•) represents beneficial ownership of less than 1%.

Shares of
Common Stock
Number
Percent
5,164,600 ·.
3,250,000
3,493,i 16
4,577,605

Name of Beneficial Owner
QVT Financial LP (I)
Capital Ventures International (2)
Gene Z. Salkind, M.D. (3)
Scott Pauerson, D.D.S. (4)
Louis lgnorro, Ph.O.(5)
Steven A. Kriegsman (6)
Max Link, Ph.D.(7)
Joseph Rubinfeld, Ph.D. (8)
Marvin R. Seltef19)
Richard L. Wennekamp (JO)
Dan Levitt, M.D., Ph.D.(12)
John Y. Caloz (I I)
Scotl Wieland, Ph.D.(13)
Benjamin S. Levin (I 4)
All executive officers and directors us a group (ten persons) (15)

9.3%
5.8%
6.3%
8.2%

~

~

336,702 ·
1,653,567

3.0%

· 361;886J
403,571

: -~~.,35.l::.-·

~

340,281

411,033 ·
160,493

.. '· 'fS6:G61•··---· ·.

•

263,125

. , ..,4;15Z6'76;''

7.4%

(I}

According to a schedule 13G filed wi1h the SEC on March 21, 2014, QVT Financial LP is a Delaware limited partnership and investment manager for QVT Fund V LP and other private
investment funds (collectively, the "Funds"). In the aggregate, these Funds own 5, I 64,600 shares of CytRx common stock. QVT Financial GP LLC, as General Partner of QVT Financial
LP, may be deemed to beneficially own the same number of shares of common stock as reported by QVT Financial LP.

(2)

According to a schedule 13G filed with the SEC on Fcbmary 7, 2014, Capital Ventures International is a Cayman Islands company. Heights Capital Management, Inc. is a Delaware
corporation and inveslmenl manager to Capital Ventures International. As such, Heights Capital Management, Inc. may exercise voting and dispositive powers over the shares shown
and may be deemed to beneficially own such shares. The principal business addresses of Capital Ven1ures lnlcrnationiil and Heighls Capital Management, Inc. are P.O. Box 897,
Winward I, Regally Office Park, West Bay Road, Grand Cayman KYl-l 103, Cayman Islands and IOI California Street, Suite 3250, San Francisco, California 94111, respectively.

(3)

Of the shares shown, Dr. Salkind has sole voting and dispositive power over 1,360,038 shares and shares voting and dispositive power with his wife, Catherine Salkind, over 2,133,078
shares. Mrs. Salkind may be deemed to beneficially own the shares shown. Dr. and Mrs. Salk ind 's address is 1165 Wrack Road, Meadowbrook, Pennsylvania 19046.

(4)

Dr. Patterson's address is 128 Spoonbill Court, Jupiter, Florida 33458-8879.

(5)

Includes 323,571 shares subject to options or warrants.

(6)

Includes 1,056,456 shares subject 10 options or warrants.

(7)

Includes 324,699 shares subject to options or warrants.

(8)

Includes 403,571 shares subjecl to options or warrants.

(9)

The shares shown are owned, ofrecord, by the Seiter Family Tmst or Seiter IRA Rollover.

( 10)

Includes 323,571 shares subject lo options or warrants.

( 11)

Includes 155,951 shares subjecl to oplions or warrants.

( 12)

Includes 249,996 shares subject to options or warrants and I 00,000 reslricted shares, of which 50,000 shares will vest on June 30, 2014, and the remaining 50,000 shares will vest over rhc
subsequent six months. provided that Dr. Levitt remains employed by us on each such date.

( 13)

Includes 156,667 shares subject to oplions or warrants.

( 14)

Consists of 258,328 shares subject to options or warrants.

(IS)

Includes 3,252.8 IO shares subject to options or warrants.
15
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Set fonh below is infonnation regarding our current executive officers (other than infonnation relating to Steven A. Kriegsman, our President and Chier Executive Officer, which is sel
forth above under .. Continuing Directors"). Each officer's age is indicated in parentheses after his name.

Daniel levifl, M.D .. Ph.D. (66)joined us in October 2009 as our ChierMedieal Officer, and was recently prnmoted to the position of Executive Vice President in 2013. Dr. Levin brings
more than 24 years or senior management experience, having spearheaded numerous drug development programs to commercialization al leading biotechnology and pharmaceutical
companies. Prior 10 joining Cy1Rx, Dr. Levin served from January 2007 to February 2009 as Executive Vice President, Research and Development al Cerimon Pharmaceuticals, Inc. Prior 10 that,
from August 2003 to April 2006, he was Chief Medical Officer and Head of Clinical and Regulatory Affairs al Dynavax Technologies Corporation, managing clinical trials for four programs and
overseeing multi-country regulatory strategies. From August 2002 lo July 2003, Dr. Levitt was Chief Operating Officer and Head of Research and Development at Affymax, Inc., and prior to that
he spent six years at Protein Design Labs, Inc., completing his tenure as that firm's President and Head of Research and Development. Dr. Levitt's past experience includes a position as Head of
Dmg Development at Geron Corporation, and Head of the Cytokine Development Uni I and Global Clinical Oncology ,11 Sandoz Pharmaceuticals Lid., and as Director, Clinical Oncology and
Immunology at Hoffmann-LaRoche, Inc. Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University. He earned both his M.D. and his
Ph.D. in Biology from the University of Chicago, Pritzker School of Medicine. Dr. Levitt has received ten major research awards and authored or co-authored nearly 200 papers and abstracts.
John Y. Ca/oz (62) joined us in October 2007 as our Chief Accounting Officer. In January 2009 Mr. Cal oz was named Chief Financial Officer. He has a history of providing senior
financial leadership in the life sciences sector, as Chief Financial Officer ofOcculogix, Inc, a NASDAQ listed, medical therapy company. Prior lo that, Mr. Caloz served as Chief Financial Officer
of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from
1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr.
Caloz was a panner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech
companies, from I 983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
Scoll Wieland. Ph.D. (55) joined CytRx in 2005 as Vice President, Clinical and Regulatory Affairs and was promoted 10 the position of Senior Vice President, Drug Development in
December 2008. Prior to that, he served in senior level positions in the areas of Drng Development, Clinical and Regulatory Affairs at various biotech firms. He spent five years at
NeoTherapeutics, Inc. serving as the Director of Product Development and was later promoted to Vice Presiden1 of Product Development. From 1990 to I 997, he served as Director of Regulatory
Affairs al CoCensys, Inc. Dr. Wieland has a Ph.D. in Biopsychology and an M.A. in Psychology from the University of Arizona. He has an MBA from Webster University. Dr. Wieland received
his B.S. in Physiological Psychology from the University of California, Santa Barbara.
Benjamin S. Levin (38) joined us in July 2004 as our General Counsel and Corporate Secretary, and since December 2013 has served additionally as Senior Vice President. From
November 1999 to June 2004, Mr. Levin was an associate in the transactions department of the Los Angeles office of O'Melveny & Myers LLP. Mr. Levin received his S.B. in Economics from
the Massachusetts Institute of Technology, and a J.D. from Stanford Law School.
David J. Haen (36) joined CytRx in October 2003 as Director of Business Development and was promoted to Vice President of Business Development in December 2007. From 1999 lo
2003, Mr. Haen worked as an associate for Kriegsman Capital Group LLC, a financial advisory firm focused on emerging companies in lhe life sciences field. Mr. Haen received a B.A. in
Communications and Business from Loyola Marymount University.
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Compensation Discussion and Analysis

Overview of Exec11tive C11mpensation Program
The Compensation Commincc of our board of directors has responsibility for establishing, implementing and monitoring our executive compensation program philosophy and
practices. Generally speaking, the Compensation Committee detennines cnmpensation of our Chief Executive Otliccr and other named executive officers, and those determinations are ratified hy
our board of directors.

~

The Compensation Committee seeks to ensure that the total compensation paid to our named executive officers is fair, reasonable and competitive. Generally, the types of
compensation and benefits provided to the named executive officers arc similar to those provided to our olher officers.
The Compensation Committee operates under a fonnal charier, copies of which are available on our website at www.cytrx.com, that govems its duties and conduct.
At the 2013 Annual Meeting of Stockholders, our stockholders, on a non-binding, advisory basis. approved the compensation of our executive officers as disclosed in our 2013 proxy
slalcmcnt. llased upon ,he icsulls of this advisor/ vole, ,he Compensation Committee has detennined to follow the stockholde;s' ;ecommcndalion by conlinuing our present compensation
policies and pracliccs.
Throughoul this Proxy Stalcmcnl, the individuals included in the Summary Compensation Table below arc referred to as our "named executive officers."

Compensation Pl,i/osopl,y and Objectives
The components of our executive compensation consist of salary, annual and special cash bonuses awarded based on the Compensation Committee's subjective assessment of the
achievement of corporate goals and each individual executive's job perfonnance, stock option grants to provide executives with longer-term incen1ives, and occasional special compensation
awards (either cash, stock or stock oplions) to reward extraordinary efforts or results such as the position interim results of our Phase 2b clinical trial of aldoxorubicin in STS or successful
capital raising activities.
The Compensation Committee believes that an effective executive compensation program should provide base annual compensation that is reasonable in relation lo individual
executive's job responsibilities and reward the achievement of strategic goals of our company. We use annual and other periodic cash bonuses 10 reward an officer's achieve men I of specific
goals, including goals related to the development of our drug candidates and replenishment and management of our working capital. We use employee stock options as a retention tool and as a
means to align the executive's long-tenn interests with those of our stockholders, with the ultimate objective of affording our executives an appropriate incentive to improve stockholder value.
The Compensation Committee evaluates both performance and compensation to maintain our company's ability to attract and retain excellent employees in key positions and to assure that
compensation provide to key employees remains competitive relative to the compensation paid to similarly situated executives of comparable companies.
Each of the corporate goals established and subsequently reviewed by the Compensation Committee results from a collaboration among our named executive officers, including the
leadership of our President and Chief Execu1ive Officer and the support of our principal legal, financial, clinical, medical and business development officers. The Compensation Committee's
assessment of the relative contribution of each named executive officer is based on periodic reports to our full board of directors regarding the progress of these business accomplishments and
the individual efforts of our named executive officers, and year-end consultations, which include discussions of performance reviews, with our President and Chief Executive Officer that arc a
normal part of the Compensation Committee's compensation dctcnninations. The Compensation Committee employs no objective measure of any individual's contribution.
The bonus amounts awarded to our eligible named executive officers are a function of their office and total compensation relative to the total compensation of our President and Chief
Executive Officer, as adjusted by their relative employee evaluation, and with consideration given to comparable company data for similarly situated employees. The bonus amounts awarded to
each named executive officer is set forth in the Summary Compensation Table.
Because of the size of our company, the small number of executive officers in our company, and our company's financial priorities, the Compensation Committee has not implemented
any pension benefits, deferred compensation plans or other similar plans for our named executive officers.
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Rttle ,if Executive Ofjicer5 i11 C11mpe115t1tion Deci.{ir,115
The Compensation Com mi nee annually detennines the compensation of our named executive officers. Our President and Chief Executive Officer, or "CEO," typically attends all
meetings of the Compensation Committee, except for executive sessions at which his compensation is determined. At the request of the Compensation Committee, our CEO provides his
assessment of the performance of our named executive officers other than himself. Our CEO also takes an active part in the discussions of the compensation of named executive officers other
rhan himself and assists in the development of a review matrix of each executive's contributions to the goals of the company that fonns the basis for some compensation determinations. The
Compensation Committee gives due consideration lo our CEO's assessments when making determinations regarding the compensation of our named executive officers. All Compensation
Committee deliberations and determinations regarding the compensation of our CEO arc made without the presence of our CEO.

Selling Executive Compensation

,vi)

Based on the foregoing objectives, the Compensation Committee has structured the company's annual cash and incentive-based cash and non-cash executive compensation to seek lo
motivate our named executives 10 achieve our company's business goals, including goals related 10 the development of the our drug candidates and management of working capital, to reward
the executives for achieving such goals, and to retain the executives. In doing so, the Compensation Committee historically has not employed outside compensation consultants. During 2013,
the Compensation Committee obtained three industry compensation surveys and used them in its compensation deliberations regarding cash and equity compensation for our executive
officers. The surveys used were an Equilar survey of public companies with a market capitalization between $50 million and S200 million, the Radford Global Life Sciences Survey, which is a
survey of public and private life sciences companies of all sizes, and a survey of public and private companies in Los Angeles provided by salary.com (which the Compensation Committee uses
10 adjust to geographic differences in cost of living).
The Compensation Commiltee utilized this data to set annual salary increases and bonus amounts for our executive officers at levels targeted at or around the third quartile of
compensation amounts provided 10 executives al comparable companies, considering each individual's experience level related to their position with us. The Compensation Committee has no
policy regarding the use of benchmarks. and we have no established policy or target for the allocation between cash and non-cash incentive compensation.
The Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities, but has not relied upon outside compensation
consultants.

Company ferformance Goals
For 2013, the Compensation Committee and the Board of Directors approved the following performance goals:
Complete the aldoxombicin Phase 2b STS clinical trial and the aldoxombicin Phase I pharmacokinetics clinical trial:
Initiate the aldoxorubicin Phase 3 STS clinical trial, and obtain FDA approval of an SPA for that study;
Complete enrollment of the lamibarotenc Phase 2b clinical trial in non-small-cell lung cancer trail;
Raise additional capital.
For 2013, the Compensation Committee determined that, with the exception of the completion of enrollment of the tamibarotene Phase 2b clinical trial (which was discontinued due 10 a
failure lo show efficacy), each of the corporate goals had either been achieved, or substantial progress towards achievement had been made, and noted the particular contributions of executive
officers to the achievement of those goals.
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/11diviJ11ul Perfor,mmce
The Compensation Committee reviews our executive officers' performance based on overall achievement of the corporate goals and a review of individual goals developed for each
executive officer every year. The Compensation Committee, with the assistance of our CEO, detennines the relative achievement of the perfonnance goals applicable to each executive officer,
and assigns a perfonnance rating based on a set of criteria set forth in an evaluation form. No specific formula is used with respect to setting any particular element of compensation based on
the individual perfonnance metrics. The score assigned lo each officer was based on a subjective assessment by our Compensation Committee members of the officer's performance against the
scoring standards of:
I234-

Consistently Exceeds Expectations
Sometimes Exceeds Expectations
Meets Expectations
Sometimes Meets Expectations
5 - Needs Improvement
The numerical job scores, with a 1.0 being the best and 5.0 being the worst, arc determined based on an initial self-assessment by the ollicer, which is subject to change based on an
evaluation of the self-assessment by the officer's direct supervisor and on the Compensation Commiltee's own assessment of the officer's job performance.
For 2013, our Compensation Committee determined that the individual performance scores indicated below were merited by the officer's respective contributions to our key business
achievements discussed above, as well as the performance of their day-to-day responsibilities. On an officer-by-officer basis, our Compensation Commiltce also considered the following:
Mr. Kriegsman 's individual perfonnance goals relate primarily to overall corporate objectives, including building stockholder value as reflected in the market capitalization of our
managing working capital, managing and directing the executive management team, and successfully developing our company's operations and personnel for future success Based on those
criteria. and noting the highly positive results of our global Phase 2b clinical trial of STS aldoxorubicin for STS and progress of our other clinical trials of aldoxorubicin, the Compensation
Committee gave a rating of 1.1 to Mr. Kriegsman.
Mr. Caloz's individual performance goals relate primarily to achievement of key financial objectives, such as managing and raising working capital, controlling spending, managing
accounting personnel and maintaining regulatory compliance. Based on those criteria, the Compensation Committee noted Mr. Caloz's role in obtaining needed working capital, his efforts 10
control expenditures, the continued improvement of our accounting department, and our compliance with filing deadlines, and gave a rating of 1.5 to Mr. Caloz.
Dr. Levin's individual performance goals relate primarily to the achievement of key strategic and clinical objectives related to our clinical research programs, including ultimate
oversight of the design and execution of our clinical programs, and analysis and implementation of new clinical opportunities improve stockholder value. Based on those criteria, the
Compensation Committee noted Dr. Levitt's efforts towards our achievement of our key clinical goals, including the initiation of multiple new clinical trials and the announcement of positive
data from our Phase 2b clinical trial ofSTS aldoxorubicin for STS and, his development of strategic plans to build value, and gave a rating of 1.5 to Dr. Levitt.
Mr. Levin's individual performance goals relate primarily lo the management of the company's legal risk, advice provided to the board of directors and management, and maintaining
regulatory compliance. Based on those criteria, the Compensation Committee noted Mr. Levin's timely and useful advice on key corporate matters that reduced corporate risk, and his work
ensuring compliance with various regulations, and gave a rating of 1.6 to Mr. Levin. Mr. Levin was also promoted to the title of Senior Vice President.
Dr. Wieland's individual performance goals relate primarily lo the execution of the objectives related to our clinical development, including planning, initiation, budgeting and
management of our clinical programs. Based on those criteria, the Compensation Committee noted Dr. Wieland's role in our achievement of key clinical goals, including the initiation of multiple
new clinical trials, and gave n rating of2.0 to Dr. Wieland.
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2013 Exec11ti1•e Ct11t1pe11satio11 Ct1mpo11e11ts
For 2013, as in recerll years, the principal components of compensation for the named executive officers were:
base salary;
annual bonuses; and
equity incentive compensation.

Base Salary
We provide named executive officers and other employees with base salary to compensate them for services rendered during the year. Generally, the base salary clement of
compensation is used to recognize the experience, skills, knowledge and responsibilities required of each named executive officer, and renects our executive officers' overall sustained
performance and contributions to our business.
During its review of base salaries for executives, the Compensation Committee primarily considers:
the negotiated terms of each executive's employment agreement, if any;
each executive's individual perfonnance;
an internal review of the executive's compensation, both individually and relative to other named executive officers; and
to a lesser extent, base salaries paid by comparable companies.
Salary levels are typically considered annually as part of our company's performance review process, as well as upon a change in job responsibility. Merit-based increases to salaries
are based on our company's available resources and the Compensation Committee's assessment of the individual's performance. This assessment is based upon written evaluations of such
criteria as job knowledge, communication, problem solving, initiative, goal-setting, and expense management. In 2013, the Compensation Committee considered our successful achievement or
substantial progress towards our corporate performance goals, and with consideration of the challenging financial environment, and our anticipation of clinical results in 2013 and beyond,
awarded increases in base salary for 2013 for most executives. Base salaries were also reviewed in light of the Equilar, Radford and salary.com survey data to validate that they were within
acceptable ranges based on market salaries.
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A1111110/ om/ Special

8lJnuses

As we do not generate significant revenue and have not commercially released any products, the Compensation Commitlee bases its discretionary annual bonus awards on the
achievement of corporate and individual goals, efforts related to extraordinary transactions, effective fund-raising efforts, effective management of personnel and capital resources, and bonuses
paid by comparable companies, among other criteria. Mr. Kriegsman's employment agreement entitles him to an annual cash bonus in an amount to be detennined in our discretion, but not less
than $150,000, and Dr. Levin's employment agreement provides that his bonus will not be less than S 150,000. Any cash bonuses to our other named executive officers are entirely in our
discretion.

~

During 2013, the Compensation Commiuee granted Mr. Kriegsman an annual cash bonus of $330,000, and granted cash bonuses 10 the other named executive officers ranging from
$ I 00,000 to $300,000, principally based on their efforts in helping us advance the development of aldoxonibicin.
Eq11ity Incentive Compensation

We believe that strong long-term corporate performance is achieved with a corporate culture that encourages a long-term focus by our executive orficers through the use of equity
awards, the value ofwhkh depends on our stock performance. We have established equity incentive plans !o provide all of our employees, including our executive officers, with incentives to
help align those employees· interests with the interests of our stockholders and to enable them to participate in the long-term appreciation of our stockholder value. Additionally, equity awards
provide an important retention tool for key employees, as the awards generally arc subject lo vesting over an extended period of time based on continued service with us.
Typically, equity awards are granted mmually at the end of each year based primarily on corporate perfonnance as a whole during the preceding year. In addition, we may grant equity
awards upon the occurrence of certain events during the year, for example, upon an employee's hire or achievement ofa significant business objective such as positive results or other progress
of our clinical trials or successful capital-raising efforls.
No formula is used in setting equity award grants and the determination of whether to granl equi1y awards, or the size of such equity awards, to our executive officers; rather, ii
involves subjective assessments by our board of directors, Compensation Commiuee and, with respect to executive officers olher than himself, our CEO. Generally, annual equity awards are
driven by our retenlion of experienced employees, and we consider individual performance and contributions during the preceding year 10 1he extent our Board of Directors and Compensation
Commiuee believe such factors are relevant. As with base salary and cash bonuses, for 2013 our Board of Directors and Compensation Committee also considered data from three surveys in
determining equity award grants to our executive officers.
In March and December, 2013, respectively, the Compensation Committee granted to Mr. Kriegsman nonqualified options to purchase 74,176 share of our common stock al a price of
$2.46 per share and 925,000 shares of our common stock at a price of$2.39 per share, which equaled the closing market prices on the dates of grant. The options vest monthly over three years,
unless Mr. Kriegsman 's employment is tenninated by us wi1hout "cause," or by Mr. Kriegsman for "good reason," in which case they vest immediately. In addi1ion, in connection with the
annual review of our other named executive officers, the Compensation Commitlee also granted an aggregate of I, I 00,000 stock options to those named executive officers. All oflhe other stock
options had an exercise price equal to the closing market price on !he dale of grant, and also vest monthly over three years, provided that such executives remain in our employ through such
monthly vesting periods. The Compensation Committee also granted Dr. Levin I00,000 shares of CytRx Corporation restricted stock, of which 50,000 shares will vest on June 30, 2014, and the
remaining 50,000 shares will vest over the subsequent six months, provided that Dr. Levitt remains employed by us on each such date.
Generally speaking, we have not taken into consideration any amounts realized by our named executive officers from prior stock option or stock awards in determining whether to grant
new stock options or stock awards. No named executive officers have exercised options since 2003.
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Retirement Plan.-., Perq11i.'<ite,,. and Otl,er Personal Benefit.'<

Our executive officers are eligible to participate in the same group insurance and employee benefit plans as our other salaried employees. These benefits include medical, dental, vision,
and disability benefits and lire insurance.
We have adopted a tax-qualified employee savings and retirement plan, our 40 I (k) Plan, for eligible U.S. employees, including our named executive officers. Eligible employees may
elect to defer a percentage of their eligible compensation in the 40 I (k) Plan, subject to 1he stalutorily prescribed annual limit. We may make ma1ching conlributions on behalf of all participanls in
the 40 I (k) Plan in an amounl detennined by our board of direclors. We did nol make any malching contribulion to 1he 40 I (k) Plan for 20 I 3. Matching contributions, if any, immediately vest, as
do all employee contributions. We intend the 40l(k) Plan, and the accompanying trust, to qualify under Sections 40l(k) and 501 of the lnlemal Revenue Code so that contributions by
employees to the 40 I (k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 40 I(k) Plan, and so that we will be able 10 deduct our
contributions, if any, when made. The tnistee under the 40 I (k) Plan, al the direction of each participant, may invest the assets of the 40 I (k) Plan in any of a number of investment options.

~

We do not provide any of our executive officers with any other perquisites or personal benefits, other than benefits to Mr. Kriegsman provided for in his employment agreement. We
are required by his employment agreement lo carry a life insurance policy for Mr. Kriegsman in the amount of$1.4 million under which Mr. Kriegsman's designee is the beneficiary. We
purchased a policy with a face value of $2 million, on which we pay the premiums, and Mr. Kriegsman immediately reimbursed the company for the premium relating to the $0.6 million of
additional coverage. We periodically review the levels of perquisites and other personal benefits provided to our named executive officers, but no changes to these benefits were made during
2013, and we do not expect any such changes in the foreseeable future.
Employment Agreements and Severance Arrangements
We have entered into wrinen employment agreements with each of our named executive officers. The main purpose of these agreements is to protect the company from business risks
such as competition for the executives• service, loss of confidentiality or trade secrets, and solicitation of our other employees, and to define our right to tenninate the employment relationship.
The employment agreements also protect the executive from termination witholll "cause" (as defined) and, in both Mr. Kriegsman and Dr. Levitt's case, entitle them to resign for "good
reason" (as defined). Each employment agreement was individually negotiated, so there are some minor variations in the tcnns among executive officers. Generally speaking, however, the
employment agreements provide for tennination and severance benefits that the Compensation Comminee believes are consistent with industry practices for similarly situated executives. The
Compensation Committee believes that the termination and severance benefits help the company retain the named executive officers by providing them with a competitive employment
arrangement and protection against unknowns such as termination without "cause" that go along with the position.
In the event of termination without "cause," the named executive officers will be entitled 10 a lump-sum payment equal lo six months of base salary ( 12 months in the case of Dr. Levitt
and 24 months in the case of Mr. Kriegsman). The named executive officers· agreements also provide for our continuation of medical benefits during the severance period (including, for Mr.
Kriegsman, payments for life insurance). If Mr. Kriegsman 's or Dr. Levin's employment is tenninaled by us without "cause," or by Mr. Kriegsman or Dr. Levitt for "good reason," within two
years following a change of control ofCytRx, they also would be entitled under their employment agreement to receive a "gross-up'' payment equal 10 the sum of any excise tax on tennination
benefits (including any accelerated vesting of his options under our Plans as described below) plus any penahies and interest. In addition, if a named executive officer's employment is
terminated by us without "cause" (or by Mr. Kriegsman or Dr. Levin for "good reason," or due to Mr. Kriegsman 's death or disability}, his unvested stock options vest immediately.

C/range of Control Arrangements

vi

The company's 2000 Long-Tenn Incentive Plan and 2008 Stock Incentive Plan provide generally that, upon a change of control of CytRx, all unvesled stock options and awards under
the Plans held by plan participants, including the named executiveofficers, will become immediately vested and exercisable immediately prior lo the elTective dale of the transaction. The
Compensation Committee believes that such "single trigger" change of control policy is consistent with the objective of aligning the interests of the named executive officer's and oflhe
company's stockholders by allowing the executives to participate equally with stockholders in the event of a change of control transaction.
The foregoing severance and change of control arrangements, including the quantification of the payment and benefits provided under these arrangements, are described in more detail
elsewhere in this Proxy Statement under the heading "Executive Compensation - Employment Agreements and Potential Payment Upon Tennination or Change in Control."
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Ow11ersl,ip G11ideli11es
The Compensation Commi1tee has no requiremenl that each named execu1ive officer maintain a minimum ownership interest in our company.
Our long-term incen1ive compensation consists solely of periodic grants of slock options to our named executive officers. The slock option program:
• links the creation of stockholder value with executive compensation:
• provides increased equity ownership by executives;
• functions as a retention tool, because of the vesting features included in all options granted by the Compensation Committee; and
• helps us to maintain competitive levels of total compensation.
We normally grant stock options to new executive officers when they join our company based upon their position with u~ and their relevant prior experience. The options granted by
the Compensation Commitlee generally vest monthly over the first three years of the ten-year option term. Vesting and exercise rights generally (except in the case of Mr. Kriegsman) cease
upon termination of employment (or, in the case of exercise rights, 90 days thereafter), except in the case of death (subject to a one-year limitation), disability or retirement. Prior to the exercise of
an option, the holder has no rights as a stockholder with respect lo the shares subject to such option, including voting rights and the right to receive dividends or dividend equivalents. In
addition lo the initial option grants, our Compensation Commiltee may grant additional options to retain our executives and reward, or provide incentive for, the achievement of corporate goals
and strong individual performance. Our hoard of directors has granted our President and Chief Executive Officer the discretion to grant up to 200,000 options to employees upon joining our
company, and to make grants from an additional ..discretionary pool" ofup to 200,000 options during each annual employee review cycle. Options arc granted based on a combination of
imli vidual co1111 ibutio11s to our company and on generdl corpornte achievements, which may include the a11ainmen1 of product development milestones (such as commencement and completion
of clinical trials) and atlaining other annual corporate goals and objectives. On an annual basis, the Compensation Committee assesses the appropria1e individual and corpora1e goals for our
executives and provides additional option grant~ based upon the achievement by the new executives of both individual and corporate goals. We expect that we will continue 10 provide new
employees with initial option grants in the future' to provide long-term compensation incentives and will continue to rely on performance-based and retention grants to provide additional
incentives for current employees. Additionally, in the future, the Compensation Commillee may consider awarding addi1ional or alternative fonns of equity incentives, such as grants of bonus
stock, restricted stock and restricted stock units.
It is our policy lo award stock options at an exercise price equal lo The NASDAQ Capital Market's closing price of our common stock on the dale of the grant. In certain limited
circumstances, the Compensation Committee may grant options 10 an executive at an exercise price in excess of the closing price of the common stock on the grant date. The Compensation
Committee has never gran1ed options with an exercise price that is less than the closing price of our common stock on the grant date, nor has it granted options which are priced on a date other
than the grant dale. For purposes of determining the exercise price of stock options, the grant date is deemed lo be the first day of employment for newly hired employees, or the dale on which
the Compensation Comminee or the Chief Executive Officer, as applicable, approves the stock option grant lo existing employees.
We have no program, practice or plan to grant stock options to our executive officers, including new executive officers, in coordination with the release of material nonpublic
information. We also have not timed the release of material nonpublic information for the purpose of affecting the value of stock options or other compensation to our executive officers, and we
have no plan to do so. We have no policy regarding the adjustment or recovery of stock option awards in connection with the restatement of our financial statements, as our stock option
awards have not been tied to the achievement of specific financial goals.
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Tax and Accounting Implications
Deduc1ibili1y ofExecmive Compe"sotio"
As part of its role. the Compensalion Commillee reviews and considers the deduclibility of executive compensation under Seclion l 62(m) of the Internal Revenue Code, which provides
1hn1 corporations may not deduc1 compcnsalion of more lhan SI ,000,000 1hat is paid to certain individuals. We believe that compensation paid to our executive officers generally is fully
deductible for federal income tax purposes. ·
Accoun1i11gfor Sl,are-Based Compe11satiot1
Beginning on January I, 2006, we accounl for share-based compensation in accordance with the requirements of ASC 718, Compe11sa1io" - Srock Compet1sa1io11. This accounting
treatment has 1101 significantly affected our compensation decisions. The Compensation Committee takes into consideration the tax consequences of compensation to the named execmive
officers, but tax considerations arc not a significant part of the company's compensation policy.

@

These policies remained in place throughout 2013, and we expccl to continue to follow them for the foreseeable fulUre.
Compensation Committee Interlocks and Insider Participation in Compensation Decisions
There are no ..interlocks," as defined by the SEC, wilh respect to any member of the Compensation Committee. Max Link, Ph.D., Joseph Rubinfcld, Ph.D., Marvin R. Scher and Richard
L. Wennckamp served as members of the Compensation Committee during 2013.
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Summary Compensalion Table
The following table presents summary information concerning all compensation paid or accrued by us for services rendered in all capacities during 2013, 2012 and 2011 by Steven A.
Kricgsman and John Y. Calo,:, who arc the only individuals who served as our principal executive and financial olliccrs during the year ended December 31, 2013, and our three other most highly
compensated executive olliccrs who were serving as executive officers as of December 31, 2013:

Summary Compensalion Tahlc

Year

Name and Princieal Position
Steven A. Kriegsman

Prcsitlca: and Chief Eiiccutivc (Jfficci

John Y. Caloz
ChiefFinancial Officer and Treasurer

Daniel Levitt, M.D., Ph.D.
Executive Vice President and Chief
Medical Officer

Benjamin S. Levin General Counsel,
General Counsel. Senior Vice President
and Secretary

Option
Awards
($)(2)(4)

Bonus
($)(1)

Snlarl ($)

AIIOrhcr
Compensation (S)
(3)

Total
($)

l.714,150

700,000

330,000
150,000
150,000

2013
2012
2011

350,000
340,000
335,000

100,000
75,000
45,000

256,800
131,000
45,600

703,800
546,llO0
425,600

2013
2012
2011

525,000
450,000
450,000

300,000
150,000
112,500

l,4!H,0U0
186,900
114,000

:.!,JO!S,UUO
786,900
676,500

2013
2012
2011

350,000
340,000

150,000
75,000

513,600
131,000

1,013,600
546,000

340,000

55,000

57,000

452,000

350,000

100,000
75,000

256,800

703,800

131,000

30,000

45,600

546,000
405,600

2013
2012
2011

700,000
700,000

Scott Wieland, Ph.D.
Senior Vice President - Drug Development 2013
2012
2011

330,000
330,000

655,000
342,000

!3,700
13,700
I0,000

2.757,850
1,518,700
1,202,000

---------(I)

Bonuses to the named executive officers reported above were paid in December of the applicable year.

(2)

The values shown in this column represent the aggregate grant date fair value of equity-based awards granted during the fiscal year, in accordance with ASC 718, "Share BasedPayment. "The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model, based on the assumptions described in Note 12 of the
Notes to Financial Statements included in this Annual Report.

(3)

This amount represents life insurance premiums.

(4)

In the case of Dr. Levitt, for 2013, this amount includes the aggregate grant date fair value of a restricted stock award granted during the fiscal 2013, as well as the aggregate grant date
fair value of an equity-based award granted during the fiscal year. The restricted stock awarded in 2013 was issued in January 2014. For 2012, the amount represents the aggregate
grant date fair value of a restricted stock award granted and issued during the fiscal year.
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2013 Grants of Plan-Based Awards
In 2013, we granted stock op1ions to our named executive officers under our 2008 Stock lncen1ive Plan as follows:
2013 Grants of Plan-Based Awards

12/10/2013
3/08/2013

All Other
Option Awards
(# ofC}1Rx
Shares!
92S,000(I)
74,176(1)

s
s

2.39

John Y. Caloz
Chier Financial Officer and Trea.,;urcr

12/10/2013

150,000(1)

Daniel Levitt, M.D., Ph.D.
Executive Vice Presidelll and Chief Medical Officer

Name

Grant Dale

Grant Date
Fair Value of
Stock and
Option Awards

Exercise Price of
Option Awards
(S/Share)

(S)

2.46

s
s

1,583,600
130,SS0

s

2.39

s

256,800

12/10/2013

S00,000(1) S

2.39

s

856,000

Benjamin S. Levin
General Counsel, Senior Vice President nnd Secretary

12/10/2013

300,000(1) S

2.39

s

513,600

Scott Wieland, Ph.D.
Senior Vice President - Dmg Development

12/10/2013

150,000(1) S

2.39

s

256,800

Steven A. Kricgsman
President and Chief Executive Officer

(I)

Options vest in 36 equal monthly installments, subject to the option holder's remaining in our continuous employ through such dates. If employment is terminated by us without
"cause" (or, in the coses of Mr. Kriegsman and Dr. Levitt, for "good reason"), unvested options will immediately vest in full.

We also granted to Dr. Levi II I 00,000 shares of CytRx Corporation restricted stock, of which 50,000 shares will vest on June 30, 2014, and the remaining 50,000 shares will vest over the
subsequent six months, provided that Dr. Levitt remains employed by us on each such date. The shares of restricted stock granted to Dr. Levitt had a grant date fair value of$627,000.
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2000 Long-Term Incentive Plan and 2008 Stock Incentive Plan
The purpose or our 2000 Long-Term Incentive Plan, or 2000 Plan, and our 2008 Stock Incentive Plan, or 2008 Plan, is 10 promote our success and enhance our value by linking the
personal interests or our employees, officers, consultants and directors to those of our s1ockholders. The 2000 Plan was originally adopted by our Board of Directors on August 24, 2000 and by
our stockholders on June 7, 200 I, wi1h certain amendments to the Plan having been subsequently approved by our Board of Direc1ors and stockholders. On May 11, 2009, our Board or
Directors approved an amendment lo 1he 2000 Plan to allow for a one-time stock op1ion re-pricing program for our employees. The 2008 Plan was adopted by our Board of Directors on
November 21, 2008 and by our slockholders on July I, 2009.
2000 Plan and 2008 Plan Descriptions

The 2000 Plan and the 2008 Plan, or the Plans, are administered by the Compensation Committee of our Board of Directors. The Compensation Committee has the power, authority and
discretion to:
designate participants;
determine the types or awards 10 grant to each panicipant and the number, terms and conditions or any award;
establish, adopt or revise any mies and regulations as ii may deem necessary or advisable to administer the Plan; and
make all other decisions and determinations that may be required under, or as the Compensation Comminee deems necessary or advisable to administer, the Plan.
Awards under the 2000 Plan
The 2000 Plan expired on August 6, 20!0, and thus no shares are available for foture grant under the 2000 Plan.
Awards under the 2008 Plan
The following is a summary description of financial instruments that may be granted to participants in our 2008 Plan by the Compensation Committee of our Board of Directors. The
Compensation Committee to date has only granted stock options to participants in the 2008 Plan.

Srock Op/ions. The Compensation Commillee is authorized to grant both incentive stock options and non-qualified stock options. The terms of any incentive stock option mus! meet
the requirements or Section 422 of the Internal Revenue Code. The exercise price of an option may not be less than the fair market value or the underlying stock on the date of grant, and no
option may have a tenn of more than IO years from the grant date.
Reslricred Srock. The Compensation Committee may make awards of restricted stock, which will be subject 10 forfeiture to us and other restrictions as the Compensation Commillee
may impose.
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Stock Bonus Awards. The Compensation Commiltee may make awards of stock bonus awards in consideration for past services actually rendered, which will be subject to repurchase
by us and such other terms as the Compensation Committee may impose.
limitations 011 Transfer; Beneficiaries. Stock Option awards under the 2008 Plan may generally not be transferred or assigned by participants other than by will or the laws of descent
and distribution. Awards of Restricted Stock or Stock Bonus awards may be transferred or assigned only upon such tetms and conditions as set forth in the award agreement or as determined
by the Compensation Committee in its discretion.
Acceleration Upon Certain Events. In the event of a "Corporate Transaction" as defined in the 2008 Plan, all outstanding options will become fully vested, subject to the holder's
consent with respect to incentive stock options, and exercisable and all restrictions on all outstanding awards will lapse. Unless the surviving or acquiring entity assumes the awards in the
Corporate Transaction or the stock award agreement provides othetwise, the stock awards will terminate if not exercised at or prior to the Corporate Transaction.

Termination and Amendment
Our Board of Directors or the Compensation Committee may, at any time and from time to time, terminate or amend the 2008 Plan without stockholder approval; provided, however, that
our board or the Compensation Committee may condition any amendment on the approval of our stockholders if such approval is necessary or deemed advisable with respect to tax, securities
or other applicable laws, policies or regulations. No termination or amendment of the Plans may adversely affect any award previously granted without the written consent of the participants
affected. The Compensation Committee may amend any outstanding award without the approval of the participants affected, except that no such amendment may diminish or impair the value of
an award.
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Holdings of Previously Awarded Equity
Equi1y awards held as of December 31, 2013 by each of our named executive orticcrs were issued under our 2000 Plan and 2008 Plan. The following table sets forth outstanding equity
awards held by our named executive orticers as of December 31, 2013:

2013 Outstanding Equity Awards at Fiscal Year-End
Option Awards
Number of Securities

Underlying Unexercised Options
(#)

Name
Steven A. Kricgim11111

F.xercisahle

President and Chief Executive
Officer

llnexerds11hle

18,566
166,650
142,843
107,143
107,143
42,857
64,286
50,000
28,571
42,857

John Y. Caloz
Chief Financial Officer and Treasurer

Daniel Levitt, M.D., Ph.D.
Executive Vice President and Chief
Medical Officer

33,330
19,045
7,143
17,857
7,143
7,143
3,571
3,571
10,714

Affairs:aiid Secretary ·

Scott Wieland, Ph.D.
Senior Vice President - Drug
Development

925,000

(I
(I
(I

55,610
333,350
71,443

(I
(I
(I

150,000
66,670
9,526

(3

100,000
500,000

(I

(4

46,751
47,61S
35,714
71,429

Benjamin.s: tcvin
General Counsel, Sr. Vice President
-Legal

(I

33,330
·2J,807 ·
14,286
14,286
14,286
14,286
14,286
12,857
21,429
22,857

(I

23,814

(I

300,000·

(I

66,670
ll,907

(I

~

~

33,330
19,045
14,286
14,286
4,286
7,143
14,286
3,571

(I

150,000

(I

66,670
9,526

(I

(I)

These options vest in 36 equal monthly installments, subject to 1he option holder's remaining in our continuous employ through such dates. If employment is terminated by us without
"cause" (or, in 1he case of Mr. Kriegsman and Or. Levi II, for "good reason"), unvestcd options will immediately vest in full.

(2)

The reported options with prices of $8.05 were re-priced to that exercise price on July I, 2009.

(3)

Represe111s 100,000 shares ofrestric1ed s1ock, of which 50,000 shares will vest on June 30, 2014, and the remaining 50,000 shares will vest over the subsequent six months, provided that
Dr. Levin remains employed by us on each such dare. These shares were awarded in December, 2013. but issued in January, 2014.

(4)

Represents restricted stock fully-vested at December 31, 2013. On December 31, 2012, Or. Levin was gnmted I00,000 of restricted stock. We reacquired 53,249 shares in order to satisfy
income tax withholding obligations, as pcrmincd under 1he agreement.
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Employment Agreements and Potential Payment upon Termination or Change in Control

Employment Agreemellt wit/, Stever, A. Kriegsma11

~

Mr. Kriegsman is employed as our Chief Execu1ive Officer and Prcsidenl pursuant lo a fourth amended and reslated employment agreemenl da1ed as of May I 0, 2012 1hat was 10 expire
on December 31, 2015. On March 4, 2014, the employmelll agreement was amended lo ex lend the expira1ion dale by lhree years to December 31, 20 I 8. The cmploymenl agreemenl will
automalically renew following lhe expira1ion date for an addi1ional one-year period, unless either Mr. Kriegsman or we elecl nol to renew ii.
In connec1ion with 1he amendmenl to his employmenl agrecmcnl, we paid Mr. Kriegsman a cash bonus of$300,000.
Under his employmenl agreement as amended, Mr. Kriegsman is entitled to receive an annual base salary of $850,000. Our board of directors ( or its Compensation Committee) will
review 1he base salary annually and may increase (bul not decrease) it in ils sole discretion. In addition lo his annual salary, Mr. Kriegsman is eligible to receive an annual bonus as detem1incd
by our board of directors (or its Compensation Comminee) in its sole discretion, but not to be less than $150,000. Pursuant to his employment agreement with us, we have agreed that he shall
serve on a full-time basis as our Chief Executive Officer and President and that he may continue to serve as Chainnan of the Kriegsman Group only so long as necessary to complete certain
current assignments.
Mr. Kriegsman is eligible 10 receive grants of op1ions 10 purchase shares of our common stock. The number and terms of those options, including the vesting schedule, will be
determined by our board of directors (or its Compensation Committee) in its sole discretion.
Under Mr. Kriegsman's employment agreemenl, we have agreed that, ifhe is made a party, or threatened 10 be made a party, lo a suit or proceeding by reason of his service 10 us, we
will indemnify and hold him harmless from all costs and expenses 10 the fullest extent permitted or authorized by our certificate of incorporation or bylaws, or any resolution of our board of
directors, to 1he extent not inconsistent with Delaware law. We also have agreed 10 advance to Mr. Kriegsman such costs and expenses upon his request ifhe undertakes to repay such
advances if it ultimately is determined that he is not entitled 10 indemnification with respect 10 the same. These employment agreement provisions are not exclusive of any other rights lo
indemnification to which Mr. Kriegsman may be entitled and are in addition to any rights he may have under any policy of insurance maintained by us.
In the event we terminate Mr. Kricgsman's employment without "cause" (as defined), or if Mr. Kriegsman terminates his employment with "good reason" (as defined), (i) we have
agreed to pay Mr. Kriegsman a lump-sum equal to his salary and prorated minimum annual bonus through lo his dale of termination, plus his salary and minimum annual bonus for a period of
two years after his termination dale, or until the cxpira1ion of the amended and restated employment agreement, whichever is later, (ii) he will be entitled to immediate vesting of all stock options
or other awards based on our equity securities, and (iii) he will also be entitled to continuation of his life insurance premium payments and continued participation in any of our health plans
through lo the later of the expira1ion of the amended and restated employment agreement or 24 months following his lennination date. Mr. Kriegsman will have no obligation in such events 10
seek new employment or offset 1hc severance payments to him by any compensation received from any subsequent reemployment by another employer.
Under Mr. Kriegsman's employment agreement, he and his affiliated company, The Kriegsman Group, arc to provide us during the term of his employment with the first opportunity to
conduct or take action with respect to any acquisition opportunity or any other potential transaction identified by them within the biotech, pharmaceutical or health care industries and that is
within the scope of lhe business plan adopted by our board of directors. Mr. Kricgsman 's employment agreement also contains confidentiality provisions relating to our trade secrcls and any
other proprietary or confidential infonnation, which provisions shal I remain in effect for five years after the expiration of the employment agreement with respect to proprietary or confidential
information and for so long as our trade secrets remain trade secrets.
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P11te11tial l'aymellf 11po11 Termi11atio11 or Clla11ge i11 C1111trol for Ste1•e11 A. K riegs111a11
Mr. Kriegsman's employment agreement contains no provision for payment to him in the event ofa change in control ofCytRx. If. however, a change in control (as defined in our 2000
Plan or our 2008 Plan) occurs during 1he lerm of the employment agreemenl, and if, during the term and within two years after the dale on which the change in control occurs, Mr. Kriegsman's
employment is tenninaled by us without "cause" or by him for "good reason" (each as defined in his employment agreement), then, in addition to the severance benefits described above, to the
cxtelll that any payment or distribution of any type by us lo or for the benefit of Mr. Kriegsman resulting from the termination of his employment is or will be subject to the excise tax imposed
under Section 4999 of the Internal Revenue Code of 1986. as amended, we have agreed to pay Mr. Kriegsman, prior 10 the time the excise tax is payable with respect 10 any such payment
(through withholding or otherwise). an additional amount that, after the imposition of all income, employment, excise and other taxes. penalties and interest thereon, is equal to the sum of ( i) the
excise tax on such payments plus (ii) any penalty and interest assessments associated with such excise tax.

I)

Employme11t Agreeme11t wit/, Da11iel Levitt, M.D., Pl,.D.
Daniel Levitt is employed as our Executive Vice President and Chief Medical Officer pursuant to an employment agreement dated as of January I, 2014 that is to expire on December JI,
2014. Dr. Levitt is entitled under his employment agreement 10 receive an annual base salary of $525,000 and is eligible to receive an annual bonus as detennined by our board of directors ( or our
Compensation Committee) in its sole discretion, but 1101 to be less than $150,000. In the event we terminate Dr. Levitt's employment without cause or Dr. Levitt resigns with good reason (as
defined), we have agreed to pay him a lump-sum equal 10 his accrned bu! unpaid salary and vacation, plus an amount equal to one year's salary under his employment agreement.

~

In connection with his new employment agreement, on January I. 2014, we granted to Dr. Levitt I00,000 shares of CytRx Corporation restricted stock, of which 50.000 shares will vest
on June 30, 2014, and the remaining 50,000 shares will vest over the subsequent six months, provided 1ha1 Dr. Levin remains employed by us on each such dale.

Employment Agree111e11t wit/, Jolln }: Caloz
John Y. Caloz is employed as our Chief Financial Officer and Treasurer pursuant to an employment agreement dated as of January I, 2014 lhal was to expire on December JI, 2014. On
March 4, 2014, the employment agreement was amended lo ex lend the expiration date for one year to December JI, 2015. Mr. Caloz is entitled under his employment agreement lo receive an
annual base salary of$J50,000 and is eligible 10 receive an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we
terminate Mr. Caloz's employment without cause (as defined), we have agreed 10 pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to six months'
salary under his employment agreement.
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Employment Agreeme,rt will, Scott Wieland, f>l,.D.

Scott Wieland is employed as our Senior Vice President - Drug Development pursuant to an employment agreement dated as of January I, 2014 that was 10 expire on December 31,
2014. On March 4, 2014, the employment agreement was amended to extend the expiration date for one year to December 31, 2015. Dr. Wieland is paid an annual base salaryofS350,000 and is
eligible to receive an annual bonus as detennined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we tenninate Dr. Wieland's employment without
"cause" (as defined), we have agreed to pay him a lump-sum equal to his accmed but unpaid salary and vacation, plus an amount equal to six months' base salary.
Employment Agreement wit!, Be11jantit1 S. Levin

Benjamin S. Levin is employed as our Senior Vice President - Legal Affairs, General Counsel and Secretary pursuant to an employment agreement dated as of January I, 2014 that was
to expire on December 31, 2014. On March 4, 2014, the employment agreement was amended to extend the expiration date for one year to December 31, 2015. Mr. Levin is paid an annual base
salary of$350,000 and is eligible to receive an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we tenninate Mr.
Levin's employment without "cause" (as defined), we have agreed to pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to six months' base salary.

32

@

@

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

Quanlification or Termination Payments and Benefits
The table below reflects the amount of compensation to each of our named executive officers in the event of termination of such executive's employment without "cause" or his
resignation for "good reason," termination following a change in control and tcnnination upon the executive's death of pennanent disability. The named executive officers are not entitled to any
payments other than accrued compensation and benefits in the event of their voluntary resignation. The amounts shown in the table below assume that such termination was effective as of
December 31, 2013, and thus includes amounts earned through such time, and are estimates only of the amounts that would be payable to the executives. The actual amounts to be paid wi II be
determined upon the occurrence of the events indicated.
Termination Payments and Henefits

Termination w/o Cause or, for Steven A.
Kriegsman and Dr. D:iniel Levitt, for
Good Reason

Name
Steven A. Kriegsman
President and Chief
Executive Officer

John Y. Cal oz
Chief Financial Officer
Daniel L(.-vitt, M.D., Ph.D.
Executive Vice President
and Chief Medical
Officer
Benjamin S. Levin
General Counsel, Senior
Vice President and
Secretary
Scott Wieland, Ph.D.
Senior Vice President Drug Development

(I}

Benefit

Severance Payment(4)
Stock Options ( I )
Ueahh Insurance (2)
Life Insurance
Bonus
Tax Gross Up (3)
Severance Payment( 4)
Stock Options (I)

Severance Payment(4)

Heforc Change in

After Ch:ingc in

Control (S)

Control !S)

13,700
300,000

300,000

2,000,000
5,700,000
80,200
13,700
300,000

Control !S)

2,000.000
5,700,000

175,000

350,000
920,000
1,350,000
2,040,000
3,700

2,040.000
3,700

350,000
1,510.000

1,510,000

350,000
920,000

920,000

675,1100

Heallh Insurance
175,000

Stock Options ( I)

Severance Payment( 4)

80,200

2,000,000
5.700,000
80,200

Disahilitl !S)

2,000,000
5,700,000
80,200
13,700
300,000

Stock Options (I)

Severance Payment(4)

Change in
Death (S)

175,000

Stock Options (I)

5,700.000
80,200

920,000

Represents the aggregate value of stock options that vest and become exercisable immediately upon each of the triggering events listed as if such events took place on December 31,

2013, determined by the aggregate difference between the stock price as of December 31, 2013 and the exercise prices of the underlying options.
(2)

Represents the cost as of December 31, 2013 for the family health benefits provided to Mr. Kricgs1m111 for a period of two years.

(3)

Each of Mr. Kriegsman 'sand Dr. Levitt's employment agreements provides that if a change in control (as defined in our 2000 Plan or our 2008 Plan) occurs during the term of the
employment agreement, and if, during the term and within two years after the date on which the change in control occurs, Mr. Kriegsman's or Dr. Levitt's employment, respectively, is
terminated by us without "cause" or by him for "good reason" ( each as defined in their respective employment agreement), then, to the extent that any payment or distribution of any
type by us to or for the benefit of Mr. Kriegsman or Dr. Levitt, respectively, resulting from the tennination of their respective employment is or will be subject to the excise tax imposed
under Section 4999 of the Internal Revenue Code of 1986, as amended, we will pay Mr. Kricgsman or Dr. Levitt, respectively, prior to the time the excise tax is payable with respect to
any such payment (through withholding or otherwise), an additional amount that, after the imposition of all income, employment, excise and other taxes, penalties and interest thereon,
is equal to the sum of(i) the excise tax on such payments plus (ii) any penalty and interest assessments associated with such excise tax. Based on each of Mr. Kriegsman's and Dr.
Levitt's past compensation and the estimated payment that would result from a termination of employment following a change in control, we have estimated that a gross-up payment
would not be required. "Good reason" as defined in each of Mr. Kricgsman's and Dr. Levitt's employment agreement includes any change in Mr. Kricgsman's or Dr. Levitt's duties or
title, as applicable, that are inconsistent with their respective positions.

(4)

Severance payments arc prescribed by our employment agreements with the named executive officers and represent a factor of their annual base compensation ranging from six months
to two years.
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Compens11tio11 or Directors
We use a combination of cash and stock-based compensation to attract and n:tai11 qualified candidates to serve on our board of directors. Directors who also arc employees of our
company currently receive no compensation for their service as directors or as members of board committees. In setting director compensation, we consider the significant amount of time that
directors dedicate 10 the fulfillment of their director responsibilities, as well as the competency and ski IIs required of members of our board. The directors' current compensation schedule has
been in place since December 2013. The directors' annual compensation year begins with the annual election of directors at the annual meeting of stockholders. The annual retainer year period
has been in place for directors since 2003. Periodically, our board of directors reviews our director compensation policies and, from time to time, makes changes to such policies based on
various criteria the board deems relevant.
Our non-employee directors receive a quarterly retainer of $6,000 (plus an additional S 12,500 for the Chainnan of the Board, $5,000 for the Chainnen of the Audit Comminee and
Compensation Committee:, and $1,500 for the Chairman of the Nomination and Governance Committee), a fee of $3,000 for each board meeting attended ($750 for board actions taken by
unanimous written consent), $2,000 for each meeting of the Audit Committee and Compensation Committee attended, and$ 1,000 for each meeting of the Nomination and Governance Committee
meeting attended. Non-employee directors who serve as the chainnan of a board committee receive an additional $2,000 for each meeting of the Nomination and Governance Commilll.-e attended
and an additional $2,500 for each meeting of the Audit Committee or the Compensation Commillee attended. In Decemher 2013, we also granted ten-year stock options lo purchase 180,000
shares of our common stock to each non-employee director at an exercise price equal to the market value of our common stock on the date of grant The options vested, in full, upon grant.
The following table sets forth the compensation paid to our directors other than our Chief Executive Officer for 2013:

Director Compensalion Table

Fees Earned or
Paid in Cash(S) (2)

Name (I)
Max LinJc, Ph.D., Chairman
Marvin R. Seher, Vice Chainnan

OptionA wards($)

104,000
86,000
39,000
62,000
66,000

Louis Ignarro, Ph.D.,'Director:
Joseph Rubinfeld, Ph.D., Director
Richard L. Wennckamp, Director

(3)

Tolal(S)

363,060
363,060
363,060
363,060
363,060

467,060
449,060

402,060
425,060

429,060

(I)

Steven A. Kriegsman does not receive additional compensation for his role as a Director. For information relating to Mr. Kriegsman's compensation as President and Chief Executive
Officer, see the Summary Compensation Table above.

(2)

The amounts in this column represent cash payments made to Non-Employee Directors for annual retainer fees, committee and/or chairmanship fees and meeting fees during the year.

(3)

In December 2013, we granted stock options to purchase 180,000 shares of our common stock to each non-employee director at an exercise price equal lo the currenc mark el value of our
common stock on the date of grant, which had an aggregate grant date fair value of $363,060 calculated in accordance with FASB ASC Topic 718. The amount recognized for these
awards was calculated using the Black Scholes option-pricing model, and renect grants from our 2008 Long-Tenn Incentive Plan, which is described in Note 12 of the Notes to
Consolidated Financial Statements.

·~
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Joseph Hubinfeld, l'h.D. C,ms11/ti11,: A,,:reeme11t

On December 2, 2008, we entered into a written consulling agreement with Joseph Rubinfeld, Ph.D., under which Dr. Rubinfeld agrees to serve as our Chief Scientific Advisor. In
exchange, we granted 10 Dr. Rubinfeld under our 2008 Stock Incentive Plan a ten-year stock option 10 purchase up to 50,000 shares of our common stock al an exercise price of $2.45 per share,
which equaled the market price of our common stock as of the grant date. The fair value of this option grant was $116,900. The stock option vested immediately upon grant as lo 7,143 of the
option shares and vested as lo the remaining option shares in 36 equal monthly installments. and is now fully vested. The consuhing agreement is terminable al any time by either party upon
notice to the other party.

~

On December I 0, 2012, we entered into an amendment to our written consulting agreement with Dr. Rubinfcld, Ph.D. to provide for the one-time grant to Dr. Rubinfcld under our 2008
Plan of an option to purchase 30,000 shares of our common stock al an exercise price of$ I .83 per share, which was equal lo the market price of our common stock on the grant date. The option
has a lenn often years and is fully vested. The fair grant date value of this option granl was $47,400Joseph Rubinfeld, Ph.D. Consulting Agreement
Code or Ethics
We have adopted a Code of Ethics applicable to al! employees, inc!udi::g our principal executive officer, principal fin:mcia! officer and principal accounting officer, a copy of which is
available on our website at www.cytrx.com. We will furnish, without charge, a copy of our Code of Ethics upon request. Such requests should be directed 10 Attention: Corporate Secretary,
11726 San Vicente Boulevard, Suite 650, Los Angeles, Califomia, or by telephone at 310-826-5648.
Hoard Leadership Structure
Our board of directors has placed the responsibilities of Chainnan with an independent non-employee member of the board, which we believe provides better accountability between
the board and our management team. We believe ii is beneficial to have an independent Chairman whose sole responsibility to us is guiding our board members ns 1hey providr: lr:ackrship to
our executive team. Our Chairman is responsible for communication among the directors, setting the board meeting agendas in consultation with the President and Chief Executive Officer and
presiding at board meetings, executive sessions and stockholder meetings. This delineation of duties allows the President and Chief Executive Officer to focus his attention on managing the
day-to-day business of the company. We believe this structure provides strong leadership for our board, while positioning our President and Chief Executive Officer as the leader of the
company in the eyes of our employees and other stakeholders.
Board ofDirectors• Role i11 Risk Oversight

In connection with its oversight responsibilities, our board of directors, including the Audit Committee, periodically assesses the significant risks that we face. These risks include, but
arc not limited to, financial, technological, competitive, and operational risks. Our board of directors administers its risk oversight responsibilities through our Chief Executive Officer and Chief
Financial Officer, who review and assess the operations of our business as well as operating management's identification, assessment and mitigation of the material risks affecting our
operations.
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PROPOSAi. 2

ADVISORY

VJ}

von: ON EXECUTIVE COMPENSATION

The Dodd-Frank Wall Street Refonn and Consumer Protec I ion Act or 20 IO en1i1les our s1ockholders lo vole lo approve, on an advisory basis, 1he compensation of our named executive
officers as disclosed in this proxy statemenl in accordance wi1h SEC rules.
Please refer to the discussion under "Executive Compensalion" for a description of the compensation of our named executive officers.
We are asking for stockholder approval or the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with SEC rules, which include the
compensation disclosed under "Executive Compensation-Compensation Discussion and Analysis," the compensation tables and the related narrative discussion following the compensation
tables. This vote is not intended 10 address any specific item of compensation, bu1 ra1hcr 1he overall compensation or our named executive officers and the compensation policies and practices
described in 1his Proxy Stalemcnt.
This vote is advisory in nature and therefore not binding on us, our Compensation Commiuce or our board of directors. Our board and our Compensa1ion Commiuee, however, value
the opinions of our stockholders. To the exlent there is any significant vote against the named execmive officer compensation as disclosed in 1his Proxy Statemenl, we will consider 1he
stockholders' concerns, and our Compensa1ion Commitlec will cvaluale whelher any actions are necessary to address those concerns.

Vote Required
The affirmative vote of a majori1y of the shares of our common s1ock presenl in person or reprcscn1cd by proxy and en1i1lcd 10 be vo1ed on Proposal 2 al 1he Annual Meeling is
required for advisory approval of1he proposal.

Recommendation of lhe board of directors
OUR BOARD RECOMMENDS A VOTE "FOR" THE APPROVAL OF THE COMPENSATION OF OUR NA.MED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT
PURSUANT TO THE CO~IPENSATION DISCLOSURE RULES OF THE SEC.

J<,
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PROPOSAL3
RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
Appointment ofBDO USA,

U.r (.. BDO")

BDO currently serves as our independent registered public accounting firm and has audited our financial statements for each of the years ended December 31, 2013, 2012 and 201 I.
BDO does not have and has not had any financial interest, direct or indirect, in CytRx, and docs not have and has not had any connection with CytRx except in its professional capacity as our
independent auditors.
Our Audit Committee has reappointed BDO to serve as our independent registered public accounting linn for the year ending December 31, 2014. The ratification by our stockholders

of the appointment of RDO is not required hy law or by our Restated Rylaws. Our hoarcl of directors, consistent wi1h the practice of many publicly held corporations, is nevertheless submitting
!hi$ appoint1nen! for nuification by :he stockholders. Jf ,his appoinuncnl is not ratified at the Annual ~1ccting, the ;\udit Committee intends to reconsider its appointment of BI)O. Even if the
appointment is ratified, the Audit Commillee in its sole discretion may direct the appointment of a different independent registered public accounting finn at any time during the fiscal year if the
Committee de1em1ines that such a change would be in the best interests ofCytRx and its stockholders.
Any material non-aud11 services 10 be provided by BDO arc subject to the prior approval of the Audit Comminee. In general, the Audit Committee's policy is lo grant such approval
where it determines that the non-audit services are not incompatible with maintaining the independent registered public accounting firm's independence and !here are cosl or other efficiencies
in ob1aining such services from the independent registered public accounting firm as compared to other possible providers.

We expect that representative~ of 8D0 will be present at the Annual Meeting, will have an opportunity 10 make a statement if they sn desire, and will be available lo respond to
appropriate questions.
Audit Fees
The fees for 2013 and 2012 from BDO for professional services rendered for the audit ofour annual consolidated financial statements and internal con1rols over financial reporting, the
review of quarterly financial s1a1emcn1s and of our shelf-Registration Statements on Form S-3 and related matters were $391,730 and S3 76,300, respectively.

Tax Fees
The aggregate fees billed by BDO for professional services for lax compliance, lax advice and tax planning were $27,225 and $23,325 for 2013 and 2012, respectively.
All Other Fees
No other services were rendered by BDO for 2013 and 2012

Pre-Approval Policies and Procedures
It is the policy of our Audit Committee 1hat all services lo be provided by our independent registered public accounting firm, including audit services and permitted audit-related and
non-audit services, mus1 be pre-approved by our Audit Comminee. Our Audit Committee pre-approved all services, audit and non-audit, provided to us by BOO for 2013 and 20 I 2.
Vote Required
The aflinnative vote of a majority of the shares of our common stock present in person or represented by proxy and entitled to be voted on this proposal al the Annual Meeting is
required for approval of this proposal.

Recommendation of Our board of directors
THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS OUR INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM.
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1
STOCKHOLDER PROPOSALS

Any proposnl which a stockholder intends 10 presenr in accordance wilh Ruic 14a-8 ofrhc Securities Exchange Acr of 1934 ar our next Annual Meeling of Stockholders 10 be held in
2015 must be received by us on or before February 23, 2015. Notice ofstockholdcrproposals submitted outside of Rule 14a-8 of the Exchange Act will be considered untimely if received by us
after that date. Only proper proposals under Rule 14a-8 which are timely received will be included in the Proxy Sratcment in 2015.
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OTII ER MATTERS
Expenses of Solicitation
We arc soliciling proxies on behalf of our board of direclors. This solici1ation is being made by mail, bu1 also may be made by telephone or in person. We and our directors, officers and
employees may also solicit proxies in person, by 1elephonc or by other clt=clronic means. These per,;ons will not he cornpensa1ed for rhese solicilalion activities.
We have engaged Alliance Advisors 10 assist in the solici1a1ion of proxies. We will pay a fee of SS,000 plus rc:asonable out-of-pocket charges and a Oat fee of $5.00 per outbound
proxy solicitation call.
We will ask banks, brokers and other institutions, nominees and fiduciaries 10 fmward our proxy materials to their principals and to obtain their authority to execute proxies and voting
instrnctions and will reimburse them for their reasonable expenses.
Delivery of Proxy Materials to Households
Some banks, brokers, and other nominee record holders may be participating in the practice of .. householding" proxy statements and annual reports. This means that only one copy of
this notice and proxy statement may have been sen I to multiple stockholders in your household. If you would prefer lo receive separate copies of a proxy statement or annual report either now
or in the fulure, please contact your bank, broker or other nominee. Upon wrillen request lo us at CytRx Corporation, 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049,
Allenlion: Corporate Secretary, or by telephone at 310-826-5648, we will promplly deliver wi1hout charge, upon oral or wrinen request, a separate copy oflhe proxy material to any stockholder
residing al an address to which only one copy was mailed. In addition, stockholders sharing an address can requcsl delivery of a single copy of annual reports or proxy statements if they arc
receiving multiple copies upon wrillen or oral request to us at lhe address and telephone number stated above.

Miscellaneous

Our management does not intend lo present any other items of business and is not aware of any mailers olhcr than those set forth in this Proxy Statement thal wi II be presented for
action at the Annual Meeting. However, if any other mailers properly come before the Annual Meeting, the persons named in the enclosed proxy intend to vole the shares of our common stock
that they represent in accordance with rheir best judgment.
Annual Report
Accompanying this Proxy Slatemenl is a letter of transmiual from our President and Chief Executive Officer, along with a copy of our Annual Report on Fonn I 0-K, without exhibits, for
the year ended December 31, 2013 filed with the SEC. These accompanying materials constitute our annual report to stockholders. We will provide, witholll charge upon written request, a
further copy of our Annual Report on Fonn 10-K, including the financial statements and the financial statement schedules. Copies of the Fonn 10-K exhibits also arc available without charge.
Stockholders who would like such copies should direct their requests in writing to: CytRx Corporation, 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049, Attention:
Corporate Secrclary.
By Order of the board of directors

Isl BENJAMIN S. LEVIN
Benjamin S. Levin
Corporate Secretary
May I, 2014
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PROXY

CytRx Corporation
11726 San Vicente Boulevard, Suite 650,Los Angeles, California 90049
Annual Meeting or Stockholders

The undersigned stockholder of CytRx Corporation (the "Company") hereby revokes all prior proxies and constitutes and appoints Steven A. Kriegsman and Benjamin S. Levin, or either one of
them, as proxy and attorney-in-fact, each with full power of substitution, to vote the number of shares of common stock of the Company that the undersigned would be entitled to vote if
personally present at the Annual Meeting of Stockholders to be held at the Hotel Bel Air, 70 I Stone Canyon Road, Los Angeles, California at I 0:00 A.M., local time, on Tuesday, June 24, 2014,
and at any postponement or adjournment thereof (the "Annual Meeting"), upon the proposals described in the Notice of Annual Meeting of Stockholders and Proxy Statement, both dated May
I, 2014, the receipt of which is acknowledged, in the manner specified below:
·
I.

Election of Directors. On the Company's proposal to elect as directors the following nominees for Class I director to serve until the 2017 Annual Meeting of Stockholders of the
Company and until his respective successor is duly elected and qualified:
For£
For£

Steven A. Kriegsman
Marvin R. Seiter

2.

Advisory Vote on Executive Compensation. On the proposal for an advisory vole lo approve the compensation of our named executive officers as disclosed in the Proxy Statement:
For

3.

Withhold Authority£
Withhold Authority£

£

Against

£

Abstain

Appoi111ment of Independent Registered Public Accounting Firm. On the proposal to ratify the appointment of BDO USA, LLP as the Company's independent registered public
accounting finn for the fiscal year ending December 31, 2014:
For

£

Against

£

Abstain

£

This Proxy, if properly executed and returned prior to the Annual Meeting, will be voted in the manner directed above. If no direction is made, this Proxy will be voted "FOR" each of
Proposals 1-3 and in the proxy holder's discretion on all other mailers that may properly come before the Annual Meeting or any adjournment or postponement thereo(

i.JP

Please sign this Proxy exactly as your name appears on your stock certificate and dale it below. Where shares are held jointly, each stockholder must sign. When signing as executor,
administrator, trustee, or guardian, please give your full title as such. If a corporation, please sign using the full corporate name by president or other authorized officer, indicating the officer's
title. !fa partnership, please sign in the partnership's name by an authorized person.
Shares Held:
Signature of Stockholder

Signature of Stockholder (if held jointly)

D a t e d : - - - - - - - - - - - ~ 2014

Dated: - - - - - - - - - - ~ 2 0 1 4

THIS PROXY IS SOLICITED ON BEHALF OF CYTRX CORPORATION'S BOARD OF
DIRECTORS AND MAY BE REVOKED BY THE STOCKHOLDER PRIOR TO ITS EXERCISE.
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